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Abstract  
 
In recent years, the effect of reactive oxygen species (ROS) on T cell function in an immune 
response has gained increasing interest. T cell mediated chronic inflammation is influenced 
by changes in the redox environment. The cellular surface redox state plays an important role 
in receptor mediated T cell stimulation. Among many modifications, the reversible nature of 
sulphenic acid modified proteins act as redox switches to control protein function. T cell 
membrane proteins contain many cysteine residues that are susceptible to this modification 
in the presence of ROS. The source of ROS could be paracrine or autocrine by the NADPH 
complex (NOX) on T cell membrane in response to stimuli. Hence, the presence of free thiols 
or antioxidants such as thioredoxin (Trx1) and peroxiredoxin (Prx2) on the surface may 
influence interaction between the T cell receptor (TCR) and antigen presenting cells (APC). 
The main aims of this study were to analyse the surface redox state during T cell activation 
and to identify potential membrane proteins that undergo sulphenic acid modification in health 
and may be relevant to Rheumatoid Arthritis (RA). This thesis has used several approaches 
to achieve these aims: (1) A cell culture model of T cell-like Jurkat cells was challenged with 
hydrogen peroxide (H2O2) and novel ROS inducing compounds termed as ROX 1 and ROX 
2. (2) Primary CD4+ T cells isolated from healthy individuals were challenged with H2O2 during 
activation with anti-CD3 and anti-CD28 antibodies. Membrane sulphenic acid modifications 
were analysed by mass spectrometry approaches. (3) Collagen induced arthritis (CIA) mice 
model was used to analyse whether ROX plays a role in disease severity. Several sulphenated 
proteins were identified on the membrane of both Jurkat and primary CD4+ T cells after 
activation. Activated T cells show increased expression of Trx1 and Prx2 on the surface along 
with reduced and oxidised thiols in vitro and ex vivo. ROX significantly inhibited T cell 
activation in human primary CD4+ T cells and WT splenocytes. Compound ROX 2 that targets 
the NOX2 complex was shown to cause increased release of superoxide anions from WT 
mouse splenocytes in comparison to Ncf1-/- mice as measured by isoluminol. Results from 
this study indicated that ROS may not only be responsible for tissue damage but rather a 
means of modulating the immune response depending on the amount and location produced. 
This observation was shown confirmed by routine treatment of CIA induced mice with ROX 2. 
A decreased trend in the severity of arthritis was observed at later onset of the disease in WT 
mice with ROX 2 and there was no observable difference in Ncf1-/- mice. Therefore, targeting 
ROS represents a promising therapeutic strategy in dampening antigen-specific T cell 
responses and T cell-mediated autoimmune diseases. Further studies are required to examine 
the possible association of Trx1 and Prx2 on the surface proteins during T cell activation and 
rheumatoid arthritis.  
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Chapter 1. General introduction 
 
1.1. Immune system and inflammation 
 
Inflammation is induced by invading pathogens or harmful stimuli. It is characterised by pain, 
heat, swelling and redness resulting in loss function of the inflamed tissue. These symptoms 
are due to host response towards antigens or toxins arising from invading pathogens such as 
pathogen-associated molecular pattern (PAMPs), lipopolysaccharide (LPS), and endotoxin 
(Mogensen 2009). The immune system that comprise of cells and anti-inflammatory/ 
resolution mediators, is responsible for activating and reducing this inflammatory response. 
The immune response is divided into innate and adaptive immunity. These two systems work 
together for the development of an effective immune response to eradicate harmful stimuli  
(Janeway et al. 2001; Lindstrom & Robinson 2010; Janeway et al. 2005) as shown in Figure 
1.1.  
1.1.1. Innate immune system 
 
The innate Immune system comprises of natural killer (NK) cells, macrophages, dendritic cells 
(DC), neutrophils, basophils and eosinophils. These cells act as a first line of defence to initiate 
an immune response during invasion of foreign bodies including bacteria or pathogens. The 
activation of phagocytic cells leads to production of reactive oxygen species (ROS), and the 
release of cytokines and chemokines; the soluble mediators which mediate signalling 
pathways and recruit more neutrophils and monocytes to the inflammatory site. These soluble 
mediators include tumour necrosis factor- α (TNF-α), interleukins- IL-1β, IL-6, IL-10, IL-4, IL-
12, IL-18 and interferon- ɣ (IFN-ɣ) (Lacy & Stow 2011).  Neutrophils bind to invading pathogen 
and ingest at the site of infection, a process named phagocytosis. Microbial PAMPs  interact 
with toll-like receptors (TLRs) on the surface of neutrophils, which  initiates a signalling 
cascade allowing phagocytosis, release of cytokines, promotes degranulation and ROS 
release (Hayashi et al. 2003; Kobayashi & DeLeo 2009). The innate immune response by 
neutrophils is divided into two phases: 1) the generation of superoxide and other ROS by 
17 
 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex on the membrane, 
and 2) the release of granules which consists of proteins and degradative enzymes (Quinn 
2004).  
1.1.2.  Adaptive immune system 
 
The adaptive immune system is more efficient due to its targeted approach and immunological 
memory and comes into play with prolonged inflammation. The main cellular players in 
adaptive immune system are T and B lymphocytes.  In order to initiate a cell mediated immune 
response by T cells, the recruitment and presentation of antigens is necessary and this is 
possible by the cells of the innate immune system including dendritic cells (DC) and 
macrophages (Janeway et al. 2001). The T cell receptor (TCR) on the cell surface is 
responsible for the interaction of a specific antigenic peptide on antigen presenting cells (APC) 
leading to their differentiation into effector T cells. These APC internalise pathogens via 
phagocytosis and present peptides to naïve T cells via the major histocompatibility complexes 
(MHC) (more detailed in section 1.4.2). The effector cells will then lead to the antibody 
production by B cells by delivering activating signals which targets specific antigens. 
Antibodies subsequently opsonise the pathogen, hence eliminating it after recognition by Fc 
receptors on innate immune cells (Janeway et al. 2005; Alberts et al. 2002). Following the 
elimination of pathogen, the activated T and B cells undergo apoptosis (Janeway et al. 2001). 
However, a few of these cells (both T and B) may differentiate into memory cells which trigger 
a quicker and robust immune response during second exposure to the antigen, also known as 
immunological memory (Janeway et al. 2005; Alberts et al. 2002).    
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a) 
 
b)  
 
 
Figure 1.1: Innate and adaptive immune response. Upon infection, phagocytic cells are 
recruited as a first line of defence. Secreted cytokines and chemokines initiate a recruitment 
of immune cells to the site of infection. Prolonged infections leads to the recruitment of APC 
to the site of infection and present antigens and secrete pro-inflammatory cytokines and 
chemokines which will then induce the maturation of T cells into CD4+ or CD8+ T cells. The 
cellular pool of CD4+ either differentiate into  Th1 or Th2 T cells and produce antibodies by 
interacting with B cells (humoral response) against infection Adapted from (Redgrove & 
McLaughlin 2014), EB- elementary bodies. b) Time course showing the immune response 
following invasion of foreign pathogen. 
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1.1.3.  T cell biology and maturation 
 
T cells derived from hematopoietic stem cells migrate into the thymus from the bone marrow. 
The T cells in the thymus carry out several maturation steps that allow differentiation into 
alternative T cell lineages. This include the choice of committing to T cell lineage over B cell 
lineage and the choice of CD4+ and CD8+ lineages and between αβ to ɣδ T cell lineages. 
Developing T cells in the thymus also known as thymocytes then go through a maturation 
process which involves surface molecule expression including cluster, CD44 an adhesion 
molecule, and CD25, α-chain of the IL-2 receptor (IL-2R) and c-Kit, stem cell growth factor 
(Starr et al. 2003). Following this phase the TCR genes RAG-1 and RAG-2 expression is 
turned on facilitating rearrangement of the TCR genes leading to the origination of  αβ to ɣδ T 
cell lineages and a lack CD4+ and CD8+ expression; these are considered as double negative 
(DN) (Dudley et al. 1995). Around 5-10% of the T cell subsets represent ɣδ thymocytes 
according to the expression of ɣδ TCR on the cell surface. The thymocytes expressing αβ 
TCR on the cell surface differentiate into double positive (DP) expressing CD4+ and CD8+ at 
the cell surface. Following this phase, negative and positive selection takes place whereby the 
thymocytes are further differentiated into either expressing CD4+ or CD8+ receptor at the cell 
surface, and are regarded as single positive cells (SP). Negative selection is the elimination 
of the DP thymocytes which strongly interact with the self-peptides. On the other hand, positive 
selection eliminates DP thymocytes that react with the TCR. The positively selected DP 
thymocytes then begin effective maturation depending on the interaction between the correct 
major histocompatibility complexes (MHC), into SP T cell lineage. Positively selected 
thymocytes become either CD8+ cytotoxic T cell which recognises MHC class I complex self-
peptides or CD4+ also known as T helper cells (Th) which recognises MHC class II peptides 
(Kindt et al. 2007; Murphy et al. 2008; Starr et al. 2003) . Mature T cells which are positively 
selected leave the thymus and enter the periphery as mature naïve T cells.  
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Figure 1.2: Schematic representation of T cell development and differentiation. T cell 
precursors migrate from the bone marrow into the thymus where they undergo positive and 
negative selection. Following migration of the positively selected cells into periphery, they can 
undergo antigen-induced activation by MHC II interacting with CD4+ T cells and MHC I 
interacting with CD8+ T cells, which results in proliferation and differentiation into T cell subsets 
(Helper T cells and cytotoxic T cells).  
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1.1.4. T cell activation and TCR signalling 
 
Naïve T cells are present in the periphery until they encounter an antigen on antigen 
presenting cells (APC) for the activation. The nature of this interaction is highly specific as it 
leads to further differentiation and proliferation of naïve T cells into several T cell subsets. The 
T cell receptor (TCR) at the surface of naïve T cells recognises MHC peptides  at the surface 
of APC, this interface is referred to as an immunological synapse (Joffre et al. 2009; Grakoui 
et al. 1999).  Additionally, efficient T cell activation also depends on co-stimulatory molecules 
and chemical mediators expressed on the surface of APC. These comprise of CD80 or CD86 
receptor on APC which interacts with either CD28 or CTLA4 expressed on naïve T cell and 
transmit necessary signal for proliferation and survival. The chemical mediators, such as 
interleukins (IFNα, IL-12, IL-4) , promote T cell differentiation into effector cells (Joffre et al. 
2009; Pennock et al. 2013). 
The TCR is a transmembrane protein which consists of peptide-MHC recognition complex (α 
and β chains) and intracellular signalling subunits (ɣ, δ, ε, and ζ chains or known as CD3 
complex) and is collectively is referred to as TCR-CD3 complex (Birnbaum et al. 2014; Cantrell 
2002). This can be also considered as a four-dimer complex.   Once the MHC is presented 
with an antigen and binds to the TCR, the cytoplasmic domain of the CD3 chains consisting 
of immunoreceptor tyrosine-based activation motif (ITAM) interacts with protein tyrosine 
kinases (PTK) of Syk, Src and Tec families consequently initiating a signalling cascade 
(Brownlie & Zamoyska 2013).  
A Src PTK member, lymphocyte-specific protein tyrosine kinase (LCK), phosphorylates ITAM 
allowing a docking site for a Syk PTK member, zeta chain-associated protein kinase 70 (ZAP-
70) via Src-homology 2(SH2) domains. ZAP70 bound ITAM in turn phosphorylates the antigen 
receptor adaptors; liker of activated T cells (LAT) and SH2 domain containing lymphocyte 
protein of 76kDa (SLP-76). LAT acts as an anchor to various signalling proteins including 
phospholipase Cγ1 (PLCγ1), GRB2-related adaptor protein (GADS), adhesion and 
degranulation-promoting adaptor protein (ADAP) and growth factor receptor bound protein 
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(GRB2). Collectively, phosphorylated LAT and SLP-76 forms a platform for signal transduction 
molecules to be recruited and assembled, forming a cascade of signalling pathways during T 
cell activation. These include the Ras signalling pathways, mitogen activated protein kinase 
(MAPK) and nuclear factor-κB (NF-κB), mainly involved in calcium signalling, cytoskeletal 
reorganisation and regulation of transcription factors. The translocation of NF-κB and nuclear 
factor of activated T cells (NFAT), which is dephosphorylated by calcineurin in the presence 
of intracellular calcium (Ca2+), into the nucleus allows transcription of cytokine related genes 
including IL-2, GM-CSF, IL-4 and TNF-α. These are essential for T cell differentiation and 
proliferation (Kuo & Leiden 1999; Lin & Weiss 2001).   
The activation of T cells by peptides on APC induces T cell proliferation and differentiation into 
T cell subsets, and this process is also controlled by locally available cytokines. Primarily, 
cytokines are produced from APC but some cytokines produced from the differentiating T cells 
enhances proliferation in a positive feedback loop thereby amplifying differentiation reaction.  
For example, CD4+ T cells when activated secrete IL-2 which induces T cell proliferation and 
differentiation. IL-2 is also secreted by CD8+ and NK cells (Malek & Castro 2010). Besides its 
main role in T cell proliferation, it is also involved in activation induced cell death and Treg and 
CD8+ T cell development. This process was shown to be regulated by IL-2 by maintaining the 
differentiated state of T cells. To allow this, secreted IL-2 in the extracellular environment binds 
to CD25 (IL-2 R) on the surface of T cells allowing further expression of the receptor by a 
paracrine effect. This is summarised in figure 1.3.        
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Figure 1.3: Schematic representation of TCR signalling. MHCII antigen presentation to TCR 
which initiates signalling cascade. The intramembrane domains are phosphorylated leading 
to phosphorylation of ZAP70 (zeta chain-associated protein kinase 70), LCK (Lymphocyte-
specific protein tyrosine kinase), SLP-76 (SH-2 domain containing lymphocyte protein of 76 
kDa molecules). LAT (Linker of activated T cells) behaves as an anchor to signalling proteins 
including GRB2 (growth factor receptor bound protein 2), GADS (GRB2 related adaptor 
protein), PCLɣ1 (phospholipase Cɣ1), NCK1 (non-catalytic region of tyrosine kinase adaptor 
protein 1), ADAP (adhesion and degranulation promoting adaptor protein) and ITK 
(interleukin-2-inducible T cell kinase). The signalling pathways initiated are MAPK (mitogen 
activated protein kinase), NFAT (Nuclear factor of activated T cells) and NF-κB (Nuclear 
factor-κB). This results translocation of transcription factors and synthesis of cytokines such 
as IL-2 (interleukin-2) which binds to CD25 (IL-2 receptor) for further proliferation and 
differentiation.    
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1.1.5. T cell differentiation 
 
CD4+ T cells which become activated via antigens on MHC II may differentiate into many 
helper subsets including Th1, Th2, Th17 and regulatory T cells (Treg). As mentioned above, 
specific cytokine signalling plays a major role in T cell differentiation into a particular subtype. 
Other factors involved are the concentration of antigen presented (Luckheeram et al. 2012).  
The differentiation of CD4+ T cells into Th1 is initiated by IL-12, which is secreted by APC. This 
causes NK cells to secrete IFNɣ suppressing Th2 differentiation. The production of these 
cytokines leads to activation of STAT1, STAT4 and Tbet transcription factors. Th1 cells 
secrete IL-2, LT-α, and IFN-γ and mainly involved in cell mediated immune response. IL-4 and 
IL-2 secretion are considered to be critical in Th2 differentiation. The transcription factor which 
regulates Th2 development is STAT6 which upregulates GATA3, c-MAF and NFATp. Th2 
cells mainly produce IL-4 which regulates transcription factors suppressing Th1 differentiation. 
They are also involved in promoting B cell growth factors hence  mediating allergic and 
humoral immune response (O’Shea et al. 2013; Zhu & Paul 2008; Feili-Hariri 2005; 
Luckheeram et al. 2012). Additionally, IL-6 has also been shown to play a role in Th2 
differentiation. IL-6 promotes IL-4 production by naïve CD4+ T cells via NFAT upregulation 
and inhibiting Th1 lineage (Diehl et al. 2000).  
Further subtypes of CD4+ T cells are Th9, Th22, Th17, follicular T cells (Tfh) and (Tregs). Th9 
are characterised as subset of Th2 T cell and transforming growth factor-β (TGF-β) is identified 
as the responsible cytokine for Th9 differentiation. Th9 are mainly involved in defence against  
helminths and in allergy and they secrete higher levels of IL-9 (Veldhoen et al. 2008; Anuradha 
et al. 2016; Tan & Gery 2012). 
The TGF-β and IL-2 cytokines are responsible for the differentiation of Treg from naïve CD4+ 
T cells. The downstream signalling following TCR interaction and TGF-β ligand receptor 
binding induces FOXP3 expression which is uniquely expressed in CD4+CD25+ Treg cells. 
Also, the secretion of IL-2 promotes expression of STAT5 which enhances the expression of 
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FOXP3. The main role of Tregs is to modulate self-tolerance by secreting TGF-β, IL-10 and 
IL-35 (Brandenburg et al. 2008; Chen et al. 2003; Luckheeram et al. 2012).  
Th17 subset is mainly differentiated in the presence of TGF- β and IL-6 cytokines. It also 
involves different steps of maturation which depend on IL-21 and IL-23. These cytokines act 
on the transcription of RORɣt, which is responsible for the production of IL-17. These cells are 
mainly observed in autoimmune conditions such as rheumatoid arthritis and multiple sclerosis. 
They are also involved in an immune response caused by invading bacteria (Marwaha et al. 
2012).   
 
 
 
 
 
  
26 
 
1.1.6. T cells and ROS 
 
Reactive oxygen species levels are known to play a part in T cell reactivity. ROS that are 
released from surrounding  cells or endogenously produced from activated T cells, could 
regulate the outcome of an immune response (Kesarwani et al. 2013a; Chen et al. 2016). 
NADPH oxidase on the membrane is responsible for releasing ROS during interaction with T 
cells. The NADPH complex consists of several NOX subunits which are located both 
intracellularly and transmembrane.  NOX2/gp91phox is located on the membranes and 
dimerises with p22phox to form flavocytochrome b558 complex. Other subunits located are in 
the cytosol (Ncf1 (p47phox), Ncf2 (p67phox) and Ncf4 (p40phox)) in resting state (Babior 
2004; Babior 1999). Sufficient levels of ROS in T cells are produced by NOX2, mitochondria 
and DUOX1 (A. V Belikov et al. 2015). 
ROS production occurs during TCR stimulation from NOX2 and mitochondria which are 
regarded as the main sources of ROS as shown by 2',7' –dichlorofluorescin diacetate (DCF-
DA)(Phillips & Griffiths 2003) and MitoSox oxidation in primary CD4+ T cells (Tse et al. 2010; 
Laura A Sena et al. 2013). H2O2 is a commonly ROS species to assess the effect of oxidative 
stress on T cell activation, mainly because it is diffusible through the plasma membrane and 
prominent source of ROS within cells  (Winterbourn 2013). 
The presence of intracellular ROS in T cells is thought to be the third signal following the 
antigen presentation and  cytokine release towards  the enhancement of T cell proliferative 
response  (Tse et al. 2007). This was shown by Los and colleagues, whereby  low levels of 
H2O2 induced the transcription factor NF-κB and IL-2 gene expression along with IL-2α 
receptor (Los et al. 1995). Also, ROS act as an essential mediator in T cell function where 
certain antioxidants such as cysteamine inhibit proliferation and IL-2 production when 
administered during the early stages of T cell activation (Hultqvist et al. 2006; Goldstone et 
al., 1995).  In recent years, the effect of ROS and the role of T cells in an immune response 
has gained increasing interest as T cells are influenced by changes in the redox environment 
(Simeoni & Bogeski 2015a). When T cells reside in highly inflammatory milieu, in the presence 
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of ROS releasing phagocytic cells, their cellular redox state has shown to be altered (Angelini 
et al. 2002).  
This was evident by increased  release of antioxidants and upregulated intake of amino acid,  
cysteine, for GSH synthesis (Levring et al. 2015). To combat high level of oxidative stress 
within inflammatory site, T cells are equipped with several antioxidant defence mechanisms 
including peroxiredoxins, superoxide dismutases and glutaredoxins (Hanschmann et al. 
2013a). 
  
T cell activity is based upon expression and interaction of many surface receptors and proteins 
with APCs. Among the amino acids, cysteine residues are prone to be modified by oxidants 
such as H2O2. This is because they may be ionised at physiological pH, are stable in a number 
of oxidation states, are least abundant and hence have a high specificity for oxidative 
posttranslational modifications (Marino & Gladyshev 2010).  Therefore, T cell proteins are 
highly susceptible for oxidative modifications. There is an increased amount of evidence 
suggesting an increase in cell surface thiol (-SH) levels in T cells when stimulated (Gelderman 
et al. 2006). Others have also demonstrated that activation leads to an increase in sulphenic 
acid (-SOH), the first reversible oxidation product of cysteine (Pellom et al. 2013; Michalek et 
al. 2007)).  
In normal physiological conditions, the balance between ROS and antioxidant systems is 
maintained, and is required for the appropriate functioning of T cells. However, any disruption 
to this equilibrium by changing the levels of ROS or antioxidants can result in T cell hypo- or 
hyper-responsiveness, which, in turn, may lead to the development of various pathologies 
including T cell-mediated Rheumatoid Arthritis (RA); a chronic autoimmune disease caused 
by reacting to self-antigens (Gelderman et al. 2006a; Phillips et al. 2010; Hultqvist et al. 2009a)  
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1.2. Oxidative stress 
 
Oxidative stress is an imbalance between reactive oxygen species (ROS) and antioxidant 
levels (Kregel & Zhang 2007). When ROS production overcomes the cellular defence systems, 
there is an alteration in redox homeostasis (Eruslanov & Kusmartsev 2010)  cellular functions 
are changed.  
 
1.2.1. Reactive oxygen species 
 
ROS are chemically reactive molecules known to cause reversible and irreversible damage to 
biomolecules including lipids, proteins, and DNA (Freeman & Crapo 1982) leading to change 
of function, or tissue injury. Levels of ROS and the microenvironment where ROS have been 
produced are important factors which determine the extent of the damage. Excess amounts 
of ROS give rise to oxidative stress which results in molecular damage such as DNA-protein 
crosslinks leading to cell death and apoptosis (Nordberg & Arnér 2001; Kamata & Hirata 
1999), Lipid peroxidation (Ylä-Herttuala 1999) and amino acid oxidation generating modified 
non-functioning protein (Stadtman & Berlett 1998; Griffiths 2000). 
However, it has been widely shown that a low level of ROS play a critical role in controlling 
infection and modulating T cell responses (Kesarwani et al. 2013a; Griffiths 2005; Chen et al. 
2016). ROS produced by various cell types in the immune system include: superoxide anion 
radical (O2•-), hydrogen peroxide (H2O2), singlet oxygen (1O2), and hydroxyl radical (•OH) and 
anion (OH-).  
Accumulating evidence suggests that ROS are not only harmful to cells and tissues but also 
behave as signalling molecules such as H2O2 (Rhee 1999).The presence of ROS at minimal 
concentrations (0.02–0.13 μM H2O2) can have beneficial effects, such as cell cycle (Sarsour 
et al. 2009) and resolving inflammation (Mittal et al. 2014). Also, moderate levels of ROS have 
been recognised to participate in intracellular signalling pathways (Finkel 2011; Apel & Hirt 
2004; Thannickal & Fanburg 2000). 
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Therefore, ROS act as mediators to change protein structure. 
1.2.2. Oxidative post translation modification 
 
The reactions of proteins with increasing amounts of free radicals lead to protein oxidation. As 
explained in section 1.2.1, the thiol groups are the major target for reversible redox 
modifications. They can be oxidised in various ways: two cysteine residues can form a 
disulphide forming an inter- or intra molecular disulphide bridge. (Forman et al. 2010; Foster 
et al. 2009; Hamnell-Pamment et al. 2005; Hanschmann et al. 2013b). However, the functional 
consequence of protein oxidation depends on the particular modification and the modified 
amino acid. This may further lead to inhibition or activation of a protein involved in signalling 
pathway. Other types of PTMs are oxidative modifications, including carbonylation, 
glutathionylation and disulphide bridge formation. 
Many thiol oxidative PTMs are considered as reversible and control metabolic pathways 
(Ghezzi et al. 2005; Ratnayake et al. 2013). However, a number of studies show the harmful 
effects of irreversible oxidative PTMs as a result of increasing ROS. Also, oxidative modified 
proteins have been linked to a number of diseases and disorders including ageing, 
degenerative disease, atherosclerosis and arthritis (Gianazza et al. 2007; Ryan et al. 2014).  
1.2.3. Other PTMs and role of ROS  
 
Other types of post translational modifications include, phosphorylation, ubiquitination, 
glycosylation, and S-nitrosylation. In some cases, these modification are influenced by the 
increase in ROS. For example increased ROS inhibits phosphorylation of tyrosine (Flescher 
et al. 1994) and PLC ɣ-1 (Cemerski et al. 2002). Additionally, glycosylation of CD45 on the T 
cell membrane is a dynamic process that modifies T-cell survival, activation and immune 
function (Earl & Baum 2008) and ubiquitination of LCK (Jury et al. 2003). ROS can also lead 
to modifications of proteins irreversibly. Reversible cysteine modifications can play in 
important role in cell signalling and function. Transcription factors including NF-κB and AP-1 
undergo reversible thiol oxidative modifications that regulate their functions (Abate et al. 1990; 
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Nishi et al. 2002). Also phosphatases such as PTEN (phosphatase and tensin homologue 
deleted on chromosome 10) and SHP-2 (Scr homology 2 domain-containing phosphatase) 
are inhibited by thiol oxidation (Kwon et al. 2004; Michalek et al. 2007; Kwon et al. 2005). 
 
1.2.4. Cysteine sulphenic acids 
 
Cysteine residues are uncommon in proteins in comparison to other amino acids, but have an 
important functional role (regulatory, catalytic) (Qu et al. 2014). This is mainly due to high 
reactive nature of cysteine hence low abundance of cysteine on protein surface (Marino & 
Gladyshev 2010). The importance of this residue is due to its unique sulphur containing 
functional thiol group (-SH) (Leninger et al. 2005; Chung et al. 2013), and plays a ubiquitous 
role in allowing proteins to react with ROS or RNS giving rise to various oxidative PTM (Rudyk 
& Eaton 2014). The redox sensitivity of the cysteine residue plays a role in ROS mediated 
signalling and function as redox switch as it was originally identified as intermediates during a 
biochemical reaction. (Barford 2004; Chung et al. 2013). However because of the unstable 
nature and difficulty in capturing, the free thiol may be oxidised to form a disulphide (intra or 
inter-molecular) bond with another available –SH (Miseta & Csutora 2000). An intermolecular 
disulphide bond occurs when two cysteine of different proteins react with each other. As the 
role of ROS in intracellular signalling become further clear, the importance and identification 
of oxidised proteins as molecular switch can be looked into. 
Likewise, reduced cysteine maybe oxidised to form cysteine sulphenic acid (RSOH) 
derivatives; intermediates to higher oxidation groups such as sulphinic (RSO2H) and sulphonic 
acid (RSO3H) derivatives which are considered to be irreversible losing protein structure and 
function. The availability of a terminal free thiol also allows formation of other (oxidative PTMs) 
Ox-PTMs including S-nitrosylation (SNO), sulfydration (SSH) and S-glutathionylation (SSG) 
(Chung et al. 2013; Leslie B Poole et al. 2004b; Poole & Nelson 2008; Ryan et al. 2014). 
Sulphenic acid and disulphide bond formation is important to maintain a reducing environment 
31 
 
as they are reversible and form a major component of cell mediated signalling pathways 
(Poole & Nelson 2008). As shown in Fig 3.1 
 
1.2.5. Detection of sulphenic acid modification 
 
Since cysteine sulphenic acid is unstable in several proteins, a number of studies have been 
carried out to monitor and identify proteins and sites that have redox-sensitive cysteines but 
with limited success. However, the selective targeting and designing of a probe to detect a 
desired functional group can be challenging. One of the first probes to be designed was 
presented 1974 by Benitez and Allison as 5, 5-dimethy-1, 3-cyclohexadione (dimedone). 
These studies have used various methods including dimedone, which traps cysteine sulphenic 
acid (Leonard et al. 2009; Reddie et al. 2008; Poole et al. 2007; Poole & Nelson 2008). The 
use of dimedone has been proven to be a useful tool to tag sulphenated proteins and further 
identification of particular protein requires advanced techniques such as mass spectrometry. 
Lately, the dimedone based technique was further optimised and tagged with fluorescence or 
biotinylated tag which allows affinity capture using streptavidin and SDS-PAGE. Biotin linked 
dimedone allows enrichment of proteins forming sulphenic acids using streptavidin HRP.  The 
first biotinylated probe was 3-(2,4-dioxocyclohexyl)propyl-5-((3aR,6S,6aS)-hexahydro-2-oxo-
1H-thieno[3,4-d]imidazole-6-yl)pentanoate (DCP-Bio1) (Poole et al. 2007). This was also used 
in this study to capture proteins undergoing sulphenic acid modification. DCP-Bio1 was first 
used to detect sulphenated proteins in CD8+ T cell lysates and identified several including 
protein tyrosine phosphates (PTPs), SHP1 and SHP2 (Michalek et al. 2007). 
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Figure 1.4. Dimedone reaction with sulphenic acid modification within proteins. Increased 
oxidative stress leads to localized cysteine sulfenic acid formation on proteins which can be 
detected using DCP-Bio1 (biotin linked dimeodone). (Adapted from Klomsiri et al 2014) 
 
So far, direct and indirect approaches have been used to detect sulphenic acid in proteins 
mainly relying on the selective targeting probes (Leonard & Carroll 2011).  
Mass spectrometry has evolved over the years as a critical tool in biological analysis. Since 
protein post translational modifications are recognised as essential for cellular signalling which 
includes the localisation and regulation of proteins, MS provides high throughput and in depth 
investigations of protein oxidative modifications. Studies with dimedone followed by MS have 
identified various sulphenated proteins and proteins which were sensitive to oxidation. 
However, the current MS technology of detecting affinity captured CySOH proteins or peptides 
still requires further optimisation for analysis of complex biological mixtures (Nelson et al. 
2010).  
Indirect approaches to detect sulphenic acid modification include the use of alkylating agents 
such as N-ethylmaleimide (NEM) and iodoacetamide (IAA) which react readily with thiolate 
anions (Ying et al. 2007). This method involves blocking all thiols with NEM then reducing –
SOH with reducing agents such as DTT. The reduced thiols can be labelled with biotin 
maleimide and identified with SDS-PAGE and western blotting and also MS analysis. This is 
described as the ‘biotin switch’ approach (Saurin et al. 2004; Furdui & Poole 2014). However, 
proteins which have no cysteine residue were identified and hence the sensitivity of the 
approach was regarded as inefficient (Saurin et al. 2004).  
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1.3. Redox regulation by antioxidants 
 
Several antioxidant enzymes are mainly involved in the detoxification of ROS such as 
catalase, superoxide dismutases (SOD), peroxiredoxins and also, low molecular weight 
peptides and proteins including GSH and thioredoxins which are present in abundant 
concentrations will react with oxidised thiols and hydrogen peroxide (Holmdahl et al. 2016).  
SOD protects cells from oxidative stress by catalysing the dismutation of superoxide radical 
anions to water and H2O2. Three isoforms of SOD are present within cells; SOD1, SOD2 and 
SOD3. SOD1 is primarily located in the cytoplasm, SOD2 is present in the mitochondria (also 
known as manganese SOD, MnSOD) and SOD3 in the extracellular matrix (Gao et al. 2003). 
SOD2 in the mitochondrion protects from normal by products of cellular processes. This is 
vital as it is the first line of defence against superoxide produced from the mitochondria, also 
regulating apoptosis (Pardo et al. 2006)  
 
Additionally, the importance of SOD2 in T cells was shown in a study with SOD2 conditional 
knockout mouse. Lack of functional SOD2 lead to an increase in superoxide which eventually 
caused apoptosis and inefficient T cell development (Case et al. 2011). This effect was later 
recovered using drugs targeting mitochondrial superoxide. This suggests that lack of 
functional scavenging of mitochondrial superoxide production can lead to abnormal T cell 
functions.  
 
1.3.1. GSH 
 
Glutathione (GSH) is the most abundant tri-peptide antioxidant present in the cells, consisting 
of L-glutamate, L-cysteine and glycine. Under normal physiological conditions, GSH exists 
either free or bound to proteins. The free cysteine acts as a target for ROS hence oxidising 
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the reduced GSH to oxidised GSSG disulphide. This can further be reduced to GSH in the 
presence of glutathione reductase and NADPH (Ghezzi 2011) leading to free reduced 
glutathione. The ratio of GSH/GSSG serves as a marker of oxidative stress and is vital for the 
cells survival and response to oxidative damage (Zitka et al. 2012; Grant & Griffiths 2007; 
Carilho Torrao et al. 2013; Phillips et al. 2010). A decrease in this ratio; reduced to oxidised 
GSH might indicate the presence of oxidative stress at cellular or tissue level (Rahal et al. 
2014). Similarly, around 1-5% of total GSH is present in its oxidised form GSSG suggesting a 
reducing milieu within the cell and so any change in this ratio can indicate the presence of 
oxidative stress (Winyard et al. 2005) The main role of GSH is studied by depletion of reduced 
glutathione using inhibitors such as buthionine sulfoximine (BSO) and has been associated 
with several diseases including rheumatoid arthritis and human immunodeficiency virus (HIV) 
(Ghezzi 2011; Sahaf et al. 2005; Gelderman et al. 2006a; Hildeman et al. 1999). Mammalian 
GSH is essential within cells as it is involved in cell proliferation and differentiation, prevention 
of apoptosis and protection against protein aggregation (Go et al. 2013a; Armstrong et al. 
2002). The synthesis of GSH depends on available cysteine in the cytoplasm and the activity 
of γ-glutamylcysteinyl ligase (GCL) enzyme. Additionally, the presence of free thiol group in 
cysteine provides GSH its antioxidant activity of ROS scavenging. However, the levels of 
cysteine in T cells are low and given the fact that T cells lack oxidised form of cysteine (cystine) 
transporter, they rely on dendritic cells for cysteine availability. In contrast APC have the 
appropriate cystine transporter and its reduced in the cytoplasm hence secreted in the 
extracellular space (Yan & Banerjee 2010). Several studies have described the important role 
of GSH in T cell function by depleting GSH using BSO. For example, depleting GSH using 
BSO impairs T cell function as measured by IL-2 secretion and this was rescued by the 
addition of endogenous IL-2 (Hadzic et al. 2005).   
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1.3.2. Trx1 
 
The Trx1 system is an essential system for protection against oxidative stress and plays a 
critical role in redox regulation. It consists of NADPH as a source of electrons, an enzyme 
thioredoxin reductase (TrxR), which catalyses the reduction of oxidised Trx1 (Trx1-S-S) to 
reduced Trx1-SH (Figure 4.2). Trx1, a 12kDa protein, has a highly conserved active site motif 
with two cysteine residues at position 32 and 35, allowing transfer of electrons to the substrate 
protein (Lee et al. 2013; Arnér & Holmgren 2000). It is primarily found in the cytosol but also 
translocated in the nucleus and on the cell surface. The expression of Trx1 can be upregulated 
in the presence of variety of stress stimuli including oxidative stress, hypoxia, 
lipopolysaccharide (LPS) and more.  In addition to its main function as redox regulating 
enzyme (reducing disulphide bonds and sulphenic acid), Trx1 also acts as an anti-
inflammatory agent and involved in apoptosis. It modulates immune response via regulating 
chemokine and cytokine activity and lipopolysaccharide (LPS) induced oxidative damage  
(Hanschmann et al. 2013a; Carilho Torrao et al. 2013; Nordberg & Arnér 2001; Nakamura et 
al. 2005). Trx1 may also be secreted via a leaderless secretary pathway exerting effects on 
adjacent T and B cells. Secretion of Trx1 is increased under oxidative stress conditions and 
inflammation (Riccardo Bertini et al. 1999; Mougiakakos et al. 2010b; Rubartelli et al. 1992). 
Hence, extracellular Trx1 may influence ligands and receptors in the surface such as IL-4 and 
CD4 (Moolla et al. 2016a; Curbo et al. 2009). Due to its various functions, Trx1 has many 
interaction partners such as apoptosis signalling kinase 1 (ASK1) and actin, where Trx1 bound 
ASK1 regulates apoptosis and preserving Trx1 degradation (Lillig & Holmgren 2007a; 
Zschauer et al. 2011). In the nucleus, it plays a role in modulating the DNA binding activity of 
transcription factors such as activator protein 1 (AP1), p53 and nuclear factor-κB (NF-κB) 
(Hirota et al. 1997; Kabe et al. 2005). Thioredoxin 2 (Trx2) is another isoform of Trx which is 
described in the literature. Trx2 is a mitochondrial redox protein sharing the common active 
site and plays an important role in embryonic development by allowing resistance to ROS-
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induced apoptosis (Nonn et al., 2003). Similar to Trx1, Trx2 knockout is embryonic lethal and 
increases TNF-α expression which leads to cell death (Zhang et al., 2004).  
Post translational modification to the free cysteine on Trx1 may influence its function and 
localisation within the cell. Glutathionylation of Trx1 leads to reduction in the enzymatic activity 
of Trx1 under oxidative stress but it is shown to regain its activity again by means of auto 
activation (Haendeler, 2006).  
Trx1 has been linked to range of diseases in which redox imbalance has been associated, 
including HIV, cardiovascular disease, neurodegenerative disease and cancer (Collet & 
Messens 2010).  
 
1.3.3. Prx 
 
Peroxiredoxins (Prxs) are a group of thiol exchange proteins which are mainly involved in 
breaking down hydrogen peroxide, peroxynitrite and organic hydroperoxides. They are also 
recognised to be the prominent members of the antioxidant defence system (Rhee & Woo 
2011; Poynton & Hampton 2014). They are susceptible to oxidation and act as redox sensors 
regulating cell signalling pathways (Fourquet et al. 2008). Mammalian Prxs are categorised 
into six different isoforms; Prx1, and 2 which are located primarily in the cytosol, Prx3 and 5 
in the mitochondria and Prx4 in the ER. 1-cys Prx6 which is located in the cytosol, lysosomes 
and vesicles (Sorokina et al. 2011; Sorokina et al. 2009). Prx1 and 2 are also associated with 
the membrane of lymphocytes (Szabó-Taylor et al. 2012a; Hanschmann et al. 2013b). Their 
biochemical function is categorised based on the active cysteine that is oxidised to sulphenic 
acid during detoxification of H2O2 and peroxynitrite. In a typical 2-Cys Prxs the sulphenic acid 
may further react with adjacent cysteine to form a disulphide whereas in 1Cys Prx, –SOH is 
reduced by low molecular weight thiol such as GSH (Poynton & Hampton 2014; Peskin et al. 
2007). 2-Cys Prx can also form decamers and the conformation regulates molecular function 
(Barranco-Medina et al. 2009; Turner et al. 2013)  The active cysteine which is sulphenated 
can also react further with H2O2 to form sulphinic acid. This has been shown to be reduced by 
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sulfiredoxin (Srx) specific to 2-Cys Prxs (Woo et al. 2005). However, this reaction is slow 
hence oxidised Prx can exist in the cells after exposure (Stacey et al. 2012). The maintenance 
of reduced Prx pool is essential as 90% of H2O2 produced in the mitochondria reacts with Prx3 
(Cox et al. 2010). Prx oxidation has been of keen interest and hence recognised as redox 
sensitive proteins and markers of oxidative stress. Prx2 was oxidised in Jurkat cells when 
treated with 20µM H2O2 (Baty et al. 2005). Therefore, Prxs are major scavengers of signalling 
ROS such as H2O2, playing a critical role in T cell redox signalling. Kwon et al, showed that 
overexpression of Prx2 increased activation of MAPK and ERK kinase pathway upon TCR 
stimulation and crosslinking by mitogens (Kwon et al. 2003). 
Posttranslational modification influences the catalytic activity of Prx and susceptibility to 
hyperoxidation. These modification include glutathionylation, phosphorylation and s-
nitrosylation, all are said to influence either the structure or the catalytic activity of Prxs (Park 
et al. 2011; Engelman et al. 2013; Chang et al. 2002) 
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Figure 1.5. Peroxiredoxin enzymatic cycle. A and B in the presence of H2O2, cysteine oxidation 
leads to cysteine sulphenic acid which reacts with adjacent cysteine to form disluphine bind.  
The peroxidatic cycle ends with the reduction of the disulfide bond by thioredoxin and 
regeneration of reduced enzyme. (A) In typical 2-Cys peroxiredoxins (Prxs), this disulfide 
forms between two monomers, whereas (B) in atypical 2-Cys Prxs and CysG- Pxs, it is 
intramolecular. (Adapted from Forquet et al. 2008)  
 
1.4. Autoimmunity and RA 
 
The main function of the immune system is to initiate an immune response to harmful stimuli. 
This response needs to be discriminated between self and foreign antigens. The immune 
system is developed to prevent an inflammatory response against host structures or cells, 
(self-antigens) commonly referred as self-tolerance (Alberts et al. 2002). This mechanism is 
developed during T cell selection, whereby T cells which recognise MHC antigens too strongly 
and self-reactive are eliminated (Lindstrom & Robinson 2010). However, a proportion of T 
cells may be released from the thymus into the blood stream thus reacting to self-antigens 
B 
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leading to an autoimmune response and Tregs play a critical role in eliminating self-reactive 
T cells (Wing & Sakaguchi 2010).  
Autoimmune disease arises when immune cells are reacting to antigen expressed in tissues 
and cells resulting in an autoimmune response. These diseases include; rheumatoid arthritis 
(RA), multiple sclerosis (MS), systemic lupus erythematosus (SLE) and psoriasis. 
RA is characterised by accumulation of inflammatory cells in the synovial membrane, these 
include lymphocytes (T and B cells), neutrophils and monocytes. The disease onset is 
characterised by swelling leading to inflammation, pain and lack of function in the joints (Scott 
et al. 2010; Bartold et al. 2010). Patients with RA show anti-citrullinated protein antibodies 
(ACPA) which are autoantibodies directed against citrullinated peptides, and rheumatoid 
factors (RF), which correlate with disease severity (Masi et al. 1976; De Rycke et al. 2004). 
RFs include antibodies against the Fc region of IgG. In most cases patients with RA show RF 
in association with ACPA, however, ACPA are more specific and used as a diagnostic marker 
such that it can even be found before typical onset of clinical symptoms (Van Der Linden et 
al. 2009; Rantapää-Dahlqvist et al. 2003; van Venrooij et al. 2002). 
RA affects approximately 0.5-1% of the world population (Silman & Pearson 2002; Smolen et 
al. 2016). The inflammatory response is characterised by the activation of T cells which also 
activates monocytes, macrophages and synovial-like fibroblasts to secrete pro-inflammatory 
cytokines including IL-6, IL-1β and TNF-α. This is also associated with infiltration of 
inflammatory cells producing ROS and RNS ultimately leading to bone and tissue destruction 
(Bennett & Griffiths 2013). The underlying cause of RA is not known yet but it is believed that 
environmental and genetic factors are involved in the pathogenesis of the disease (Symmons 
et al. 1997; MacGregor et al. 2000), proposing that genetic factors make up to 60% 
contribution. Since RA is an aggressive chronic inflammatory disease, early diagnosis and 
effective treatment is essential. However, there is no cure for the disease yet but the treatment 
available may relieve the symptoms. these include Disease Modifying Anti-Rheumatic Drugs 
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(DMARDs) which are targeted toward specific abnormalities of the immune system such as 
TNF-α blockers infliximab, adulimumab (Kahlenberg & Fox 2011). 
 
1.4.1. The immunogenetics of RA 
 
Since RA is a complex disease, the genetic element is also complex thus depending on 
several genes and interactions. The first gene associated with RA was human leukocyte 
antigen (HLA), this was found in 1976 (Stastny 1976). The molecular diversity of HLA-DR1 
still remains dominant genetic factor which contributes to RA (Olsson et al. 2016). HLA-
DRB104 has been consistently found to confer increased risk of RA development and 
susceptibility (Gregersen et al. 1986; Weyand et al. 1992). This leads to approximately 30% 
of RA risk due to HLA genes (Deighton et al. 1989) making HLA the critical genetic factor in 
RA. However, some non-HLA genes have also been suggested to be associate with RA, such 
as protein tyrosine phosphatase non-receptor 22 (Gregersen 2005). PTPN22 is critical in the 
regulation of immune response and cell signalling. A single nucleotide polymorphisms in 
PTPN22 (Begovich et al. 2004), leads to weaker TCR signalling hence failure to delete self-
reactive T cells in the thymus and decreased Treg function (Vang et al. 2005). In addition, 
cytotoxic T lymphocyte associated antigen-4 (CTLA-4), peptidyl arginine deiminase, type IV 
(PAD4) genes antihave been associated with RA (Orozco et al. 2006; Suzuki et al. 2003; 
Foulquier et al. 2007). 
 
1.4.2. Models of arthritis  
 
Various animal models have been developed to better understand the disease aetiology and 
pathways involved. The risk factors can be controlled including genetic manipulation and 
environmental conditions can be maintained. However, the limitation of animal models may 
be that the factor that initiates the disease in humans is unknown whereas in animals there is 
a detailed cause of the disease which is more or less reproducible. These include; pristane 
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induced arthritis, arthritis induced by bacteria, collagen induced arthritis and collagen antibody 
induced arthritis.                      
1.4.2.1. Pristane induced Arthritis (PIA) 
 
Pristane induced arthritis includes the use of mineral oil pristine leading to severe arthritis in 
dark agouti (DA) rats after two weeks (Vingsbo et al. 1996). This model provides high 
resemblance to human RA as it shows symmetrical disease development and serum RF 
(Wernhoff et al. 2003). Despite, the absence of antigens in this model, PIA was shown to be 
T cell driven and MHC II dependent (Holmdahl et al. 1992; Holmberg et al. 2006). However, 
this was only observed in the chronic phase of the disease. PIA is specific to rats and not 
inducible in species other than rats, though some studies show PIA in mice (Hopkins et al. 
1984), but the disease severity and phenotype is different.       
1.4.2.2. Collagen induced arthritis (CIA) 
 
This model is normally induced in rats and mice; mice CIA is a widely used model for CIA. It 
involves immunisation with type II collagen, a major collagen found in cartilage. Together with 
the adjuvant, clinical symptoms of arthritis develop after 2-3 weeks of immunisation. The 
disease is similar to PIA and human RA, however it can be easily be differentiated as CIA 
involves an immune response towards a known antigen as opposed to PIA (Holmdahl et al. 
1992). CIA is dependent on both T and B cells together with pathogenic antibodies which 
attacks the joints (Corthay 1999; Svensson et al. 1998).   In vivo activation of T cells require 
glycosylated CII molecules to be presented as peptides by APC. The particular APC is not 
identified yet but is likely to be macrophages compared to DCs as the latter present collagen 
antigen poorly (Holmdahl et al. 2002). The immune synapse formed by the interaction of MHC 
II and T cells doesn’t not provide sufficient information on the pathogenesis of CIA, although 
provides a better scope for further analysis.                              
1.4.2.3. Collagen antibody induced arthritis (CAIA) 
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CIA is associated with the autoantibody production against type II collagen, ACPA and IgG. 
The anti-type II collagen is detectable a few weeks after immunisation and hence if the serum 
from a CIA immunised mouse is transferred to non-immunised mice, they may develop arthritis 
(Stuart & Dixon 1983; Holmdahl et al. 1990). This demonstrates the basic mechanism of CAIA, 
that disease transfer is achieved as the mice are injected with CII antibodies. Following this 
model, various cocktails have been developed allowing identification of autoantibody epitopes 
and the role of humoral autoimmunity in RA (Asquith et al. 2009). The clinical symptoms of 
CAIA is similar to CIA, but the onset of CAIA is immediate within 1-2 days of injection. The 
elimination of this model based on adaptive immunity is that it is one of few models or arthritis 
that is not dependent on T and B cells, however, CII reactive T cells have been shown to 
increase the severity (Nandakumar et al. 2004). The innate immune system is involved after 
collagen antibody binding to cartilage recruits neutrophils and activates macrophages 
(Nandakumar et al. 2003b).                    
1.4.2.4. Arthritis induced by bacteria 
 
A number of bacteria are known to cause arthritis in animal models suggesting that infection 
may play a role in the induction of an autoimmune disease. One example of this may be Lyme 
arthritis whereby bacteria such as Borrelia burgdorferi can accumulate in joints leading to 
swelling and arthritis. This form of arthritis show a similar clinical symptoms to humans and 
essentially the bacteria is also found in synovial fluid of humans with RA (Nocton et al. 1994). 
Additionally, mice infected with this bacteria develop RA (Masuzawa et al. 1992). Furthermore, 
Staphylococcus aureus is the main cause of septic arthritis which can persist in the joints for 
a long time. It also develops in rats and mice when injected with the bacteria (Bremell 1999; 
Bremell et al. 1991; Bremell et al. 1994). Other structures from the bacteria including cell wall, 
DNA and proteins can also lead to arthritis in animals. For example, mycobacteria arthritis in 
rats, whereby rats develop arthritis when induced with Mycobacterium tuberculosis in specified 
adjuvant (Pearson 1956). This further lead to the use of complete Freund adjuvants (CFA) in 
current arthritis models, which consists of mineral oils, emulsifier and bacteria (Freund 1947). 
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The use of autoantigens together with CFA completely diminished tolerance in rats resulting 
in an autoimmune disease (Lipton & Freund 1953). 
1.4.2.5. Other models of RA 
 
In addition to inducible models of arthritis, there are other spontaneous models of RA such as 
transgenic genetic modification technology which develop arthritis. These include the 
overexpression of TNF-α or IL-1 (Keffer et al. 1991; Niki et al. 2001). Genetic modification in 
TNF-α leads to the development of chronic inflammatory polyarthritis and mice treated with 
antibodies against TNF-α showed prevention against the disease. This is useful in terms of 
recognising the pathology of the effector cytokines in the progression of the disease and the 
inflammation involved in cartilage and bone destruction. Furthermore, a single gene mutation 
arthritis models such as the SKG mouse, single mutation is found e.g. in ZAP-70 which is a 
signal transduction molecule in T cells shown in Fig 1.3 (Sakaguchi et al. 2003; Chan et al. 
1992). The SKG model represents RA by showing high levels of RF and anti-CII 
autoantibodies resembling clinical RA (Sakaguchi et al. 2003). One possibility of the 
pathological mechanism leading to RA due to mutation in ZAP70 can be the alteration in 
thymic selection. However, despite the presence of autoreactive T cells in the periphery, 
arthritis development is mainly dependent on foreign infectious bacteria (Yoshitomi et al. 
2005).  
 
1.4.3. ROS in inflammation and RA 
 
A vast amount of evidence suggests the association of oxidative stress in RA. The role of ROS 
in chronic inflammation is presently changing from being toxic agents, which causes damage, 
to being considered as a crucial part of signalling pathways and therefore as a regulators. This 
was shown in mice, where neutrophil cytosolic factor 1 (Ncf1) or p47phox mutation leading to 
decreased NADPH oxidase 2 (NOX2) complex-derived ROS.  Ncf1-/- mice show severe 
symptoms of arthritis compared to WT mice and increased susceptibility to the disease in 
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pristine induced arthritis in rats (K. A. Gelderman et al. 2006; Hultqvist & Holmdahl 2005).  The 
levels of oxidative stress and cells unable to undergo apoptosis correlates strongly with 
hyporesponsiveness of T cells in the synovial joints. T cells from the synovial fluid have been 
shown to produce high levels of ROS compared to T cells in the periphery (S I Gringhuis et al. 
2000). However, the levels of ROS in rheumatoid joints is controversial as (Pantano et al. 
2006) have shown that cytosolic levels of ROS were inversely proportional to disease severity. 
Also in the presence or absence of mitogenic stimuli, T cells from rheumatic patients do not 
show an increase in ROS levels compared to healthy patients (Phillips et al. 2010).  
T cells in the joints are hyper-activated but show poor TCR response leading to hypo-
responsiveness (Maurice et al. 1997). This may be due to the PTNP22 gene associated with 
RA, which has a cysteine residue in the protein that may be prone to oxidation. Furthermore, 
other proteins involved in TCR signalling have also been suggested in the development of RA. 
This include LAT protein, which is phosphorylated by the phosphorylation of ZAP70. Oxidation 
of LAT may lead to dissociation from the membrane and eventually poor TCR mediated 
signalling  (S I Gringhuis et al. 2000). Furthermore, ROS may also have a direct effect on the 
assembly of T cell activation complex in membrane localisation (Lu et al. 2007) as a result, 
regulation by the redox status of the intracellular thiol pool on TCR signalling (Hehner et al. 
2000). Several reviews in the literature have summarised activation induced oxidative 
modification which has an influence on receptor-coupled signalling pathway in T cells (Simeoni 
& Bogeski 2015a), further linking  increased ROS, loss of GSH, protein oxidation and NF-κB 
activation. Cysteine residues as described earlier, are the most conserved and specific to 
oxidative post translational modifications. H2O2 first oxidises cysteine thiols to form sulphenic 
acid, which is reversed by Trx1 and Grx (Hanschmann et al. 2013b) 
Moreover, formation of sulphenic acid may lead to other post-translational modifications, for 
example; disulphide formation, glutathionylation and nitrosylation which may impair T cell 
function by inactivation of proteins. Several proteins have been shown to be regulated by 
sulphenation; these include kinases, phosphatases, proteases, ion channels, adaptor proteins 
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and cytoskeletal components. (Nathan & Cunningham-Bussel 2013; Holmström & Finkel 
2014; Leslie B Poole et al. 2004a; Dickinson & Chang 2011; Ratnayake et al. 2013). 
Furthermore, depletion of GSH leads to cellular localisation of LAT, which is phosphorylated 
by tyrosine kinases altering its conformation (Gringhuis et al. 2000; Gelderman et al. 2006b). 
This further supports oxidation of an essential cysteine residue may result in loss of protein 
function and TCR signalling (Griffiths 2004; Cemerski et al. 2003).  
1.5. Hypothesis and aims 
 
An increase in ROS results protein modifications including protein sulphenic acid formation, 
where -SOH has been considered to play an important role in protein function under both 
normal physiological and stressful conditions. T cell activation is associated with reversible 
cysteine sulphenic acid formation which is an important mechanism by which T cells 
modulates signalling and proliferation (Michalek et al. 2007). Furthermore, several proteins 
have been identified to undergo sulphenic acid modification following TCR stimulation 
including actin and protein tyrosine phosphatases and that sulphenic acid was essential for 
phosphorylation, calcium flux and proliferation of CD4+ and CD8+ T cells. Previous studies 
show that increased Trx1 in plasma from RA patients together with higher number of IL-17 
secreting cells expressing Prx2 on the surface. The prominent role of Trx1 and Prx2 on the 
surface of these T cells is unknown.  Therefore, redox alteration and oxidative PTMs may be 
common biomarkers associated with increased risk of autoimmune diseases. This raises an 
interesting question regarding the role ROS may be playing in RA disease activity and 
severity. Overall, this suggests that loss of intracellular ROS in RA disease may promote T 
cell mediated autoimmunity. 
Taking the previous evidence into consideration, this thesis aimed to identfy the localisation 
of membrane-bound reducing proteins and redox markers during T cell activation. The work 
extended to a mouse model of RA. Also, to identify possible membrane proteins which 
undergo sulphenic acid modification under stress condition and activation of T cells. 
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To address this question, the main objectives were: 
- To optimise and develop a method to capture sulphenic acid modification in Jurkat T 
cells using commercially available probe DCP-Bio1. 
- To mimic oxidative stress in T cells using buthionine sulfoximine and Auranofin and 
analyse the distribution of Trx1 and Prx2 and intracellular GSH levels. 
- Characterise the effects of T cell activation on Trx/Prx distribution in the presence of 
H2O2 and to identify possible binding targets as proteins sulphenated on the membrane 
of activated CD4+ T cells 
- To understand the surface redox state and redoxins on T cells in CIA mouse model 
and how ROS affect the response to TCR stimulation. 
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Chapter 2. Materials and Methods  
 
2.1. Materials 
 
All chemicals were purchased from Sigma (Poole, UK) or Fisher Scientific (Loughborough, 
UK) unless stated otherwise. Cell culture and general plastic ware were obtained from Thermo 
Fisher Scientific (Loughborough, UK). Needles and syringes for blood collection were 
purchased from BD (Becton, Dickinson and company, Oxford, UK). VACCUETE® 
ethylenediaminetetraacetic acid (EDTA) and VACCUETE® heparin tubes were purchased 
from Griener Bio-One Ltd. (Stonehouse, UK).  Recombinant Trx1 was purchased from R&D 
(UK).  
2.2 Methods 
 
2.2.1. Cell culture and reagents  
 
Jurkat T cells, derived from a 14 year boy with T cell acute lymphoblast leukaemia, were 
purchased from Sigma Aldrich (UK) proved by European Collection of Authenticated Cell 
Cultures (ECACC). They were cultured in Rosewell Park Memorial Institute (RPMI) 1640 with 
L-glutamine, 10% foetal bovine serum (FBS), penicillin (1000 Uml-1) and streptomycin (10,000 
µg/ml-1) purchased from Gibco Life Technologies (Paisley, UK). 
Jurkat T cells were passaged until reached ~ 80% confluency. On the day of treatment, the 
cells were washed with complete RPMI and counted using a haemocytometer and plated in a 
12 well plate at an assay-dependent concentration.  
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2.2.2. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)  
 
2.2.2.1. Reagents  
 
Reagent Description  
Buffer 1 for the resolving gel 1.5M Tris base and 0.4% w/v SDS at pH 8.4 
Buffer 2 for the stacking gel 1.5M Tris base, 0.4% w/v SDS at pH 6.8 
Ammonium persulphate (APS) 10%w/v 1g APS in 10ml of distilled water  
Running Buffer  3g Tris base, 14.4g Glycine and 1g SDS in 
1L of distilled water 
Transfer buffer 4.5g of Tris base, 21.6g glycine, 300ml 
methanol in 1200ml of distilled water 
Tris buffered saline buffer (TTBS) 12g NaCl, 6g Tris base in 1L distilled water 
at pH 7.4 containing 0.05%v/v Tween 
TEMED N,N,N’,N’- tetramethylethyleneamine 
Acrylamide  Acrylamide/bis acrylamide 30% solution 
Non-reducing sample buffer  Tris (1M, pH 6.8), glycerol (50% v/v), SDS 
(10% w/v), bromophenol blue (0.5% w/v) 
Blocking Buffer  3% w/v semi-skimmed milk in TTBS 
Ponceau Red stain 0.1 % (w/v) in 5% acetic acid 
Coomassie brilliant blue (CBB) G250 0.1% w/v CBB G250, 10% v/v acetic acid, 
50% v/v Methanol 
Destain Solution 40% v/v Methanol, 10% v/v, acetic acid and 
50% v/v distilled water  
Table 2.1. Solutions for SDS-PAGE and Western blotting 
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Reagent  10% resolving  15% resolving 3% stacking 
Distilled water  5 ml 3ml 4.87ml 
Buffer 1 3 ml 3ml  
Buffer 2   1.87ml 
Acrylamide 4ml 6ml 0.75ml 
TEMED 100µl 100µl 100 µl 
APS 10µl 10 µl 10 µl 
Table 2.2. Reagents used for composition of SDS-PAGE resolving and stacking gel. 
 
2.2.2.2. SDS gel electrophoresis and western blot 
 
The protein samples were separated using polyacrylamide gel electrophoresis. The glass 
plates were assembled according to the manufacturer’s instructions and resolving and 
stacking gels were prepared (BioRad, UK). Methanol (Fisher, UK) was overlayed on the 
surface of the gel to protect from air and the gels were allowed to set for 15min. After the 
resolving gel was set, methanol was drained and 3% stacking gel was pipetted in. A comb 
was then inserted into the stacking gel and it was left to set for 15min. The protein samples 
were prepared by mixing 1:1 with Laemmli sample buffer (Sigma, UK) for reducing conditions 
and 1:2 with 2X non-reducing buffer for non-reducing conditions and heated at 95°C in a heat 
block for 10min. The gel apparatus was set up and filled with running buffer (followed by 
loading of the samples and markers (Kaleidoscope, Precision plus protein, Bio Rad, UK). The 
gel was run at 115V for 1hour 45min. 
The gel was then transferred to 0.2µm polyvinylidene difluoride membrane (PVDF) membrane 
(GE Healthcare, Amersham, UK) that was soaked in 100% methanol for 5min and transfer 
buffer prior to use. The transfer was run at 240mA for 1h 45min and the membrane was 
blocked overnight at 4°C with 3%w/v BSA in Tris buffered saline (TTBS). Primary antibody for 
Trx1 expression was mouse monoclonal [3A1] anti-Trx1 (Abcam, 1:2000) incubated for 2hours 
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on the rocker at room temperature and the membrane was washed 6 times every 5min. The 
secondary antibody used was goat anti-mouse polyclonal IgG Fc specific peroxidase (A1068, 
Sigma) 1:10,000 in TBST (0.1% w/v BSA) incubated for 2h at room temperature and washed 
6 times every 5min and developed using ECL technique (GE Healthcare, Amersham, UK). A 
1:1 mixture of reagents from the ECL kit was added to the membrane and left for 3min in 
absence of light. The membrane was developed using the G-Box chemi (Syngene, Geneflow, 
UK). The loading control antibodies including rabbit polyclonal anti-CD3 (ab16044, Abcam), 
rabbit polyclonal to NF-kB p65 (ab 16502, Abcam) and anti-β-actin produced in mouse 
(A5316, Sigma). 
2.2.2.3. Coomassie staining  
 
SDS-Page gels were stained with Coommassie blue G250 (0.1%w/v) for 1h on the shaker. 
Gels were then destained overnight using destaining solution with frequent change of the 
destain solution. Once the gel background was clear, the gels were analysed by G:BOX Chemi 
HR 1.4 imaging system and GeneTools 4.03 image analysis software (Syngene, Cambridge, 
UK). 
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2.2.3. Protein quantification by bicinchoninic assay (BCA) 
 
The BCA assay was performed to determine the total protein concentration in the cell lysates 
or the plasma for further experiments. Unknown protein concentration was determined by 
adding 200µl CuSO4 and BCA solution (1:50- v/v) to 10µl of either the unknown sample or 
BSA standards ranging from 0-1mg/ml.  
Protein concentration 
(mg/ml) 
BSA (µl) Water (µl) Final volume (µl) 
0.0 0 10 10 
0.2 2 8 10 
0.4 4 6 10 
0.6 6 4 10 
0.8 8 2 10 
1.0 10 0 10 
Table 2.3. Reagents volume required to prepare the standard curve to determine protein 
concentrations. 
 
A standard curve was generated plating BSA standards in triplicates on a 96 well plate with 
final volume of 10µl. The 96 well plate was incubated at 37°C for 30min and the absorbance 
was measured at 570nm (BioTek Instruments Inc., Swindon, UK) 
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2.2.4. Membrane protein extraction  
 
2.2.4.1. Reagents 
 
Mem-PER Membrane protein extraction kit was obtained from Pierce (Thermo-Fisher, UK) 
2.2.4.2. Protocol 
 
The Mem-PER kit uses a mild detergent which allows the solubility of membrane proteins. 
Jurkat T cells (5x106) or CD4 T cells (1x106) were harvested and protein fractions were isolated 
using the MEM-PR membrane protein isolation kit (Thermo Fisher). Briefly, cells were washed 
twice in cell wash buffer included in the kit. This was followed by centrifugation in 750µl 
permeabilisation buffer (Thermo Fisher) with protease inhibitor cocktail (1:100) (P8340, 
Sigma, UK) at 16,000g for 15min. Cytosolic protein fractions were collected and the pellet was 
re-suspended in 500µl solubilisation buffer (Thermo Fisher) and incubated for 1hour at 4°C 
with constant mixing. Following the incubation, the extracts was centrifuged at 16,000g for 
15min at 4°C and the supernatant containing membrane proteins was collected and stored in 
-20°C for further experiments.  
Membrane protein fractions were dialysed using Slide-A-Lyzer dialysis cassettes (0.5ml, 
Thermo scientific). Briefly, 500µl of the protein sample was inserted into the cassette using a 
syringe and the cassette was dialysed in a dialysis buffer (75mM aminocaproic acid, 2mM Bis-
Tris), 200 times the volume of the protein sample. Firstly, dialysis was or 2h at 4°C and then 
the dialysis buffer was changed, followed by dialysis for another 2h. The dialysis buffer was 
changed again and dialysed overnight at 4°C. Protein samples were collected from the 
cassette the following day and protein concentration was measured again using BCA assay.   
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2.2.4.3. Membrane protein validation 
 
To validate the efficacy of membrane protein extraction, 5x106 Jurkat T cells were collected 
and cytosolic proteins (CP) and membrane proteins (MP) fraction isolated according to the 
protocol described above. MP were dialysed and analysed by western blot with antibodies 
against CD3 and NF-kB p65 (Abcam, UK). Briefly 20µg of CP or MP were separated on 15% 
gel and transferred to a PVDF membrane. The membrane was blocked with 3% BSA in TTBS 
at 4°C and probed for rabbit polyclonal IgG anti-CD3 (ab16044, Abcam, UK) and Rabbit 
polyclonal IgG anti-NF-kB p65 (ab7970, Abcam, UK) (1:1000) in TTBS 0.02% BSA w/v for 2h 
at RT. Followed by an incubation with secondary goat anti-rabbit (1:10000) for 2h at RT.  
 
2.2.5. Protein identification by mass spectrometry  
 
2.2.5.1. Reagents  
 
Acetic acid, Acetonitrile (ACN) and methanol were purchased from Fisher Scientific (Thermo 
Fisher Scientific). Trypsin gold was purchased from Promega, UK.  
 
2.2.5.2. Protocol  
 
Proteins separated on gels were briefly stained with Coomassie brilliant blue (CBB) G250 as 
previously described in section 2.2.2 and either the selected protein bands or sections of lanes 
were excised and destaining with (10% v/v acetic acid, 40% v/v methanol and 50% v/v distilled 
water). Briefly, the gel pieces were washed in 50% v/v ACN 50mM ammonium bicarbonate 
(ABC) and incubated at 37°C on a thermoshaker (Thermo Fisher Scientific, UK) at 550rpm 
until the pieces were clear. Washed gel pieces were resuspended in 150μl of 100% v/v ACN 
and incubated for 10min at RT. The samples were dried until the ACN was removed. The gel 
pieces were reduced with the reducing solution (10mM DTT in 50mM ABC (Ammonium 
bicarbonate)) at 56°C with shaking for 30-45min and allowed to cool down at RT. 
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Subsequently, the samples were alkylated with iodoacetamide (IAA) (55mM in 50mM ABC) 
and incubated at RT in the dark for 30min. The excess solution was discarded and the gel 
pieces were resuspended in 200µl 100% v/v ACN. Reduced and alkylated gel pieces were 
enzymatically digested with trypsin solution (25x) (Trypsin gold, sequencing grade, Promega, 
UK) solubilised in digestion solution (3mM ABC) overnight at 37°C. The peptides were 
collected using 50uL ACN and sonicated for 15min (this step was repeated twice). The 
supernatants were dried in a centrifugal concentrator for 1-2h and resuspended in 15µL of 3% 
v/v acetonitrile in 0.1% v/v formic acid (Fisher, UK) in distilled water.  
2.2.5.3. Protocol: Mass spectrometry 
 
Extracted dried peptides dissolved in ACN/formic acid were transferred into a borosilicate vial 
and placed into the automated sampler at 10°C (Dionex 3000, Thermoscientific, UK). 
Approximately half of the sample was injected onto the trap column (PepMapTM, C18, 5 µm, 
100 Å, 300 µm x 1 mm, ThermoScientific, UK). Trapped peptides were washed with 2% 
acetonitrile in aqueous 0.1 % formic acid for 3minutes at a flow rate of 30μl/min. Peptides were 
separated on the analytical column (AcclaimTM, PepMapTM C18, 3 µm, 100 Å, 75 µm x 150 
mm, ThermoScientific, UK). Electrospray was formed by spraying the nanoLC eluate at 2500 
V using the PicoTipTM emitter (New Objective, Germany). Data was obtained on the 5600 
TripleTof (AB Sciex, UK) Mass Spectrometer in information dependent mode.  
2.2.5.4. Data analysis 
 
The obtained files were subjected to Mascot Daemon search (v2.5) against the Swissprot 
database to identify the peptides with the following parameters: mass tolerance of 0.1 Da for 
MS and 0.6 Da for MS/MS spectra, maximum of 2 trypsin missed cleavages, human 
taxonomy, and variable modifications of methionine oxidation and cysteine 
carbamidomethylation. 
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2.2.6. Cell viability  
 
2.2.6.1. Determination of cell viability using trypan blue exclusion 
 
Trypan blue is a stain which dyes the cells with damaged cell membranes. Cells were collected 
and mixed with equal volumes of trypan blue solution. This was loaded onto a 
haemocytometer for the determination of viable and non-viable cells.  
Viability %= number of viable cells/total number of cells (live and dead) x 100 
 
2.2.6.2. Cell viability using Annexin V by flow cytometry 
 
Briefly, 1x105 cells were washed in PBS/BSA (1% w/v) and resuspended in 500µl binding 
buffer (150mM NaCl, 10mM HEPES, 2.5mM CaCl2) and incubated with 5µl of anti-human 
Annexin V FITC (EBioscience, Hatfield, UK) for 15min and analysed by flow cytometry 
acquiring 10,000events.  
 
2.2.7. Primary CD4+ T cell activation  
 
2.2.7.1. Reagents 
 
Lymphoprep was purchased from Axis-Shield (Dundee, Scotland). Bovine serum albumin 
(BSA) was purchased from Thermo Fisher (Loughborough, UK). Untouched CD4+ T cell 
isolation kit was from Invitrogen. Anti-CD3 and anti-CD28 antibodies were purchased from 
ebioscience (Hatfield, UK) 
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2.2.7.2. Volunteers 
 
Blood was collected from healthy donors between 25-35 years old (n=5). Ethical approval was 
granted by Aston University Ethics Committee (Ref: 802) 
Fresh blood (20ml) was collected from healthy consenting volunteers by venepuncture into 
VACCUETE® EDTA tubes. Briefly, 20ml of fresh blood was diluted with PBS with (0.1%w/v 
BSA) at 1:2.5 and layered over 11ml of Lymphoprep. 25ml of the layered gradient was 
centrifuged at 160g for 15min without deceleration followed by further centrifugation at 350g 
for 20min after discarding the top layer of plasma to wash off the platelets. After centrifugation, 
the layer between the plasma and the Lymphoprep containing the mononuclear cells, was 
collected and washed twice with PBS (0.1% w/v BSA) to remove excess Lymphoprep. The 
cells were counted and re-suspended in complete RPMI 1640. 
 
2.2.7.3. CD4+ T cell Isolation by negative isolation and activation 
 
Isolated PBMCs were re-suspended in 100µl isolation buffer (Ca2+Mg2+ free PBS with 0.1% 
w/v BSA and 2mM EDTA) and 20µl antibody mix (Dynabeads untouched human CD4+ T cell 
kit, Invitrogen) was added then incubated for 30min at 4°C. The cells were washed with 
isolation buffer (2ml) and centrifuged at 350g for 8min at 4°C. Meanwhile 100µl of MyOne 
Dynabeads (Dyanbeads untouched human CD4+ T cells, Invitrogen) was washed in 1ml of 
isolation buffer. The supernatant was discarded after placing the beads in a magnet. The 
beads were re-suspended in 100µl isolation buffer and added to the cells and incubated for 
30min at room temperature with gentle mixing and rotation. 2ml of isolation buffer was added 
and the bead bound cells was mixed by pipetting up and down roughly 10 times. After placing 
the tube in the magnet for 2min the supernatant containing untouched human CD4+ T cells 
were isolated. This step was repeated and combined with previously isolated cells. Finally the 
cells were counted on the haemocytometer prior to further experiments.   
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Isolated CD4+ T cells were resuspended in RPMI 10% FBS and 1% penicillin streptomycin for 
stimulation. 1x106 cells/ml were stimulated with anti-CD3 (OKT3 clone, (1μg/ml) and anti-
CD28.2 (2μg/ml) for 24, 48 and 72h. Following optimisation, the cells were stimulated in the 
presence NOX-2 compounds (Redoxis AB, Lund, Sweden) at 12.5μM and or H2O2 at 20µM. 
The cells were collected after 30min and 24h for appropriate analysis. After 24h at 37°C, the 
supernatants were collected and stored in -20°C until further analysis. 
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2.2.8. Analysis of surface proteins by flow cytometry 
 
2.2.8.1. Reagents  
 
Fc antibodies were obtained from Abcam (Cambridge, UK), eBioscience (Hatfield, UK), BD 
Biosciences and Bio legend (UK) as described in the table below. 
 
Antigen Description Supplier Product code 
Trx1 Mouse monoclonal 
[3A1] to Thioredoxin 
Abcam ab16965 
Prx2 Rabbit monoclonal 
[EPR5154] to 
Peroxiredoxin 2 
Abcam ab109367 
CD25 Mouse monoclonal 
[BC96] to IL2 
Receptor with APC 
Abcam ab134477 
CD4 human  Mouse monoclonal 
anti-CD4 PE 
Abcam ab1155 
CD4 mouse  Rat anti-mouse CD4-
PE, Rat anti anti-
mouse -FITC 
BD Biosciences  553048/553651 
Secondary antibody 
to Trx1 
goat anti-mouse 
polyclonal 
conjugated dylight-
488  
Abcam ab96879 
Secondary to Prx2 Goat anti-Rabbit IgG 
Secondary Antibody, 
Alexa Fluor 488 
Invitrogen A-11034 
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IC to Trx1 IgG2b isotype 
control antibody  
Abcam ab 91366 
    
Table 2.4. Antibodies used for analysing exofacial markers and proteins 
2.2.8.2. Protocol 
 
After the treatments, the cells were washed and resuspended in PBS/BSA (1% w/v) followed 
by incubation with the appropriate antibodies and the corresponding isotype control on ice for 
20min and analysed using the flow cytometer FC500 (Beckman-Coulter, High Wycombe, UK) 
and or Attune NxT Flow cytometer (Thermoscientific, Sweden). Data was analysed by flowing 
software v2.5.  
 
2.2.9. Cytokine quantification by sandwich enzyme linked immunosorbent assay 
(ELISA) 
 
2.2.9.1. Reagents  
 
BSA was purchased form Thermo Fisher Scientific. Human IL-2 and TNF-α ELISA 
development kit were purchased from ebioscience affymetrix.  
2.2.9.2. Protocol  
 
The secretion of IL-2 and TNF-α in cell culture supernatants was quantified using the 
manufacturer’s instructions. Briefly, 96 well plates (Nunc, Maxisorp) were coated with a 
capture antibody and incubated overnight at 4°C. Duplicates of standards or samples were 
added to a monoclonal antibody specific for IL-2 or TNF-α, respectively, pre-coated 96-well 
plate and incubated for 2 hours at RT. After, the plate was incubated with human IL-2 or TNF-
α conjugate, respectively, for 1 hour at RT. Four washes with wash buffer were performed 
between incubation steps. The plate was then incubated with substrate solution for 30 minutes 
at RT and protected from light and the colorimetric reaction stopped with stop solution. 
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Absorbance of each well at 450 nm was measured in a plate spectrophotometer (BioTek 
Instruments Inc., Swindon, UK) and concentration of the cytokines interpolated from a 
standard curve (IL-2 and TNF-α: 3.1 to 1000 pg/mL). Correction of wavelength was performed 
at 570 nm. 
 
2.2.10. Competition Trx1 ELISA 
 
2.2.10.1. Reagents  
 
Recombinant Trx1 was purchased from R&D (UK), skimmed milk was purchased from Tesco, 
SIGMAFASTTM  OPD was from (Sigma, UK) 
 
2.2.10.2. Protocol 
 
Trx-1 (0.2μg/ml) 50μl/well was applied to a Nunc microtiter 96 well plates (Nunc, Maxisorb) in  
50mM carbonate buffer (1.59 g/L sodium carbonate (Na2CO3) 2.93 g/L sodium hydrogen 
carbonate (NaHCO3) pH9.6 in distilled water) and incubated for 1 hour at 37°C. The plate was 
washed 3 times with 250μl of PBS containing 0.05% v/v Tween-20 (PBST) and were gently 
tapped on absorbent tissue paper. Following washing, nonspecific sites were blocked by 
adding skimmed milk 4% w/v in PBS, 200μl/well for overnight at 4°C. Standard curve 
(2.5μg/ml-0μg/ml) was prepared using recombinant human Trx1 protein (25μl/well). The 
supernatants (25μl/well) were plated in triplicates. Mouse monoclonalanti-Trx1 (25μl of 1:2000 
in PBS, ab16965; Abcam) was added to all standards and samples and was incubated at 37°C 
for 2 h. Following incubation, wells were washed with PBST (250μl) 3 times and 200μl of 
peroxidase conjugated anti-mouse antibody (A1068, Sigma, UK) (1:5000) was added to each 
well. The plate was incubated at 37°C for 1h. Following washing 3 times with PBST (250μl), 
and 50μl of substrate solution containing o-phenylenediamine (Sigma, UK) and hydrogen 
peroxide in 0.15 M citrate-phosphate buffer was added. During incubation at room 
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temperature, colour development was observed from 2 to 10 min. The colour reaction was 
stopped with the addition of 2M sulphuric acid (H2SO4) (50μl/well). Absorbance was measured 
at 490 nm in a microplate reader (BioTek, UK). 
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2.2.11. Glutathione assay (GSH) 
 
GSH is the major antioxidant system in the cells and its present in a reduced form. Total GSH 
and GSSG was determined using the recycling assay which involves the oxidation of GSH to 
GSSG in the presence of DTNB (Gherghel et al. 2005). The colour change can be detected 
by spectrophotometry. Oxidised GSSG can be regenerated to GSH in the presence of GSR 
and NADPH and measures the total GSH available.   
2.2.11.1. Reagents 
 
Reagents Description 
Stock buffer 125mM Sodium phosphate, 6.3mM 
disodium EDTA (monobasic anhydrous), pH 
7.5 
Daily buffer 3mg NADPH in 10ml stock buffer 
SSA 1g of SSA acid in 1ml distilled water 
Reduced GSH 10mM of GSH in 5ml of distilled water  
Glutathione reductase 4U/ml in stock buffer  
DTNB 6mM 5’, 5’ – Dithio-bis (2-nitrobenzoic acid) 
in stock buffer 
Oxidised Glutathione (GSSG) 5mM GSSG in distilled water 
Vinylpyridine 20µl per standards well; 2 µl per sample 
Triethanolamine 20µl per standards well; 2 µl per sample 
Table 2.5. Reagents required for GSH assay  
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2.2.11.2. Protocol for reduced GSH 
 
 
Table 2.6. Reagent combination required for the standard curve for total GSH determination 
 
Cells were collected in 1.5ml micro centrifuge tubes and centrifuged at 6600 x g (Eppendorf 
centrifuge 5415D) for 1.5min. The supernatants were removed and PBS (0.5ml) was added 
to re-suspend the cell pellet. The tubes were centrifuged at 6600 x g for 2.5min and the 
supernatant was discarded. 3.3µl of SSA was added, vortexed and centrifuged immediately 
at 13000g for 1.5min then 96.6µl of stock buffer was added. When preparing plasma, 1% of 
SSA was directly added to 100 µl of plasma and 25µl of sample/standards (0-80µM) were 
loaded into a 96well plate. 150µl of daily buffer and 50µl of DTNB was added and incubated 
for 5min at 37°C. 25µl of the enzyme glutathione-S-reductase was added and the plate was 
read at 410nm after 0, 1, 2, 5 and 10min on a plate reader (BioTek instruments, Swindon, UK). 
GSH concentration was interpolated from the standard curve and data was analysed using 
GraphPad Prism 6/7. 
 
 
 
 
 
 
 
Concentration GSH (µl) SSA (µl) Water (µl) 
0µM 0 33.3 966 
20µM 2 33.3 964 
40µM 4 33.3 962 
60µM 6 33.3 960 
80µM 8 33.3 958 
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2.2.11.3. Protocol for oxidised GSH (GSSG) 
 
 
Table 2.7. Reagent combination required for standard curve for GSSG determination 
 
Briefly, cells/plasma were collected in 1.5ml micro centrifuge tubes and centrifuged at 6600 x 
g (Eppendorf centrifuge 5415D) for 1.5min. The supernatants was removed and PBS (0.5ml) 
was added to re-suspend the cell pellet. The tubes were centrifuged at 6600 x g for 2.5min 
and the supernatant was discarded. 3.3µl of SSA was added, vortexed and centrifuged 
immediately at 13000g for 1.5min then 96.6µl of stock buffer was added. 25µl of 
sample/standards (0-8µM) were loaded into a 96well plate. 20µl of Vinylpyridine and 
Triethanolamine was added to the standards and 2µl of both was added to the samples to 
stabilise the glutathione (Mcgill & Jaeschke 2015).  150µl of daily buffer and 50µl of DTNB 
was added and incubated for 5min at 37°C. 25µl of the enzyme glutathione-S-reductase was 
added and the plate was read at 410nm after 0, 1, 2, 5 and 10min and the data was analysed 
using GraphPad Prism 6/7 
 
2.2.12. Data analysis 
 
Unless specified, all data obtained was analysed using GraphPad Prism v6/7 as mean and 
standard error of mean (SEM). Experiments were performed in at least three independent 
replicates. Comparison between more than two columns was performed using one way 
analysis of variance (ANOVA) followed by Tukey’s/Sidaks multiple comparison test. Statistical 
significance was defined as * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001 and **** p-
value < 0.0001. 
Concentration GSSG(µl) SSA (µl) Water(µl) 
0µM 0 33.3 966 
2µM 0.4 33.3 965.6 
4µM 0.8 33.3 965.2 
6µM 1.2 33.3 964.8 
8µM 1.6 33.3 964.4 
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Chapter 3. Proteins which may undergo sulphenic acid modification on 
the membrane and cytosol in Jurkat T cells  
 
Preface 
 
Protein oxidation is an unavoidable process that can be reversible and irreversible. Protein sulphenic 
acids are reactive by-products of cell signalling. Hence this chapter focused on understanding protein 
oxidation in Jurkat T cells including sulphenic acid, disulphide and carbonyl formation with the goal of 
identifying novel proteins which may undergo sulphenic acid modification on the membrane of T cells 
under conditions of oxidative stress. Novel proteins on the membrane of Jurkat T cells were identified 
to undergo sulphenic acid modification. Some of the proteins identified to undergo sulphenic acid 
modification are in line with those reported in the literature.  
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3.1. Introduction  
 
Oxidation of proteins within cells can be due to a normal enzymatic reactions, and from ROS 
released from innate cells including H2O2, hypochlorous acid (HOCl) and nitric oxide (NO), 
and the regulated release of cellular oxidants for signalling purposes (Poole 2015). ROS are 
now recognised as signalling molecules which influence a range of biological activities 
(Bennett and Griffiths 2015). T cell protein thiol oxidation can arise due to either; an increase 
in ROS/RNS, lack of free thiols or antioxidants due to oxidation (Ratnayake et al. 2013). The 
cellular redox state in cells is maintained through three main redox couples CySS/Cys, 
GSH/GSSG and Trx1-SS/ Trx1-SH which reduce oxidised proteins in the presence of free 
radicals (Jones 2004). In any case when the difference between production of ROS and 
removal is disrupted, cells are said to be under oxidative stress, which eventually leads to 
irreversible modifications of proteins, lipids and nucleic acids (Kesarwani et al. 2013b). 
Reversible thiol modifications are a mediator of cell signalling caused by ROS; the initial 
product of cysteine oxidation by H2O2 or peroxynitrite is cysteine sulphenic acid (Nelson et al. 
2010; Poole et al. 2004). These sulphenic acid modifications can be either directly reduced by 
thiol by antioxidants or form a disulphide bond with cysteine residues in the same or another 
protein. Sulphenic acid can also undergo irreversible modification including sulphinic and 
sulphonic acid.  
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Figure 3.1 Oxidative modification of cysteine thiols. Reactive thiols (green) in their stable form are 
oxidised by reactive nitrogen species (RNS) and reactive oxygen species (ROS) including H2O2 and 
peroxynitrite to form a sulphenic acid product which is reversibly oxidised and may be reduced in the 
presence of reductants or antioxidants. Irreversibly modified (sulphonic or sulphonic acid, red) species.  
Adapted from (Poole & Nelson 2008) 
  
 
 
 
Membrane proteins and susceptibility to oxidation 
Cell membranes are involved in maintaining cellular homeostasis providing a semi-permeable 
barrier between the intra- and the extracellular environment. Cell membranes consist of a lipid 
bilayer and approximately 50% is comprised of membrane proteins which include receptors, 
channels, enzymes and structural proteins that are responsible for interaction between 
adjacent cells, cytoskeleton contact, signalling and surface recognition (Cooper & Hausman 
2007). T cell membrane proteins (MP) are involved in CD3/TCR engagement with MHC-I or II 
by antigen presenting cells. This is the initial step of T cell activation which subsequently 
activates downstream signalling pathways that are essential for an immune response. It is 
widely known that MP contain many cysteine residues and are susceptible to oxidative 
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modifications during T cell activation and increasing ROS (Redegeld et al. 1997; A. V. Belikov 
et al. 2015). Therefore changes in the redox state of extracellular proteins may result in 
changes in the redox sensors and cell activation by ligands (Reyes et al. 2005). However, 
there is not much information in the literature regarding which of the MP undergo sulphenic 
acid modification. Ca2+ entry by Ca2+ ATPase is essential for T cell activation, and the function 
of this redox-sensitive protein is markedly affected by any alteration in the redox state (Lewis 
2001). Several biochemical studies indicate the sensitivity of proteins to oxidation, some of 
which are responsible for calcium trafficking intra- and extracellularly  (Simeoni & Bogeski 
2015b; Belikov et al. 2015). For example, Orai1 which is a calcium transporter, is believed to 
be inhibited in the presence of H2O2 and Orai3 activity is oxidation-dependent (Bogeski et al. 
2010). Also, a redox sensitive cysteine thiol on STIM1 has been reported to lower its affinity 
for Ca2+ (Hawkins et al., 2010). 
Therefore, this chapter aims to explore protein oxidation and identify proteins which may 
undergo sulphenic acid modification on the membrane and cytosol of T cells under normal 
and oxidised conditions. 
 
The objectives of this chapter are as follows: 
1. To isolate cytosolic and membrane proteins 
2. To optimise oxidation conditions for Jurkat T cell membrane proteins 
3. To investigate the effect of H2O2 on the distribution of protein sulphenic acid 
modifications 
4. To identify proteins which are sulphenated on the T cell membrane and cytosol 
5. To  further explore the effect of H2O2 on T cell function 
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3.2. Methods  
 
3.2.1 Membrane protein isolation  
Cytosolic and membrane proteins were isolated from Jurkat T cells as described in the section 
2.2.4 above and analysed under either reducing or non-reducing conditions by SDS-PAGE. 
 
3.2.2. Analysis of protein oxidation and or aggregation 
CP and MP (20µg) were briefly treated with different concentrations of H2O2 (50μM-2mM) for 
30min on ice followed by addition of IAA (10mM) and catalase to block the free thiols and stop 
the reaction by decomposing H2O2 to water (H2O) and oxygen (O2). The samples were 
concentrated using a vacuum concentrator and separated by reducing and non-reducing SDS-
PAGE as described above. The proteins on the gel were transferred onto a PVDF membrane. 
Following transfer, the membrane was incubated with 1mM DNPH in 2M HCL in the dark for 
1h. The membrane was washed 6times for 30min with TTBS (0.05% v/v Tween) and blocked 
overnight with TTBS (0.1%v/v Tween) at 4°C.  
 
3.2.3. Calcium flux assay 
Calcium influx was detected by Fluo-3AM (Invitrogen). Briefly, 1x106 Jurkat T cells were 
incubated with 4µM of Fluo-3AM at room temperature in the dark. The cells were washed with 
PBS and resuspended with PBS pH 7.2 supplemented with 1mM calcium chloride (CaCl2) and 
20mM HEPES. Cells were allowed to rest for 15min for de-esterification of the dye before 
measuring calcium flux on a fluorescence plate reader at 10 sec intervals for 30min, Excitation 
506nm: Emission 526nm.  
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3.2.4. Protein sulphenic acid detection in Jurkat T cells 
Jurkat T cells were lysed and CP and MPs were isolated respectively. 50µg of CP and MP 
were exposed to different concentrations of H2O2 for 30 minutes in the presence of 0.5mM 
DCP-Bio1 which binds to any –SOH formed due to oxidation. 10mM of IAA was added. The 
samples were resuspended in Laemmli buffer and analysed by SDS PAGE and western 
blotting.  
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3.3. Results  
 
3.3.1. Protein purity after membrane isolation 
 
To identify those proteins which can be oxidised on the membrane and in the cytosol, 
membrane and cytosolic protein fractions were isolated from Jurkat T cells after treatment with 
H2O2. Their purity was assessed by analysing proteins specific to the membrane and 
cytoplasm including CD3Ɛ chain which forms part of the TCR receptor complex on the T cell 
membrane and the p65 subunit of the cytosolic protein NF-κB. The protein content of each 
fraction was measured by BCA assay. The samples were dialysed into dialysis buffer (75mM 
amino-n-caproic acid which improves membrane protein solubility and 5mM Bis-Tris pH7.0) 
to allow desalting and concentrating. After blotting for the CD3Ɛ chain, Figure 3.2a shows that 
a band of approximately 23kDa, and the intensity of CD3ε in the membrane (M) fraction 
appears to be higher compared to the cytosolic (C) lane. This suggests that good enrichment 
has taken place.  
 
Also to further confirm the purity, protein samples were analysed for a cytosolic specific 
protein, the p65 subunit of NF-κB which is present abundantly inside the cell and mediates 
transcription and cell survival. After blotting for p65 in Figure 3.2b, both protein fractions 
yielded a band of approximately 65kDa, however the band intensity was different. The 
cytosolic protein fraction showed a greater intensity of p65 compared to membrane proteins 
lane (M). The low intensity band present in the M lane may possibly be due to possible 
contamination. 
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a) Western blot analysing CD3 Ɛ                                       b) Western blot analysing NF-κB p65  
                        M      C      MW standards                                     M        C    MW standards 
                     
 
 
                                                                                    
 
                                                                                                                     
Figure 3.2: Western blot analysis of membrane and cytosolic marker CD3Ɛ and NF-κB. 4x106 
Jurkat T cells were fractionated into membrane and cytosol by using MEMPR kit (Thermo 
scientific); 20µg protein was separated using 15% SDS PAGE and transferred to PVDF 
membrane, blocked and probed with a) primary rabbit anti-CD3Ɛ  (1:1000, 2h); secondary 
goat anti-rabbit (1:10,000) b) Primary rabbit anti- NF-κB p65 (1:1000, 2h); secondary goat anti-
rabbit HRP (1:10,000, 2h). This data is representative of two independent experiments. M= 
Membrane fraction, C= Cystosolic fraction 
 
 
 
 
3.3.2. Protein lysates treated with different concentration of hydrogen peroxide  
 
CPs and MPs were isolated and treated with different concentrations of hydrogen peroxide to 
allow oxidation and formation of aggregates. Figure 3.3a shows that separation of proteins by 
SDS-PAGE in the absence of reducing agents such as DTT and β-mercaptoethanol 
demonstrates formation of aggregates and disulphides. The intensity of a band at 
approximately 60kDa increases with increase in concentration of H2O2, this may be the 
catalase which is a tetramer consisting of four equal subunits with a MW of ~60kDa which was 
only added in the treated samples. Additionally a band of higher MW approximately 240kDa 
was observed under non reducing conditions, possibly a catalase tetramer. The bands 
indicated with a black arrow are visible in treated CP or MP while lacking in untreated lane. 
50kDa 
37kDa 
 
25kDa 
 
90kDa 
75kDa 
50kDa 
CD3ε  
NF-κB-p65 
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This suggests that higher concentrations of peroxide lead to formation of aggregates and or 
disulphides. On the other hand CP and MP proteins when separated in the presence of β-
mercaptoethanol, are reduced and thus no disulphides or significant bands are visible.   
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a) 
H2O2(mM)      2      0.2   0.05      0     MW standards            2      0.2   0.05      0    MW standards  
 
 
 
 
 
 
 
 
 
                         
 Membrane                                                                           Cytosol 
 
b) 
H2O2(mM)  2     0.2      0.05     0        MW standards   2        0.2         0.05    0        MW standards 
 
 
 
 
 
 
 
 
 
                          
Membrane                                                                           Cytosol 
Figure 3.3: SDS PAGE showing separation of cystosolic and membrane protein from H2O2 
treated Jurkat T cells. 20µg of cytosolic and membrane proteins were treated with increasing 
concentrations of H2O2 for 30min on ice. 10mM IAA and catalase was added to stop the 
reaction. Protein fraction were concentrated and resuspended in 2x sample buffer with or 
without reducing agents and separated on 12% SDS PAGE. The gel was stained with 
Coomassie blue for visualisation  of bands. a) non-reducing SDS. Black arrows at ~40 kD 
indicates protein aggregates in both CP and MP blots and b) reducing SDS PAGE. 
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-50 
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-90kDa 
-50 
-35 
 
-90kDa 
-50 
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-90kDa 
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3.3.3. Hydrogen peroxide leads to carbonyl modification 
 
In order to assess protein oxidation, the determination of protein bound carbonyls (aldehydes 
and ketones) has been used as the most common method (Frijhoff et al. 2015). Protein 
carbonyls can be detected using various methods based on derivatisation of the carbonyl 
group. Figure 3.4a below shows the effect of hydrogen peroxide on CP and MP. Lysates 
treated with 200µM H2O2 show multiple bands, with the majority below 50kDa, compared to 
untreated lysates when derivatised with DNPH.  
a)                                                                                     b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: SDS-PAGE showing protein carbonyl modification when treated with 200µM H2O2. 
20µg of CP and MP were treated with 200µM H2O2 for 30min on ice followed by 10mM IAA 
and catalase in the treated samples. The protein fraction were separated on 15% SDS PAGE 
and derivatised using DNPH. a) Carbonyl western blot. b) Gel showing loading control. This 
blot is representative of three independent experiments.   
Cytosol                  -         -         +         + 
Membrane          +         +         -          -     
H2O2 (200µM)   +          -         +         -  
Cytosol                  -         -         +         + 
Membrane          +         +         -          -     
H2O2 (200µM)   +          -         +         -  
-90kDa 
-50 
-35 
-26 
 
-90kDa 
-50 
-35 
-26 
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3.3.4. Protein sulphenic acid modification in Jurkat T cells 
 
In order to detect protein sulphenic acid modification in T cells, the biotinylated dimedone 
based probe (DCP-Bio1) was used to capture sulphenic acid modified proteins. Cytosolic and 
membrane proteins were isolated and 20µg of CPs and MPs were treated with increasing 
concentration of H2O2 in the presence of DCP Bio1 (0.5mM). Proteins incubated with 0.5mM 
H2O2 show significant bands when probed with streptavidin HRP compared absence of DCP-
Bio1 as shown in Figure 3.5 below suggesting that the proteins have suphenic acid 
modification. Oxidants including H2O2, peroxynitrite, or lipid hydroperoxides are capable of 
forming cysteine sulphenic acids by oxidizing cysteines (Nelson et al. 2010). Also, the 
treatment with hydrogen peroxide leads to increasing band intensity of MPs, suggesting that 
H2O2 leads to an increase in sulphenic acid modification in the membrane proteins of jurkat T 
cells. However, treatment of H2O2 leads to decreased intenstity of sulphenic acid modification 
in cytosolic protein fraction.  
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a)                                                                        b) 
 H2O2(mM)       2    0.2  0.05 0  -DCP  MW standards          2   0.2 0.05   0 –DCP MW standards             
                                                                                                                   
 
 
 
 
 
 
 
 
                       Membrane                                                                 Cytosol  
 
 
 
 
 
 
 
 
  
                       Coomassie Loading control                        Coomassie Loading control 
 
 
Figure 3.5: SDS-PAGE showing protein sulphenic acid modification in Jurkat T cells in the 
presence of increasing concentration of H2O2. CPs and MPs were treated with increasing 
concentration of H2O2 in the presence of 0.5mM DCP-Bio1 and 10mM IAA for 30min. The 
protein fractions were resuspended in Laemmli buffer and separated on 15% SDS PAGE and 
analysed by Western blotting using HRP conjugated streptavidin for biotinylated probe 
detection; (1:1000) for 2h and developed using ECL. a) Membrane proteins (MP) and loading 
control below and b) Cytosolic proteins (CPs) and loading control below. This is a 
representative of 3 independent replicates. n=3 
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3.3.5. Streptavidin beads capture to purify modified proteins 
 
In order to capture sulphenic acid modified proteins for further identification, streptavidin 
magnetic beads were used to capture biotinylated proteins in the absence or presence of H2O2 
(200µM). CPs were separated by SDS-PAGE and Figure 3.6a shows distinct bands around 
30 and 15kDa and low intensity bands around 50kDa in both treated and untreated lanes 
showing that a number of proteins within the cytosol are sulphenated. Figure 3.6b shows 
similar bands representing sulphenated proteins in MP as observed in the cytosolic fraction. 
However, the intensity of the bands increases with the treatment of H2O2 suggesting that H2O2 
leads to further sulphenic acid formation. A lower MW high intensity band was observed in the 
presence of DCP-Bio1 which may indicate the streptavidin monomer.  
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Cytosolic fraction                                                                      Membrane fraction 
 
Figure 3.6: SDS-PAGE and western blot showing proteins undergoing sulphenic acid 
modification.20 µg of membrane and cytosolic proteins were treated with 200uM H2O2 
alongside DCP-Bio1 at 0.5mM for 30min. Catalase and IAA (10mM) was added in the treated 
samples and modified proteins were captured with Magnabind streptavidin beads (200μL) and 
incubated for 30min at room temperature with rotation. The supernatant was collected after 
placing the samples on a magnet. The beads were boiled at 95C for five min with Laemmli 
buffer (40uL) and 20uL was separated on 15% SDS. Transferred and blocked with 3% BSA 
overnight. The membrane was probed with streptavidin-HRP (1:1000) for 1:30min and 
developed using ECL. This is a representative of three independent replicates, n=3. 
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3.3.6 Mass spectrometry identification of membrane proteins containing 
sulphenic acid modification. 
 
In order to identify proteins that contain sulphenic acid modifications, the gel lanes in figure 
3.7 were cut in three sections (white boxes) and digested by trypsin as described in the 
methods sections above 2.2.5. Trypsin digestion allows the identification of several proteins 
considered to have sulphenic acid modification. To note, the hits with the highest scoring were 
serum albumin and keratin and these were not considered as keratin contamination is likely 
during trypsin digestion and albumin is the most abundant protein within cell culture media.  
In order to narrow down the dataset results, MW of proteins which match up to the position of 
migration on the gel were divided into sections 1,2 and 3 as presented in tables below (table 
3.1-3.4). In addition, the proteins were grouped based on their molecular function using 
PANTHER database. 
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Figure 3.7: SDS-PAGE showing sulphenated proteins after streptavidin capture. 20 µg of 
membrane and cytosolic proteins were treated with 200µM H2O2 in the presence of 0.5mM 
DCP-Bio1 for 30min. Catalase and IAA (10mM) was added and modified proteins were 
captured with magnabind streptavidin beads (200µL) and incubated for 30min at room 
temperature with rotation. The supernatant was collected after placing the samples on a 
magnet. The beads were boiled at 95°C for five min with Laemmli buffer (40µL) and 20µL was 
separated on 10% SDS PAGE followed by Coomassie staining. this is representative of one 
experiment. 1,2, 3 show different sections based on molecular weight in the tables  
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Section 3 
 
 
 
 
 
 
 
Section 2 
ACCESSION SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION  
ACTG_HUMAN 4015 41766 15 Actin, cytoplasmic 2  
TBB5_HUMAN 6285 49639 11 Tubulin beta chain  
TCPQ_HUMAN 1027 59583 11 T-complex protein 1 subunit theta  
TBB4B_HUMAN 4709 49799 10 Tubulin beta-4B chain  
KPYM_HUMAN 763 57900 10 Pyruvate kinase PKM  
EF1A1_HUMAN 792 50109 9 Elongation factor 1-alpha 1  
TCPB_HUMAN 601 57452 9 T-complex protein 1 subunit beta  
TBA1A_HUMAN 2550 50104 8 Tubulin alpha-1A chain  
SERA_HUMAN 895 56614 8 D-3-phosphoglycerate dehydrogenase  
TCPA_HUMAN 280 60306 8 T-complex protein 1 subunit alpha  
ALBU_HUMAN 2866 69321 8 Serum albumin  
TCPH_HUMAN 259 59329 7 T-complex protein 1 subunit eta  
EWS_HUMAN 66 68436 7 RNA-binding protein EWS  
PLSL_HUMAN 626 70244 7 Plastin-2  
TCPD_HUMAN 312 57888 6 T-complex protein 1 subunit delta  
TCPE_HUMAN 446 59633 6 T-complex protein 1 subunit epsilon  
TCPG_HUMAN 305 60495 6 T-complex protein 1 subunit gamma  
PGK1_HUMAN 32 44586 5 Phosphoglycerate kinase 1  
EF1G_HUMAN 221 50087 5 Elongation factor 1-gamma  
HNRPK_HUMAN 437 50944 5 Heterogeneous nuclear ribonucleoprotein K  
COR1A_HUMAN 65 50994 4 Coronin-1A  
RUVB2_HUMAN 45 51125 4 RuvB-like 2  
TCPZ_HUMAN 88 57988 4 T-complex protein 1 subunit zeta  
PA2G4_HUMAN 42 43759 3 Proliferation-associated protein 2G4  
PUR6_HUMAN 209 47049 3 Multifunctional protein  
RUVB1_HUMAN 78 50196 3 RuvB-like 1  
ANT3_HUMAN 225 52569 3    Antithrombin-III  
SYFA_HUMAN 117 57528 3 Phenylalanine--tRNA ligase alpha subunit  
IRGQ_HUMAN 22 62678 3 Immunity-related GTPase family Q protein  
HSP7C_HUMAN 36 70854 3 Heat shock cognate 71 kDa protein  
RAE1_HUMAN 39 73429 3 Rabproteins 
geranylgeranyltransferasecomponent A1  
 
 
ACCESSION SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION 
HSP7C_HUMAN 468 70854 9 Heat shock cognate 71 kDa protein  
TANC1_HUMAN 39 202093 6 Protein TANC1  
ZC3HD_HUMAN 38 196519 5 Zinc finger CCCH domain-containing protein 
13  
FLNB_HUMAN 28 277990 5 Filamin-B  
 
NMD3A_HUMAN 42 125385 4 Glutamate receptor ionotropic, NMDA 3A  
KIF2C_HUMAN 21 81261 3 Kinesin-like protein KIF2C  
UBP45_HUMAN 39 91675 3 Ubiquitin carboxyl-terminal hydrolase 45  
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Section 1 
ACCESSION SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION 
PRDX1_HUMAN 593 22096 8 Peroxiredoxin-1  
RS3_HUMAN 363 26671 8 40S ribosomal protein S3  
RAN_HUMAN 134 24408 6 GTP-binding nuclear protein Ran  
RL12_HUMAN 230 17808 5 60S ribosomal protein L12  
RLA0_HUMAN 268 34252 5 60S acidic ribosomal protein P0  
H2B1H_HUMAN 135 13884 4 Histone H2B type 1-H  
RS16_HUMAN 51 16435 4 40S ribosomal protein S16  
PRDX2_HUMAN 255 21878 4 Peroxiredoxin-2  
RAB1A_HUMAN 30 22663 4 Ras-related protein Rab-1A  
CYBP_HUMAN 38 26194 4 Calcyclin-binding protein  
RS3A_HUMAN 74 29926 4 40S ribosomal protein S3a  
H2AV_HUMAN 37 13501 3 Histone H2A.V   
NDKB_HUMAN 45 17287 3 Nucleoside diphosphate kinase B  
COF1_HUMAN 84 18491 3 Cofilin-1  
RS7_HUMAN 70 22113 3 40S ribosomal protein S7  
RS5_HUMAN 188 22862 3 40S ribosomal protein S5  
 
Table 3.1: Proteins identified for lane 1 in Fig 3.7; untreated CP  
 
 
Section 3 
ACCESSION SCORE MASS NUM. OF 
SEQUENCE
S 
DESCRIPTION 
ANR12_HUMAN 26 235507 5 Ankyrin repeat domain-containing protein 12  
ABCA3_HUMAN 20 191239 5 ATP-binding cassette sub-family A member 3  
SMC4_HUMAN 19 147091 3 Structural maintenance of chromosomes protein 4  
 
Section 2 
ACCESSION SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION 
DHE3_HUMAN 11211 61359 17 Glutamate dehydrogenase 1, mitochondrial  
ACTG_HUMAN 5835 41766 14 Actin, cytoplasmic 2  
TCPH_HUMAN 26 59329 9 T-complex protein 1 subunit eta  
TBB5_HUMAN 4055 49639 9 Tubulin beta chain  
TBB4B_HUMAN 1921 49799 8 Tubulin beta-4B chain  
CATA_HUMAN 1259 59719 7 Catalase  
ALBU_HUMAN 1953 69321 6 Serum albumin  
TCPG_HUMAN 51 60495 6 T-complex protein 1 subunit gamma  
TBA1A_HUMAN 1916 50104 6 Tubulin alpha-1A chain  
HSP7C_HUMAN 358 70854 5 Heat shock cognate 71 kDa protein  
TCPZ_HUMAN 65 57988 5 T-complex protein 1 subunit zeta  
TCPB_HUMAN 233 57452 5 T-complex protein 1 subunit beta  
EF1A1_HUMAN 1666 50109 4 Elongation factor 1-alpha 1  
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PGK1_HUMAN 26 44586 4 Phosphoglycerate kinase 1  
PLST_HUMAN 41 70766 3 Plastin-3  
ENTP7_HUMAN 22 68916 3 Ectonucleoside triphosphate diphosphohydrolase 7  
HNRH1_HUMAN 58 49198 3 Heterogeneous nuclear ribonucleoprotein H  
PUR6_HUMAN 31 47049 3 Multifunctional protein ADE2  
 
Section 1 
ACCESSION SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION 
SMKR1_HUMAN 17 7087 1 Small lysine-rich protein 1  
PRDX1_HUMAN 726 22096 10 Peroxiredoxin-1 
RL12_HUMAN 233 17808 6 60S ribosomal protein L12  
RS3_HUMAN 225 26671 5 40S ribosomal protein S3  
COF1_HUMAN 82 18491 4 Cofilin-1  
RL11_HUMAN 75 20240 4 60S ribosomal protein L11  
TEX30_HUMAN 33 25568 4 Testis-expressed protein 30  
H2B1L_HUMAN 69 13944 3 Histone H2B type 1-L  
RS10_HUMAN 49 18886 3 40S ribosomal protein S10  
PRDX2_HUMAN 267 21878 3 Peroxiredoxin-2  
CC134_HUMAN 40 26544 3 Coiled-coil domain-containing protein 134  
PGAM2_HUMAN 17 28748 3 Phosphoglycerate mutase 2  
RLA0L_HUMAN 28 34343 3 60S acidic ribosomal protein P0-like  
GSTP1_HUMAN 60 23341 3 Glutathione S-transferase P  
Table 3.2: Proteins identified for lane 2 in Fig 3.7; CP treated with 200µM H2O2 
 
 
 
Section 3 
ACCESSION SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION 
HYOU1_HUMAN 632 111266 21 Hypoxia up-regulated protein 1  
TLN1_HUMAN 76 269599 17 Talin-1  
ENPL_HUMAN 936 92411 15 Endoplasmin  
EF2_HUMAN 787 95277 14 Elongation factor 2  
C1TC_HUMAN 143 101495 11 C-1-tetrahydrofolate synthase, cytoplasmic  
GANAB_HUMAN 226 106807 10 Neutral alpha-glucosidase AB  
SND1_HUMAN 135 101934 10 Staphylococcal nuclease domain-containing protein 1  
FLNA_HUMAN 100 280564 9 Filamin-A  
PYR1_HUMAN 39 242829 7 CAD protein  
TERA_HUMAN 29 89266 7 Transitional endoplasmic reticulum ATPase  
P5CS_HUMAN 61 87248 7 Delta-1-pyrroline-5-carboxylate synthase  
ACON_HUMAN 228 85372 6 Aconitate hydratase, mitochondrial  
FLNB_HUMAN 27 277990 5 Filamin-B  
ZC3HD_HUMAN 33 196519 5 Zinc finger CCCH domain-containing protein 13  
AFF3_HUMAN 39 133394 5 AF4/FMR2 family member 3  
SC31B_HUMAN 39 128615 5 Protein transport protein Sec31B  
IPO5_HUMAN 37 123550 5 Importin-5  
UBA1_HUMAN 155 117774 5 Ubiquitin-like modifier-activating enzyme 1  
ERAP2_HUMAN 37 110391 5 Endoplasmic reticulum aminopeptidase 2  
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TRPC6_HUMAN 23 106258 5 Short transient receptor potential channel 6  
MCM4_HUMAN 21 96498 5 DNA replication licensing factor MCM4  
HNRPU_HUMAN 104 90528 5 Heterogeneous nuclear ribonucleoprotein U  
TFR1_HUMAN 233 84818 5 Transferrin receptor protein 1  
XRCC5_HUMAN 22 82652 5 X-ray repair cross-complementing protein 5  
MCM7_HUMAN 45 81257 5 DNA replication licensing factor MCM7  
CFA57_HUMAN 35 144870 4 Cilia- and flagella-associated protein 57  
SYAC_HUMAN 37 106743 4 Alanine--tRNA ligase, cytoplasmic  
IMB1_HUMAN 334 97108 4 Importin subunit beta-1  
SC23A_HUMAN 38 86105 4 Protein transport protein Sec23A  
TRPM7_HUMAN 21 212561 3 Transient receptor potential cation channel subfamily M 
member 7  
ERAP1_HUMAN 135 107166 3 Endoplasmic reticulum aminopeptidase 1  
PDPR_HUMAN 25 99301 3 Pyruvate dehydrogenase phosphatase regulatory subunit, 
mitochondrial  
 
 
Section 2 
ACCESSION  SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION 
CH60_HUMAN 6685 61016 28 60 kDa heat shock protein, mitochondrial  
ACTG_HUMAN 3190 41766 15 Actin, cytoplasmic 2  
ATPA_HUMAN 994 59714 15 ATP synthase subunit alpha, mitochondrial  
PDIA3_HUMAN 951 56747 12 Protein disulfide-isomerase A3  
KPYM_HUMAN 435 57900 12 Pyruvate kinase PKM  
PGK1_HUMAN 387 44586 9 Phosphoglycerate kinase 1  
SERA_HUMAN 629 56614 9 D-3-phosphoglycerate dehydrogenase  
TBA1B_HUMAN 2394 50120 8 Tubulin alpha-1B chain  
IDHP_HUMAN 816 50877 8 Isocitrate dehydrogenase [NADP], mitochondrial  
GLYM_HUMAN 397 55958 8 Serine hydroxymethyltransferase, mitochondrial  
TBB5_HUMAN 3466 49639 7 Tubulin beta chain  
TBB4B_HUMAN 2596 49799 7 Tubulin beta-4B chain  
HNRPK_HUMAN 689 50944 7 Heterogeneous nuclear ribonucleoprotein K  
ALBU_HUMAN 3436 69321 7 Serum albumin  
PTBP1_HUMAN 386 57186 6 Polypyrimidine tract-binding protein 1  
VAT1_HUMAN 151 41893 5 Synaptic vesicle membrane protein VAT-1 homolog  
EF1A1_HUMAN 498 50109 5 Elongation factor 1-alpha 1  
TCPB_HUMAN 76 57452 5 T-complex protein 1 subunit beta  
TCPG_HUMAN 35 60495 5 T-complex protein 1 subunit gamma  
RBP56_HUMAN 64 61793 5 TATA-binding protein-associated factor 2N  
TCPD_HUMAN 115 57888 4 T-complex protein 1 subunit delta  
TCPQ_HUMAN 403 59583 4 T-complex protein 1 subunit theta  
TCPE_HUMAN 72 59633 4 T-complex protein 1 subunit epsilon  
DHE4_HUMAN 174 61395 4 Glutamate dehydrogenase 2, mitochondrial  
AIFM1_HUMAN 308 66859 4 Apoptosis-inducing factor 1, mitochondrial  
ODP2_HUMAN 54 68953 4 Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex, 
mitochondrial  
CODA1_HUMAN 25 69907 4 Collagen alpha-1(XIII) chain  
IDH3B_HUMAN 374 42157 3 Isocitrate dehydrogenase [NAD] subunit beta, 
mitochondrial  
THIL_HUMAN 149 45171 3 Acetyl-CoA acetyltransferase, mitochondrial  
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ACADM_HUMAN 65 46559 3 Medium-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
AATM_HUMAN 34 47487 3 Aspartate aminotransferase, mitochondrial  
SAHH_HUMAN 55 47685 3 Adenosylhomocysteinase  
HNRH1_HUMAN 234 49198 3 Heterogeneous nuclear ribonucleoprotein H  
SUCB1_HUMAN 31 50285 3 Succinate--CoA ligase [ADP-forming] subunit beta, 
mitochondrial  
ANT3_HUMAN 175 52569 3 Antithrombin-III  
QCR1_HUMAN 52 52612 3 Cytochrome b-c1 complex subunit 1, mitochondrial  
ATPB_HUMAN 343 56525 3 ATP synthase subunit beta, mitochondrial  
TCPZ_HUMAN 52 57988 3 T-complex protein 1 subunit zeta  
TCPH_HUMAN 45 59329 3 T-complex protein 1 subunit eta  
CATA_HUMAN 71 59719 3 Catalase  
HNRPL_HUMAN 68 64092 3 Heterogeneous nuclear ribonucleoprotein L  
     
 
Section 1 
ACCESSION  SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION 
PRDX1_HUMAN 255 22096 7 Peroxiredoxin-1  
ADT2_HUMAN 27 32831 6 ADP/ATP translocase 2  
STMN1_HUMAN 89 17292 4 Stathmin  
RAB1B_HUMAN 89 22157 4 Ras-related protein Rab-1B  
RAN_HUMAN 447 24408 4 GTP-binding nuclear protein Ran  
RS7_HUMAN 26 22113 3 40S ribosomal protein S7  
RAB7A_HUMAN 110 23475 3 Ras-related protein Rab-7a  
HCD2_HUMAN 93 26906 3 3-hydroxyacyl-CoA dehydrogenase type-2  
ERP29_HUMAN 32 28975 3 Endoplasmic reticulum resident protein 29  
ELAV1_HUMAN 22 36069 3 ELAV-like protein 1  
 
Table 3.3: Proteins identified for lane 3 in Fig 3.7; untreated MP 
 
Section 3 
ACCESSION SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION 
VWF_HUMAN 29 309058 7 von Willebrand factor  
CO6A6_HUMAN 22 247019 7 Collagen alpha-6(VI) chain  
GRP78_HUMAN 537 72288 7 78 kDa glucose-regulated protein  
TANC1_HUMAN 36 202093 5 Protein TANC1  
ZC3HD_HUMAN 33 196519 5 Zinc finger CCCH domain-containing protein 13  
HYOU1_HUMAN 282 111266 5 Hypoxia up-regulated protein 1  
AGRB2_HUMAN 29 172544 4 Adhesion G protein-coupled receptor B2  
MINT_HUMAN 33 402004 3 Msx2-interacting protein  
NMD3A_HUMAN 36 125385 3 Glutamate receptor ionotropic, NMDA 3A  
GANAB_HUMAN 31 106807 3 Neutral alpha-glucosidase AB  
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Section 2 
 
ACCESSION SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION 
CH60_HUMAN 8447 61016 35 60 kDa heat shock protein, mitochondrial  
ACTG_HUMAN 6348 41766 15 Actin, cytoplasmic 2  
DHE3_HUMAN 5598 61359 15 Glutamate dehydrogenase 1, mitochondrial  
GRP75_HUMAN 740 73635 12 Stress-70 protein, mitochondrial  
TBB5_HUMAN 3029 49639 10 Tubulin beta chain  
KPYM_HUMAN 102 57900 10 Pyruvate kinase PKM  
TBB4A_HUMAN 1926 49554 8 Tubulin beta-4A chain  
PGK1_HUMAN 129 44586 7 Phosphoglycerate kinase 1  
TBA1A_HUMAN 1474 50104 7 Tubulin alpha-1A chain  
CATA_HUMAN 2248 59719 7 Catalase  
K1C14_HUMAN 521 51529 6 Keratin, type I cytoskeletal 14  
ATPB_HUMAN 384 56525 6 ATP synthase subunit beta, mitochondrial  
PTBP1_HUMAN 173 57186 6 Polypyrimidine tract-binding protein 1  
ALBU_HUMAN 858 69321 6 Serum albumin  
GRP78_HUMAN 431 72288 6 78 kDa glucose-regulated protein  
ANKR6_HUMAN 17 79922 6 Ankyrin repeat domain-containing protein 6  
GNAS2_HUMAN 233 45636 5 Guanine nucleotide-binding protein G(s) subunit alpha 
isoforms short  
PDIA6_HUMAN 489 48091 5 Protein disulfide-isomerase A6  
HNRH1_HUMAN 297 49198 5 Heterogeneous nuclear ribonucleoprotein H  
ENOA_HUMAN 76 47139 5 Alpha-Enolase 
GLYM_HUMAN 135 55958 5 Serine hydroxymethyltransferase, mitochondrial  
PDIA3_HUMAN 99 56747 5 Protein disulfide-isomerase A3  
TCPB_HUMAN 48 57452 5 T-complex protein 1 subunit beta  
ATPA_HUMAN 287 59714 5 ATP synthase subunit alpha, mitochondrial  
TCPG_HUMAN 59 60495 5 T-complex protein 1 subunit gamma  
EFTU_HUMAN 315 49510 4 Elongation factor Tu, mitochondrial  
EF1A1_HUMAN 98 50109 4 Elongation factor 1-alpha 1  
COR1A_HUMAN 50 50994 4 Coronin-1A  
SERA_HUMAN 41 56614 4 D-3-phosphoglycerate dehydrogenase  
PLSL_HUMAN 213 70244 4 Plastin-2  
HSP7C_HUMAN 215 70854 4 Heat shock cognate 71 kDa protein  
IDH3B_HUMAN 37 42157 3 Isocitrate dehydrogenase [NAD] subunit beta, 
mitochondrial  
ILF2_HUMAN 165 43035 3 Interleukin enhancer-binding factor 2  
HNRPK_HUMAN 364 50944 3 Heterogeneous nuclear ribonucleoprotein K  
AIFM1_HUMAN 31 66859 3 Apoptosis-inducing factor 1, mitochondrial  
G3P_HUMAN 358 36030 2 Glyceraldehyde-3-phosphate dehydrogenase 
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Section 1 
ACCESSION SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION  
RS16_HUMAN 112 16435 4 40S ribosomal protein S16   
HCD2_HUMAN 91 26906 4 3-hydroxyacyl-CoA dehydrogenase type-2   
ADT2_HUMAN 49 32831 4 ADP/ATP translocase 2   
PROF1_HUMAN 41 15045 3 Profilin-1   
NDK8_HUMAN 27 15519 3 Putative nucleoside diphosphate kinase   
COF1_HUMAN 176 18491 3 Cofilin-1   
RAB1A_HUMAN 82 22663 3 Ras-related protein Rab-1A   
RS5_HUMAN 199 22862 3 40S ribosomal protein S5   
RAB7A_HUMAN 113 23475 3 Ras-related protein Rab-7a   
RAN_HUMAN 195 24408 3 GTP-binding nuclear protein Ran   
SMD3_HUMAN 21 13907 2 Small nuclear ribonucleoprotein Sm D3  
PPIA_HUMAN 30 18001 2 Peptidyl-prolyl cis-trans isomerase A   
PRDX2_HUMAN 398 21878 2 Peroxiredoxin-2   
BID_HUMAN 16 21981 2 BH3-interacting domain death agonist   
MOB1A_HUMAN 20 25064 2 MOB kinase activator 1A   
NDUV2_HUMAN 43 27374 2 NADH dehydrogenase [ubiquinone] flavoprotein 2, 
mitochondrial  
 
PGAM2_HUMAN 46 28748 2 Phosphoglycerate mutase 2   
ERP29_HUMAN 69 28975 2 Endoplasmic reticulum resident protein 29   
VDAC3_HUMAN 104 30639 2 Voltage-dependent anion-selective channel protein 3   
ECHM_HUMAN 25 31367 2 Enoyl-CoA hydratase, mitochondrial   
SRP14_HUMAN 47 14561 1 Signal recognition particle 14 kDa protein   
PA1B3_HUMAN 24 25718 1 Platelet-activating factor acetylhydrolase IB subunit gamma   
PRDX3_HUMAN 46 27675 1 Thioredoxin-dependent peroxide reductase, mitochondrial   
NUD22_HUMAN 29 32560 1 Nucleoside diphosphate-linked moiety X motif 22   
HCDH_HUMAN 99 34272 1 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial   
ETFA_HUMAN 47 35058 1 Electron transfer flavoprotein subunit alpha, mitochondrial   
O52B2_HUMAN 33 36160 1 Olfactory receptor 52B2   
 
Table 3.4: Proteins identified for lane 4 in Fig 3.7; MP treated with 200µM H2O2 
 
 
 
 
 
 
 
 
 
 
 
89 
 
a) 
b) 
c)             d) d)             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Proteins identified which undergo sulphenic acid modification grouped based on 
their molecular function. a) Untreated cytosolic proteins, b) Treated cytosolic proteins (200μM 
H2O2). c) Untreated membrane proteins, d) Treated membrane proteins (200μM H2O2). 
Proteins identified by Mascot daemon database and grouped based on their molecular 
function by PANTHER gene ontology database. 
 
 
 
 
 
 
 
 
90 
 
3.3.7 Hydrogen peroxide inhibits NMDA calcium influx in Jurkat T cells. 
 
T cells express NMDA receptors as shown by previous studies (Miglio et al. 2005) and LC 
MS/MS results in section 3.3.6 showed that NMDA receptor is sulphenated in Jurkat T cell 
cytosolic fraction and this sulphenation is lost after treating with H2O2 (Table 3.1 section 3 
compared to table 3.2 section 3). Also, NMDA is sulphenated in the membrane after H2O2 
treatment. In order evaluate the effects and importance of NMDA receptor on T cell function 
and calcium influx under oxidising conditions, T cell NMDA receptor was stimulated with the 
agonist glycine/glutamate in the presence or absence of H2O2. Glycine and glutamate 
stimulates the receptor and increases calcium in T cells compared to stained control (Figure 
3.9a). However, in the presence of 10µM H2O2 there was a decreased flux of calcium via the 
NMDA receptor suggesting that excess H2O2 leads to inactivation of the receptor thus 
decreased calcium influx (Figure3.9b) which might affect further T cell function. 
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Figure 3.9: The effect of H2O2 on calcium influx by NMDA receptor. Jurkat T cells were 
incubated with Fluo3AM for 1h at room temperature in the dark. After washing, cells were 
resuspended in PBS supplemented with HEPES and CaCl2. NMDA receptor was stimulated 
with 100µM glycine/glutamate (positive control) and or H2O2 (10µM) in the presence or 
absence of NAC (10mM) and the calcium flux was measured using a fluorescence plate reader 
for 30min at intervals of 10s. The data was normalised to unstained control. a) RFU from 0-
10min, b) Δ RFU at 2min and 0min, Data represents the mean and SEM of three independent 
experiments, n=3. ANOVA. Excitation 506nm: Emission 526nm. 
 
a) 
b) 
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3.4. Discussion 
 
Cysteine oxidative modification of proteins by ROS has gained increasing interest leading to 
the development of chemical reagents to detect cysteine sulphenic acid. Redox biology 
focuses on three major areas; identification of the nature of oxidation and protein targets, 
quantification of the extent of the modification and precise sites, the functional consequences 
on the individual protein activity due to the extent of the modification (Furdui & Poole 2014). 
Oxidative modification of cysteine to sulphenic acid has been regarded as an significant post-
translational modifications in proteins and protein function under oxidative stress and 
physiological conditions (Poole & Nelson 2008; Leonard & Carroll 2011; Roos & Messens 
2011). 
The aim of this chapter was to develop and identify the proteins that may be sulphenated on 
the T cell membrane and cytosol. This chapter has looked into protein aggregation and 
modifications including carbonyl modification and sulphenic acid in both the cytosol and 
membrane proteins. Furthermore, the effect of H2O2 was also assessed on sulphenic acid 
formation in specific CP and MP.  
A range of enzymes are responsible for production of H2O2, which is necessary for receptor 
mediated cellular activities including DNA synthesis, chemotaxis, and cell cycle progression 
(Page et al. 2000; Lee et al. 2002) 
Under normal conditions, cells maintain a reducing environment in the presence of reducing 
agents. However, an increase in ROS concentration which exceeds the cellular capability to 
remove them, termed oxidative stress, can result in protein aggregation, disulphide formation 
and fragmentation (Squier 2001; Tabner et al. 2005). This was briefly observed in CP and MP 
treated with increasing concentration of H2O2 and separated under non-reducing conditions. 
A few bands which were observed in lanes with H2O2 indicated with an arrow which were not 
visible in the untreated samples. However, this experiment was to give an understanding on 
the extent of protein oxidation. A study by (Zhang et al. 2015) showed that the oxidation of 
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proteins in the presence of H2O2 led to protein aggregation but this was not observed when 
proteins were separated in the presence of DTT. Protein aggregation is likely, but not limited 
due to cysteine oxidation and disulphide bond formation in the presence of H2O2  (Zhang et al. 
2015; Grune et al. 1997). Furthermore, protein disulphides are known to be the most common 
covalent link between amino acids in proteins formed in oxidising environment (Yi & Khosla 
2016). Variety of these motifs are involved in redox reactions and act as switches in response 
to oxidative stress. The treatment with H2O2 shows some bands which are not present in the 
absence of low concentrations of H2O2. This may be due to the disulphide link formed in 
excess of peroxide. This is further reduced by the dithiol-disulphide exchange reaction, which 
is catalysed by oxidoreductases including members of the PDI and Trx1 family which are also 
present extracellularly (Söderberg et al. 2013). However, there is no known enzyme 
responsible for cysteine disulphide reduction. Reduction of CySS can also be achieved by 
GSH but is limited by GSH availability (Jones 2004). In the presence of an excess oxidative 
stress, protein thiols may react with adjacent cysteine thiols to form a disulphide bond. 
However, the formation of disulphide bonds between cysteine of the same proteins may be 
essential for protein folding in the endoplasmic reticulum (ER) and protein-protein interaction 
and to enable secondary and higher structures of proteins such as antibodies. Thus the 
reduction may be essential for the protein function. However, sulphenation may not be a result 
of an oxidative environment.  
Carbonylation is the most common marker to assess protein oxidation (Weber et al. 2015; 
Trachootham et al. 2008; Frijhoff et al. 2015). In this chapter, it was observed that H2O2 leads 
to protein carbonyl formation which is an irreversible form of protein modification. Protein 
carbonyls are not formed as a result of a specific oxidant and are formed early during oxidative 
stress, and are thus regarded as a marker of general protein oxidation. Additionally, protein 
carbonyls are often used as an indicator of protein oxidation as they are easily detectable and 
present in high levels in vivo compared to other modifications (Dalle-Donne et al. 2006). 
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Previously, it has been shown by Ratnayake 2015 in our lab (unpublished data) that resting T 
cells undergo sulphenic modification and when treated with BSO, a number of proteins were 
identified to form the sulphenic acid PTM. The work in this chapter has followed up this work 
and showed proteins sulphenated on the membrane of T cells when treated with H2O2. 
A Jurkat cell model was optimised to capture proteins with sulphenic acid on the membrane 
and cytosol which further allowed identification proteins which undergo during T cell activation 
in the later chapter. Firstly, the cell fractions including CP and MP were treated at different 
concentrations of H2O2. This showed a number of bands of increasing intensity with increasing 
concentrations of H2O2 in the CP and MP fraction. However, when CP were treated with H2O2, 
decreasing band intensity was observed. This might be due to the irreversible modification 
due to excessive oxidative stress caused by increasing H2O2 concentration. A study by 
Charles et al, showed cells treated with high concentrations of H2O2 did not show a significant 
sulphenation and suggested that proteins may be undergoing irreversible oxidation such as 
sulphinic or sulphenic acid, at a rate faster then the reaction of biotin-linked dimedone to 
sulphenic acid (Charles et al. 2007) 
Several proteins have been identified as sulphenated including proteins that are responsible 
for T cell function and redox regulation. From the proteins identified from MS, a small number 
of them are involved in oxidation-reduction process as shown in the chart characterising 
proteins based on their molecular function, including Prxs, alpha enolase and protein 
disulphide isomerases. In support of this, several cytosolic proteins identified in this chapter 
have also been shown in the literature to undergo reversible cysteine oxidation (Baty et al. 
2005). 
At least six different isoforms of Prx have been identified in mammalian cells (Wood, Poole, et 
al. 2003; Hofmann et al. 2002). Prxs are important in keeping the toxic H2O2 and peroxynitrite 
in low levels and also involved in cellular processes such as proliferation, differentiation and 
apoptosis (Leslie B. Poole et al. 2004). Prx-1 is classified to have two conserved cysteines, 
out of which one is oxidised to cysteine sulphenic acid and then forms a disulphide with the 
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other. Under normal physiological conditions, this is reduced by NADPH dependent Trx1 and 
TrxR to regenerate reduced cysteines for Prx 1-5, while Prx 6 requires other antioxidants such 
as GSH (Watanabe et al. 2017; Smith-Pearson et al. 2008; Kang et al. 1998; Fisher et al. 
1999).  
In addition, the role of Prxs as regulators of H2O2 mediated cell signalling may be implicated 
in human diseases including neurodegeneration and cancer (Wood, Poole, et al. 2003; 
Georgiou & Masip 2003). Given their main role of monitoring H2O2 levels, any modifications to 
Prxs activity can alter redox dependent signalling pathways. Under high levels of oxidative 
stress, the cysteine residues can further be oxidised to sulphinic or to sulphonic acid, both of 
which can inactivate the protein (Wood, Poole, et al. 2003; Wood, Schröder, et al. 2003). Prx1 
and Prx2 were identified to be sulphenated on the membrane. Also, peroxiredoxin 1 and 2 are 
sulphenated in the cytosol irrespective of H2O2 treatment suggesting Prxs can be oxidised to 
form sulphenic acid under normal conditions. Recent findings also show Prx1 is sulphenated 
under normal physiological conditions (Hall et al. 2009; Devarie-Baez et al. 2016) 
However, recently the hyper oxidation of Prxs is shown to be reversible by sulfiredoxin, thereby 
reactivating the protein activity (Chang et al. 2004).  The mechanism of Prxs activity is quite 
interesting such that these abundant antioxidant can be inactivated by its own substrate. This 
in fact may be due to the sensitivity to the peroxide levels and thus protect the normal cellular 
metabolism by preventing H2O2 accumulation.  
α-enolase was also one of the proteins identified when T cell membranes were treated with 
H2O2. Intracellularly, α-enolase is responsible for dehydration of 2-phosphoglycerate to 
phosphoenolpyruvate during glycolysis. It is also highly present on the membranes of various 
cell types including B cells, macrophages, and T cells (Plow et al. 1991) it’s main role is to 
interact with plasminogen receptors on the membrane which allows extracellular proteolysis 
(Díaz-Ramos et al. 2012). α-enolase is known to undergo several PTM. α-enolase undergo 
phosphorylation and has been associated with pancreatic cancer (Tomaino et al. 2011), 
diabetic rat hearts showed nitration of tyrosine residues in α-enolase (Lu et al. 2010) and 
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carbonylation of α-enolase was shown in human myoblasts under oxidative stress (Baraibar 
et al. 2011). This chapter has showed that α-enolase undergoes sulphenic acid modification 
on the membrane of T cells. This was also shown by affinity capture in HEK 293 cells (Nelson 
et al. 2010). The inactivation or loss of α-enolase may lead to a decrease in localised 
plasminogen activation which may perhaps affect cell migration (Bennett et al. 2015; 
Majumdar et al. 2004). However, it still remains to fully understand how these PTM can affect 
α-enolase catalytic activity, protein stability and localisation. This will further provide an insight 
of how they play an important role in pathological conditions. Interestingly, Enolase α, 
peroxiredoxin 1, T complex protein 1 are found to undergo sulphenic acid modification in this 
study and according to the literature, these proteins were glutathionylated in T cells (Fratelli et 
al. 2002b). This observation may be explained that the above proteins undergo sulphenic acid 
modification followed by glutathionlyation. 
Sulphenic acid affects protein function as shown by Benitez and Allison, whereby they 
presented the first evidence of sulphenic acid by using dimeodone (5.5-dimethyl-1,3-
cyclohexadione), suggesting it can be used as a diagnostic tool for identification of 
sulphenated proteins. They identified GAPDH, which has an active cysteine at Cys149 to be 
sulphenated (Cowan-Jacob et al. 2003; Benitez & Allison 1974). The results from this study 
also identifies GAPDH as one of the protein undergoing sulphenylation. GAPDH is widely 
known to be sulphenated and its oxidation is linked to protein function (Maller et al. 2011; 
Peralta et al. 2015; Baty et al. 2005).  
Additionally, protein disulphide isomerase was also identified to be sulphenated in MP of 
Jurkat cells. PDI is mainly located in the endoplasmic reticulum but studies show it is secreted 
and associated with the cell surface (Jiang et al. 1999). Cell surface PDI is mainly involved in 
thiol disulphide exchange reaction, whereby it catalyses the reduction of protein disulphide 
bonds (Jiang et al. 1999). For example, PDI forms a disulphide and with glycoprotein 120 on 
the surface of cells promoting HIV entry in vivo (Wang et al. 2010). Through this process, PDI 
may be oxidised hence forming a sulphenic acid.  
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Cell-cell adhesion is important in inflammation and wound healing. Actin has one cys residue 
exposed to the molecular surface which is likely to undergo oxidation. Results from this study 
show actin is also sulphenated. As PDI is shown to form a disulphide bridge during cell 
adhesion rearranging the cytoskeleton, it may be possible that this disulphide bridge is formed 
via sulphenic acid formation (Sobierajska et al. 2014). Also, oxidation of actin cysteine residue 
to sulphenic acid may lead to glutathionylation (mixed disulphide formed when reacted with 
GSH) (Johansson & Lundberg 2007).   
Cofilin is an actin binding protein which plays a role in T cell migration and activation (Samstag 
et al. 2013). Cofilin in human T cells  has cysteine residues (at positions 39, 80, 140, and 148), 
which makes it more susceptible to oxidation leading to cofilin regulation via thiol modifications 
(Klemke et al. 2008). Cysteine oxidation in cofilin leads to T cell hypo-responsiveness and cell 
death by necrosis. This impairs actin dynamics during antigen presentation and synapse 
formation. Studies show treatment with H2O2 causes inter or intra molecular disulphide 
formation, inter molecular disulphide bridge between cysteines leads to cofilin dimers 
(Pfannstiel et al. 2001; Klemke et al. 2008). However, this study shows for the first time that 
cofilin is sulphenated in T cells further supporting that the idea that cofilin is susceptible to get 
oxidised, which may further impair T cell migration. -SOH is an inevitable intermediate for 
disulphide bond formation (Rehder & Borges 2010) and may promote protein-protein 
interaction. 
 
Various methods to detect sulphenic acid modification have been described (Poole et al. n.d.; 
Furdui & Poole 2014). Detection of sulphenic acid using DCP-Bio1 identifying via MS/MS 
analyses has provided promising outcomes in the past but with limitations. Mainly because 
the sulphenated sites were not identified. Here, this study has used similar technology hence 
limited to the peptides which are identified after enrichment following the use of streptavidin 
beads. Perhaps, different ionisation method may detect peptides with oxidised cysteines or 
labelled proteins analysed on LC-MS/MS. Another approach would be to trypsin digest the 
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peptides followed by biotin affinity capture of labelled peptides analysed by LC-MS/MS 
(Nelson et al. 2010). Although washing and streptavidin beads are used to capture biotinylated 
proteins, there may be some false positives. To directly identify oxidised cysteine, affinity 
capture of biotinylated peptides can be performed after trypsin digestion of proteins (Shin et 
al. 2007; Dennehy et al. 2006). The result of false positive without cysteine oxidation sites may 
be due to protein-protein interactions. For example, the labelled protein interacts with a protein 
which maybe pulled down and identified as sulphenated. Also, higher concentrations of the 
dimedone reagent can lead to non-specific binding to proteins.  
 
Additionally, since the first reversible oxidation of cysteine is sulphenic acid formation and was 
shown to be important in response to ROS, the specificity of dimedone based capturing of –
SOH has been looked into recently in the sense of specificity to Cys-SOH (Forman et al. 2017). 
This is because the thiols can also exist in the form of polysulphides (Cys-SSnH) or 
hydropersulphide (Cys-SSH). This has been shown to undergo sulphenic acid modification. 
DCP-Bio1 is capable of detecting protein with the presence of Cys-SSnH and an example was 
shown in a study by Heppner et al, whereby they confirmed the presence of Cys-SSH in EGF 
or ATP stimulated H292 cell lysates, particularly in protein tyrosine kinases which are 
susceptible to H2O2 (Heppner et al. 2018). This indicate the presence of possible further 
intermediate of reversible cysteine oxidation, which is yet to be characterised.  
The treatment with H2O2, did not yield a significant identification of new proteins. This may be 
due to the concentration used was not enough to oxidise majority of proteins within the lysate 
mixture. Also, it may suggest that the proteins are oxidised even further to higher oxidation 
states including disulphide and sulphinic acid formation (Brennan et al. 2004). Hence, these 
oxidation do not bind to DCP-Bio1 further showing the specificity of DCP-Bio1 to sulphenic 
acid modification only (Charles et al. 2007). However, several other proteins have been 
identified in the presence of H2O2, these include glutathione transferase P, a protein with 
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glutathione transferase activity. This can possibly be inactivated by sulphenation followed by 
glutathinoylation (Shen et al. 1991; Baty et al. 2005). 
Isocitrate dehydrogenase [NAD] undergoes sulphenic acid modification and others have 
shown that it is susceptible to increased ROS and oxidative modifications in turn damaging 
protein activity (Lee et al. 2001). However, the MP sample has pulled out mitochondrial 
proteins. This may be due to the approach taken to isolate membrane proteins which uses 
detergents to extract and solubilise total membrane proteins. 
Likewise, cysteine sulphenic acid modification is important as it may behave as a molecular 
switch to either activate or deactivate protein function. It was reasonable to follow up from the 
identified sulphenated proteins and how it may affect T cell function following exposure to 
increased oxidative stress. Ionotropic glutamate receptors are believed to be involved in 
regulating activation and proliferation in T cells, (Boldyrev et al. 2005; Ganor et al. 2003) 
including some evidence suggesting the role of N-methyl-D-aspartate receptor (NMDA) in 
Ca2+ signalling (Lombardi et al. 2001; Miglio et al. 2005; Affaticati et al. 2011). Also, an 
increase in intracellular Ca2+ is one of the key signals in T cell activation after TCR 
engagement.  To investigate the effects of possible modifications to membrane receptors 
responsible for T cell function, the cells were exposed to glycine and glutamate in the presence 
or absence of H2O2 and calcium influx was measured. The results obtained clearly showed 
that H2O2 decreased calcium influx and the treatment with NAC restored the calcium levels as 
100µM of glycine and glutamate and increases calcium influx in a study by (Guo et al. 2017). 
However, NMDA is not a key receptor responsible for Ca2+ influx and has low permeability for 
calcium. Similarly, the T cell membrane contains of plasma membrane Ca2+ ATPase (PMCA) 
which is mainly involved in Ca2+ signalling across the membrane (Lewis 2001). Furthermore, 
to further elaborate the effect of low calcium levels is due to NMDA activity, competitive and 
non-competitive NMDA receptor agonists would further clarify the results observed. These 
may include MK-801 and ketamine or amantadine as they have been shown to inhibit PHA 
induced T cell proliferation (Miglio et al. 2005). Additionally, this has been shown in a study by 
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the same group; whereby the NMDA channel blocker MK-801, inhibited PHA induced T cell 
proliferation but not IL-2 secretion suggesting that NMDA activity may modulate early phases 
of T cell activation and this was confirmed by surface CD25 expression. RA T cells have 
consistently shown reduced intracellular GSH levels, signifying presence of stress within cells. 
Treatment of T cells with NAC restores GSH levels and phosphorylation and localisation of 
LAT and hence promoting activation of T cells (Simeoni & Bogeski 2015b; S I Gringhuis et al. 
2000).   
 
This chapter has identified potential sulphenated proteins in T cell cytosol and membranes, a 
number of proteins consistent with earlier work done by either the literature or Ratnayake 2015 
(unpublished data). Additionally, an experiment was designed to look at oxidation of NMDA 
receptor function showing an effect on NMDA receptor-mediated Ca2+ influx. It is sensible to 
speculate that –SOH may behave as a redox switch and post translational regulator and 
increased oxidation may inhibit or activate protein function.   
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Chapter 4. GSH depletion influences intracellular Trx1 and Prx2 levels in 
T cells 
Preface 
 
Redox alteration is associated with a progressive decline in immune function that contributes 
to age-related diseases, including altered T cell function and proliferation and differentiation 
to different lineages. Key antioxidants are involved in removing ROS and maintaining the 
cellular redox state of the cell; these include GSH, Prx and Trx systems. However, the extent 
and role of Trx1 and Prx2 on the surface of T cells is poorly understood. Hence this chapter 
looked at the relationship of these antioxidants and membrane association in the presence of 
oxidative stress. These data suggest that the T cell responds to oxidative stress conditions via 
Trx, Prx and GSH system. Also, increased expression of Trx1 on the surface of Jurkat T cells 
may suggest that Trx1 distributes to the membrane when in oxidised form.  
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4.1 Introduction  
 
Growing evidence suggests that the cellular redox state affects various aspects of cellular 
function and since T cells are critical part of an immune response, any imbalance in the cellular 
redox state may affect or modulate the T cell reactivity (Kesarwani et al. 2013a). Recent 
evidence suggests the interaction between intracellular T cell redox environment and 
membrane proteins which can ultimately influence downstream T cell function (Mougiakakos 
et al. 2010b; Gelderman et al. 2006b; Carilho Torrao et al. 2013). 
A network of antioxidant systems that are distributed in the cytoplasm and various organelles 
in the cells are described to exist in humans. (Rahal et al., 2014). Many key regulators of redox 
signalling have been known and expressed in all organisms namely the glutathione, 
thioredoxin and peroxiredoxin (Lillig & Holmgren 2007a; Lillig et al. 2008; Hanschmann et al. 
2013a). The glutathione (GSH) redox system is described to be the most abundant antioxidant 
system in the cells (Hanschmann et al. 2013a; Peskin et al. 2016).  Cellular GSH concentration 
is dependent on gamma-glutamyl cysteinyl ligase (GCL), a heterodimer of modifier (GCLM) 
and catalytic (GCLC) ligase enzymes for its synthesis (Harris et al., 2015). During oxidative 
stress such as a decrease in protein thiols, the synthesis of GSH is increased to restore the 
redox state of the cell. The ratio of oxidised and reduced GSH, GSH to GSSG ratio is one of 
the most abundant signals of the redox status in mammals (Zitka et al. 2012). A decrease in 
this ratio; reduced to oxidised GSH might indicate the presence of oxidative stress at cellular 
or tissue level (Rahal et al., 2007).  
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Figure 4.1: GSH synthesis and recycling. The combination of L-Glutamate and L-cysteine is 
catalysed by glutamate cysteine ligase (GCL) in the presence of adenosine triphosphate (ATP) 
to form L-ɣGlutamyl-L-cysteine. Glycine is added in the presence of glutathione synthase 
(GS). The enzyme glutathione reductase (GSR) catalyses the reduction of oxidised 
glutathione (GSSG) back to reduced GSH in the presence of nicotinamide adenine 
dinucleotide phosphate (NADP). And the enzyme glutathione peroxidase (GSH-PX) catalyses 
GSH to GSSG in the presence of reactive oxygen species (ROS) (Guildford and Hope 2014). 
 
 
Trx1 is a conserved,  small protein (MW) of 12kDa with several redox active cysteine residues, 
found primarily in the cytosol and is translocated in the nucleus and associated in the cell 
membrane (Holmgren, A. 1985; Collet & Messens 2010; Carilho Torrao et al. 2013; Holmgren 
& Lu 2010). Recent evidence suggests that Trx1 is also secreted into the extracellular 
environment (Hanschmann et al. 2013a). The most favourable reaction for Trx1 is to reduce 
oxidised Prxs within a redox system. This suggests Prx as a favourable interaction partner of 
Trx1 during combating stressful conditions (Winterbourn & Hampton 2008).  
The Trx1 system is crucial and essential for protection against oxidative stress and plays a 
critical role in redox regulation of cells. This system consists of NADPH as a source of 
electrons, an enzyme thioredoxin reductase (TrxR) which catalyses the reduction of oxidised 
Trx1 (Figure 4.2) and indirectly, peroxiredoxin (Prx). Through its redox active cysteine 
residues, Trx1 maintains the cellular environment in a reduced state by receiving electrons 
from NADPH. In the presence of TrxR, reduced Trx1 transfers electrons thus reducing 
oxidised proteins including Prx with disulphide bonds (Arnér & Holmgren 2000). Depending 
on its cellular localisation Trx1 is involved in variety of physiological functions within the cell 
(Arner and Holmgren 2000) including; cell proliferation, cell growth and survival, apoptosis and 
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regulation of transcription (Lillig and Holmgren 2007). Trx1 catalyses reduction of disulphide 
bonds and quenches reactive oxygen species (ROS) by coupling with Trx-dependent 
peroxidases, or peroxiredoxins.  
 
 
Figure 4.2: The thioredoxin antioxidant system. Trx1 interacts with other proteins by donating 
electrons leading to oxidation of Trx1. Oxidised Trx1 is then reduced in the presence of TrxR 
enzyme and NADPH. (Adapted from Matsuo et al. 2002) 
 
Peroxiredoxins (Prxs) are highly conserved proteins that act as redox sensors and monitor 
signs of oxidative stress. They are divided into 6 isoforms (Prx1-6). 2-Cys Prx (Prx 1-4) have 
an additional conserved cysteine residue responsible for resolving the oxidised cysteine 
(Smith-Pearson et al. 2008). Prxs have been found to be present in different locations within 
the cells; Prx 1, 2 and 4 have been predominantly found in the cytoplasm and also have been 
found in the nucleus (Oberley et al. 2001; Seo et al. 2000; Kang et al. 1998). Prx2 has been 
previously described as being associated with the membrane of lymphocytes (Szabó-Taylor 
et al. 2012a) and Trx1 is one of the reducing partners of Prx2 (Szabó et al. 2009). They are 
mostly known as the antioxidants which remove excessive amounts of H2O2 and peroxynitrite 
(Peskin et al. 2016; Winterbourn & Hampton 2015; Randall et al. 2013; Jarvis et al. 2012).  
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Figure 4.3: The link between antioxidants and the maintenance of cellular redox state through 
reduction of H2O2. Reduced molecules are proteins with hydrogen and disulphide and or 
sulphenation shows oxidation. Trx1-SS oxidised thioredoxin, Trx1-(SH)2- reduced thioredxoin,  
Prx-SS oxidised peroxiredoxin, Prx-(SH)2- reduced peroxiredoxin, Prx-SOH- sulphenated 
peroxiredoxin, Grx- glutaredoxin, Grx (SH)2 – reduced glutaredoxin, GSR - glutathione 
reductase, GSH - reduced glutathione, GSSG - oxidised glutathione, RSSG- glutathionylated 
protein, NADP+ - oxidised NADP, NADPH - reduced NADPH, RSSR - protein disulphide, 
RSOH -sulphenated protein, RSH - reduced protein, ARF - auranofin,  
 
Even though, Trx1 and Prx2 together with GSH constitute a key system in redox balance, the 
relationship between them and the significance of redox enzymes as redox modifiers has not 
been completely understood in the context of their membrane association and distribution. 
Hence, this chapter aims to increase the understanding of how Trx1 and Prx2 are affected by 
the absence of GSH. Improved understanding of any changes in expression or distribution of 
Trx1 and Prx2 might improve our understanding of redox regulation in T cell responses. The 
objectives of this chapter are as follows: 
- To optimise non-toxic BSO concentration to inhibit GSH synthesis 
- To investigate Trx1 oxidation in absence of TrxR 
- To examine the effect of BSO and ARF on Trx1 and Prx2 distribution using western 
blot analysis and flow cytometry 
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4.2. Methods  
 
4.2.1. Jurkat T cell culture  
 
Jurkat T cells were cultured according to the methods section 2.2.1. 
4.2.2. Cell treatments  
 
Jurkat T cells were passaged until reached certain confluency ~3-5x105/ml in a T75 tissue 
culture flask. On the day of treatment the cells were washed with complete RPMI and counted 
using a haemocytometer and plated in a 12 well plate at an assay-dependent concentration.  
Cells were lysed with RIPA buffer, briefly, harvested cells were centrifuged at 4°C and wash 
with ice-cold PBS. Ice cold RIPA buffer was added and agitated for 30mins at 4°C. The 
sample was resuspended with 25 guage needle and centrifuged at 16,000 x g for 20 minutes 
in a 4°C pre-cooled centrifuge. After centrifugation, the supernatant was collected and 
analysed for further experiments. Protein concentration was determined by BCA assay as 
described in 2.2.3. 
 
4.3.3. Surface and total staining for Trx1 and Prx2 
 
1x106 of BSO and ARF-treated (0 and 25µM; 24h, 0 and 25µM, 2h) T cells were collected and 
washed twice with PBS by centrifugation at 300g for 5 minutes. The cells were resuspended 
in PBS (1%FBS), aliquoted into separate tubes for individual staining (5x105/per surface stain). 
To label, they were incubated with primary anti-Trx1 (ab16965, 1µl/106cells)) and or rabbit 
anti-Prx2 and mouse IgG2b isotype control (ab91366 1µl/106cells) for 30min in the dark. 
Following one wash, the cells were incubated with goat anti-mouse IgG H&L (DyLight® 488) 
(ab96879 1µl/106 cells) for 30min in the dark. The cells were analysed on cytomics FC 500 
(Beckman Coulter). 
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For total Trx1 and Prx2 staining the cells were permeabilised with 0.1% w/v saponin. The 
permeabilised samples were incubated with primary antibody primary anti-Trx1 (ab16965, 
1µl/106cells) and or rabbit anti-Prx2 and mouse IgG2b isotype control (ab91366 1µl/106cells) 
for 30min in the dark. Following one wash, the cells were incubated with goat anti-mouse IgG 
H&L (DyLight® 488) (ab96879 1µl/106 cells) for 30min in the dark. The cells were analysed 
on cytomics FC 500 (Beckman Coulter). 
4.2.4. GSH Assay  
 
Intracellular GSH and GSSG was determined by GSH recycling assay as described in the 
methods section 2.2.11. 
 
4.2.5. SDS PAGE and WB 
 
Membrane and cytosolic proteins were isolated as described in the methods section 2.2.4. 
Isolated CP and MP were separated under reducing and non-reducing conditions according 
to the protocol described in 2.2.2 above.   
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4.3. Results 
 
4.3.1. BSO depletes GSH levels in Jurkat T cells  
 
In order to investigate whether an alteration in cellular redox state leads to redistribution on 
Trx1 within the cells and develop a suitable model for inducing oxidative stress, Jurkat T cells 
were treated with buthionine sulphoximine (BSO), which inhibits the enzymatic activity of ɣ-
glutamylcysteine synthetase (ɣ-GCS). After 24h incubation, BSO depleted intracellular 
reduced GSH (untreated 85.74±20.12; 25µM 26.12±1.95 and 50µM 20.86±5.683 nmol/mg of 
protein) levels significantly in Jurkat T cells (Figure 4.4a). To examine the toxicity of BSO, the 
Jurkat T cell viability was measured using trypan blue exclusion. The cell viability was not 
affected at concentrations up to 50µM BSO over 24 hours showing that BSO was not toxic to 
Jurkat T cells (Figure 4.4b).  
 
a)                                                                                             b) 
C o n tr o l 2 5 µ M  5 0 µ M  
0
5 0
1 0 0
1 5 0
N
o
r
m
a
li
s
e
d
 G
S
H
C
o
n
c
e
n
tr
a
ti
o
n
(n
m
o
l/
m
g
 o
f 
p
r
o
te
in
)
*
**
B S O  c o n c e n tra tio n
 
Figure 4.4: BSO depletes GSH levels in Jurkat T cells without affecting cell viability. Jurkat T 
cells (1x106/ml) were treated   with 25 µM or 50 µM BSO for 24h. a) Intracellular GSH levels 
were determined by GSH recycling assay. b) Cell viability was measured the following day by 
trypan blue exclusion. Data represents the mean and standard error of the mean of three 
experiments, n=3 **p <0.0075, ANOVA with Dunnett’s test 
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4.3.2. ARF increases monomeric and dimeric Trx1 in Jurkat T cells  
 
In order to manipulate Trx1 redox state, Jurkat T cells were treated with auranofin (ARF). The 
toxicity of ARF was first examined by treating Jurkat T cells with 25µM or 50µM concentrations 
of ARF and Jurkat cell viability was assessed by trypan blue exclusion method (Figure 4.5a). 
Treatment with ARF at concentrations at 25µM or 50µM for 2h did not affect cell viability. 
Monomeric form of Trx1 was detected at 12kDa and dimeric form detected at 25kDa after 
separating on a non-reducing SDS PAGE (Figure 4.5b) The presence of 25kDa band on a 
non-reducing gel suggests that the treatment of Jurkat T cells with ARF leads to formation of 
dimers by a disulphide bridge and the intensity of the dimer increases with increasing 
concentration of ARF.  
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Figure 4.5: Effect of increasing concentrations of ARF on cell viability and Trx1 oxidation. 
1x106 Jurkat cells were treated with 0, 25 and 50µM of ARF for 2h. a) Cell viability was 
measured after 2h by trypan blue exclusion. Data shown is the mean and standard error of 
the mean n=3. b) Non-reducing SDS-PAGE-western blot for Trx1 and β-actin. Blots were 
probed with monoclonal mouse anti-β actin (1:30,000 for 2h) and mouse anti-human Trx1 
(1:1000, 2h ab16965) before detection with goat anti-mouse IgG HRP (1:10,000 for 2h, A1068) 
developed using ECL detection kit. This blot is representative of three independent 
experiments. 
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4.3.3. ARF depletes GSH levels in Jurkat T cells 
 
In order to examine the effect of ARF on intracellular GSH, Jurkat T cells were treated with 
ARF (25µM, 2h) and total cellular GSH levels were measured after treatments. The data 
(Figure 4.6) confirms observations in Figure 4.4a, that 25µM BSO depleted GSH levels 
compared to control (untreated 144.5±22.77 and BSO 25µM 11.08±5.49) whereas Jurkat T 
cells treated with ARF also show a significant decrease in GSH levels when normalised to the 
total protein concentration in the cell (ARF 25µM; 67.64±11.23; p<0.006). Both BSO and ARF 
treatments also reduced the level of GSSG in Jurkat cells (Figure 4.6b), however no statistical 
significance was observed. 
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Figure 4.6: Effect of BSO and ARF on GSH and GSSG concentration. 1x106 Jurkat cells were 
treated with 25µM of BSO for 24h, GSH level was measured by the DTNB recycling assay 
using glutathione reductase. Data represents mean and SEM, one way ANOVA, Dunnett's 
multiple comparisons test ****p<0.0001, **p<0.006. 
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4.3.4. The redox state of Trx1 in the presence of BSO and ARF 
 
In order to evaluate Trx1 redox state and to investigate whether any mixed disulphides of Trx1 
are observed in Jurkat T cells under redox stress where the cells were treated with BSO 
(25µM, 24h) and ARF (25µM; 2h). Cells were lysed with RIPA buffer and the lysates were 
separated in 15% SDS PAGE gel under reducing (β-mercaptoethanol) and non-reducing 
conditions by eliminating β-mercaptoethanol. Non-reducing conditions prevent the breakdown 
of disulphide bridges and aid the identification of proteins that are associated with Trx1 under 
oxidative stress. A 12kDa band was detected in reducing condition as seen from Figure 4.7a. 
Additionally, reduced Trx1 expression was increased when the cells were treated with BSO 
after 24h.  
In addition, Figure 4.7b show a number of protein bands in non-reducing SDS-PAGE-WB 
conditions. High molecular weight bands of approximately 37kDa were observed when protein 
samples were separated under non-reducing conditions, irrespective of BSO or ARF 
treatment.  
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               a) Reducing western blot                                                  b) Non-reducing western blot  
 
                                                                                            
                                                                                              
 
 
 
 
 
 
 
 
 
                                  Ponceau red                                                               Ponceau red  
 
 
Figure 4.7: Western blot analysis of Trx1 expression after BSO and ARF treatment. 1x106/ml 
Jurkat T cells were treated with BSO 25µM; 24h and ARF 25µM; 2h in complete RPMI and 
lysed using RIPA buffer. Proteins (20µg) were separated using 15% SDS PAGE in reducing 
(a) and non-reducing (b) conditions and transferred to PVDF membrane, blocked with 3% BSA 
and probed with primary mouse anti-human Trx1 ((1:1000) for 2h) and goat anti-mouse  IgG 
HRP (1:10,000 for 2h, A1068). (1:20,000) for 2h and developed using ECL detection kit. This 
blot is representative of three independent experiments. b) Non-reducing blot in 4X non-
reducing buffer.  
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4.3.5. Membrane and cytosolic distribution of Trx1  
 
To explore whether the distribution of Trx1 between membrane and cytosol is different under 
oxidative stress, the membrane and cytosolic proteins were extracted after Jurkat T cells were 
treated with BSO and ARF. Trx1 is accumulated in the cytosol when cells were treated with 
BSO as shown in Figure 4.8a and Figure 4.8c) which shows an increased band intensity in 
ARF-treated cells compared to untreated in the cytosol relative to protein loaded. this was 
shown by probing the cytosolic proteins with NF-κB, which is the most abundant protein within 
the cytosol. On the other hand, Figure 4.8b shows a band of approximately 12kDa confirming 
the presence of Trx1 in the membrane, but no change to the intensity was observed between 
the untreated and BSO treated cells (Figure 4.8c). However, Trx1 is distributed to the 
membrane when the cells were treated with ARF compared to untreated cells (Figure 4.8b 
and 4.8d). The membrane was later re-probed for CD3Ɛ as loading control for membrane 
proteins to verify the protein loaded.  
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Figure 4.8: Reducing SDS PAGE WB showing that Trx1 expression in the cytosol and 
membrane of Jurkat T cells under oxidative  stress. 4x106 jurkat T cells treated with BSO 
25µM; 24h and ARF 25µM; 2h in complete RPMI. Membrane and cytoslic protein fractions 
were isolated and protein concentration measured using BCA assay. 20µg protein was 
separated using 15% SDS PAGE and transferred to PVDF membrane, blocked with 3% BSA 
overnight and probed with mouse anti-human Trx1 (1:1000);2h) and goat anti-mouse  IgG 
HRP (1:10,000 for 2h, A1068). Rabbit anti-CD3Ɛ  antibody (1:1000; 2h) and rabbit anti-NF-κB 
p65 (1:1000, 2h) and secondary goat anti-rabbit (1:10000; 2h) developed with ECL reagent. 
a) cytosolic and b) membrane proteins. These blots are representative of three independent 
experiments. c) and d) Semi quantitative analysis of Trx1 distribution of cytosolic and 
membrane proteins analysed by ImageJ software. Data represents three independent 
experiments n=3, on way ANOVA, Dunnetts multiple comparison test. 
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4.3.6. Trx1 distribution using flow cytometry  
 
To further explore membrane distribution of Trx1 under oxidative stress conditions, the 
expression of Trx1 was analysed on the surface by flow cytometry.  
Jurkat cells were treated with 25 µM BSO and 25µM ARF and analysed using flow cytometry 
(Figure 4.9a). Trx1 expression in the presence of 25 µM BSO was decreased on the surface 
compared to untreated control. The MFI value which shows surface Trx1 expression per cell 
was 77.49±4 and 81.72±5.5 for BSO treated and untreated Jurkat cells. However, 25µM ARF 
treatment significantly increased (MFI; 370.9±120.8) surface Trx1 expression.   
To further investigate whether the redistribution of Trx1 is specific to ARF treatment and to 
rule out the possibility other stress conditions such as serum starvation, Jurkat T cells were 
treated with indicated concentrations of serum in the media for 24h to induce serum-starvation 
stress and the distribution of Trx1 was analysed. Figure 4.9d shows no change in total Trx1 
according to nutrient availability and surface Trx1 appeared to be lower in serum starved cells 
(Figure 4.9c). 
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     c)                                                                                                        d)           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Distribution of Trx1 onto the surface of Jurkat cells. 1x106/ml Jurkat T cells were 
treated with BSO 25μM and ARF 25μM for 24h and 2h respectively. The cells were collected 
and analysed for a) MFI of cells expressing surface Trx1 and b) cells permeabilised using 
0.1% w/v saponin to analyse total Trx1. Data represents the mean and standard error of the 
mean of three independent experiments n=3. **p< 0.0012. Additionally, 1x 106 Jurkat cells 
treated with 0%, 1% and 10% FBS RPMI media for 24h and Trx1 distribution was analysed c) 
on the surface and d) total trx1. Data represents one independent experiment. Mouse anti-
human Trx1 IgG2b (ab16965; 1μl/106 cells; 20min) goat anti-mouse IgG H&L (DyLight® 488) 
(ab96879 1μl/106 cells; 20min) and mouse IgG2b isotype control (ab91366 1μl/106cells). Trx1 
positive cells were gated at 1% of the isotype control and the data was collected for 10,000 
events and analysed using Flowing software v 2.5.1.  
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4.3.7. Prx2 levels is increased on the membrane when treated with ARF. 
 
In order to evaluate the association of Prx2 with T cell membrane, the level of Prx2 expression  
was also investigated  in the membrane and cytosol fractions in the presence or absence of 
BSO and ARF (Figure 4.10). Increased band intensity of Prx2 was observed when Jurkat cells 
were treated with BSO compared to the untreated control. Jurkat cells treated with ARF show 
a significant increase in membrane Prx2 according to the densitometry (Figure 4.10d). This 
suggests that Prx2 is likely to  be distributed in the membrane at low intracellular GSH and  
Trx1 levels.  However,  no visible difference  in the band intensity was observed in the cytosol.  
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a)                                                                                              b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
        Ponceau red stain                                                                              Ponceau red stain 
 
c)                                                                                                               d) 
 
 
 
 
 
 
 
 
 
Figure 4.10: SDS-PAGE showing cytosolic and membrane distribution of Prx2 when Jurkat T 
cells are treated with BSO and ARF. 1x106 Jurkat T cells treated with BSO 25µM;24h and 
ARF 25µM; 2h in complete RPMI. Membrane and cytoslic protein fractions were isolated and 
protein concentration measured using BCA assay. 20µg protein was separated using 15% 
SDS PAGE and transferred to PVDF membrane, blocked with 3% BSA overnight and probed 
with rabbit anti-Prx2 (ab109367; 1:1000);2h) and goat anti-rabbit HRP (1:5000 for 2h). 
developed with ECL reagent. a) cytosolic and b) membrane proteins.  These blots are 
representative of three independent experiments.  Semi quantitative analysis of Prx2 in the c) 
cytosol and d) membrane. Data represents three independent experiments n=3, analysed by 
ImageJ software. One way ANOVA, Dunnetts multiple comparison test, *p<0.04 
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4.3.8. Prx2 distribution using flow cytometry 
 
In order to support the result obtained in Figure 4.10, surface Prx2 levels were also determined 
using flow cytometry. T cells show a significant increase in surface Prx2 when treated with 
ARF (MFI; 364.2±10.18) as shown in Figure 4.11 as compared to untreated (MFI; 171.2±3.55). 
However, BSO treatment did not change Trx1 distribution on to the membrane (MFI; 
180.1±3.43). This suggests that membrane-bound Prx2 level is greater when cells treated with 
ARF. Additionally, this supports the result obtained using western blot analysis, whereby Prx2 
level is increased when treated with ARF consistent with WB. Furthermore, no difference was 
observed in the total Prx2 levels when treated with BSO and ARF, similar result obtained as 
previously on western blot.  
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Figure 4.11. Distribution of Prx2 onto the surface of Jurkat cells. Jurkat T cells (1x106/ml) were 
treated with BSO 25µM for 24h and ARF for 2h respectively. The cells were collected and 
analysed for a) MFI of surface Prx2 and b) MFI values for total Prx2 in the cells. Rabbit anti-
Prx2 (ab109367; 1μl/106 cells; 20min) goat anti-rabbit IgG H&L (DyLight® 488) (A-11034; 
1μl/106 cells; 20min). Prx2 positive cells were gated at 1% of the unstained control and the 
data was collected for 10,000 events and analysed using Flowing software v 2.5.1. Data 
represents mean and SEM of three independent experiments. n=3, one way ANOVA Tukey’s 
multiple comparison test ****p<0.0001.  
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4.3.9. Trx1 secretion when treated with BSO and ARF 
 
In order to further understand whether the increase in surface Trx1 associates with changes 
to extracellular secretion, the cells were treated with BSO and ARF and the secreted Trx1 was 
determined using competition ELISA in the supernatants (Figure 4.12). There is no significant 
difference in the extracellular secreted Trx1 levels when treated with BSO or ARF.  
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Figure 4.12. Level of secreted Trx1 when treated with BSO and ARF. Jurkat T cells were 
treated with BSO 25µM for 24h and ARF for 2h respectively. The supernatants were collected 
after centrifugation and analysed for Trx1 by competition ELISA. Data represents three 
independent experiments, n=3. 
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4.4. Discussion 
 
The work in this chapter shows that non-toxic concentrations of BSO lead to increased Trx1 
in the cytosol of Jurkat T cells. For the first time, this study has shown ARF leads to an increase 
in surface Trx1 and an accumulation of Trx1 intracellularly in aggregated forms. Moreover, 
surface Prx2 increases in the presence of ARF however, no difference was observed when 
the T cells were treated with BSO. 
 
It is established that there is a significant decrease of immune cell function during ageing and 
age related diseases, which leads to immune dysfunction and reduced antigen specific 
immune response. One of the main characteristic of ageing T cells is accumulative oxidative 
stress (Espino et al., 2012), resulting protein- thiol oxidation and eventually changing protein 
function. The presence of oxidative stress with age is widely accepted and T cell studies reveal 
a direct association between altered T cell function and increased oxidative stress (reviewed 
by Bennett and Griffiths 2012). The presence of thiol (-SH) group allows GSH to initiate its 
scavenging effects (Jones et al. 2002). It also acts as the most abundant antioxidant within 
cells. Increased oxidative stress may arise due to lack of free thiols on protein surface or 
intracellularly and oxidation of thioredoxin and GSH leading to accumulation of ROS/RNS. 
Based on these observations this study was focused on investigating the effect of key 
antioxidant systems; the GSH, Trx and Prx system. These antioxidant systems were 
manipulated by adding BSO and ARF, which inhibited the synthesis of GSH and TrxR activity 
respectively. To confirm the activity of BSO on GSH levels, Jurkat T cells were treated with 
different concentration of BSO. BSO is widely used in vivo studies to deplete GSH levels by 
inhibiting ɣ-GCS synthesis and disrupt cellular GSH redox system. This affects a range of 
cellular mechanisms including cell proliferation (Go et al., 2013). This allowed the selection of 
optimum concentration of BSO (25μM) to inhibit GSH synthesis in the cells without being toxic 
to cells. Next, Jurkat T cells were treated with ARF to inhibit TrxR activity at different 
concentrations to obtain the optimum concentration without affecting the cell viability. ARF is 
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a gold compound that inhibits the catalytic activity of thioredoxin reductase (TrxR). It is also 
used to treat rheumatoid arthritis and as an anticancer drug (Go et al., 2013). WB suggests 
that ARF leads to oxidation of Trx1 by inhibiting TrxR activity although, ARF causes cell death 
and necrosis if treated for longer; 6h at 5µM (higher doses). Cox et al. 2008 showed that ARF 
causes cell death in Jurkat lymphomas and that it disrupts the mitochondrial redox 
homeostasis thus leading to apoptotic signalling events. Apoptosis signalling kinase 1 plays a 
major role in cytokine and stress-induced apoptosis including TNF (Saitoh et al. 1998; Liu et 
al. 2000). Since ASK1, which regulates apoptosis, is reduced by Trx1, Trx1 oxidation will lead 
to activation of forms of ASK1 found in the mitochondria and cytoplasm which are respectively 
inhibited by reduced form of Trx1. Even though ARF mediated TrxR inhibition promotes 
apoptotic or necrotic pathways, this action is depends on ARF concentration and cell type. For 
example; Jurkat cells treated with ARF for 24h significantly reduced number of viable cells. In 
contrast, apoptosis resistant B9 cell line did not show a decrease in viability but no increase 
in total number of cells was observed suggesting that ARF at 2µM for 24h inhibits proliferation 
(Cox et al., 2008). Oxidation of Trx1 leads to accumulation of intracellular ROS and cell death 
(Du et al. 2013). In this study ARF at 25µM results in accumulation of oxidised Trx1 after 2h.  
This is due to the inhibition of TrxR enzyme which is responsible to keep Trx1 in a reduced 
state. The mechanism of how ARF inhibits TrxR is not clear.  However, according to 
pharmacological studies, ARF reacts with Selenocysteine 496 of TrxR  by forming a diselenide 
bridges with the residue (Becker et al. 2000). Additionally, a study suggests that ARF leads to 
oxidation of all Prxs including Prx2, and that Prx2 was more sensitive to oxidation then Prx1 
in the cytoplasm (Cox et al. 2008). This explains the relationship between Trx1 and Prx2 and 
that oxidation of Trx1 when treated with ARF may also lead to Prx2 oxidation.   
 
Mammalian cells have variety of antioxidant mechanisms which allow to maintain cellular 
redox state. However, decreased GSH levels in ARF treated cells may show that the way cell 
responds to oxidative stress is linked such that GSH and Trx system might play a role together 
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to eliminate ROS by using NADPH as a source of electrons (Sobhakumari et al., 2012). 
Increased band intensity of Trx1 in the presence of BSO suggests accumulation of Trx1 in the 
cytosol in the absence of GSH. Also, reduced intracellular GSH level is also decreased in the 
absence of reduced Trx1 as shown in results. Under physiological conditions, the maintenance 
of redox states of Trx1 and GSH depend on each other and respond similarly to acute oxidative 
stress (Watson and Jones 2003). Additionally, a study showing the increase in Trx1 
expression genes in GCLM knock out models and suggests that the Trx system can efficiently 
reduce ROS levels and can be regenerated by TrxR in a GSH independent manner (Harris et 
al., 2015), and upregulation of Trx activity is observed in low levels of GSH in acute liver failure 
(ALF) mice (Ruszkiewicz and Albrecht 2015). Additionally, a study by Go et el showed that 
Trx1 redox state was not affected by BSO treatments up to 200µM, but was significantly 
oxidised at 500µM in HT29 cells (Go et al. 2013b). This suggests that lower concentration of 
BSO is not sufficient to alter the redox state of Trx1.  
Furthermore, to maintain a reducing environment, the expression of Trx1 is increased 
interacting with a number of binding partners. Increased expression of Trx1 in the cell has 
been shown in variety of stress conditions including oxidative stress, cellular stress and viral 
infections (Nakamura et al., 1999). On the other hand TrxR can reduce other proteins (Go et 
al 2013), which can affect several cellular functions such as detoxification of ROS and actin 
cytoskeletal control in neutrophils (Fang et al. 2005; Thom et al. 2012) .  
The results obtained from western blotting of the protein samples in the absence of β-
mercaptoethanol show a broad smearing of high molecular weight bands suggesting that 
possible interaction partners bound to Trx1 are linked by a disulphide bridge under non-
reducing conditions. There are a number of binding partners which bind to Trx1 in order to 
restore their redox state within the cells in addition to controlling the protein activity and 
biological function as reported in literature. These include Prx, and intracellular proteins e.g. 
ASK-1, Txnip, transcription factors such as NF-kB, AP-1 and actin (Hirota et al. 1999; Kabe et 
al. 2005; Zschauer et al., 2010;Lillig & Holmgren 2007b);). In order to detect Trx1 binding 
126 
 
protein partners as reported in literature, western blotting of the targeted protein might be 
useful in the future. 
Additionally, co-immunoprecipitation techniques will be a more useful approach to target 
protein binding partners of Trx1. By targeting the Trx1 using anti-Trx1 it may be possible to 
pull down the entire protein complex and thus identify the unknown partners of the complex. 
Additionally, other native techniques including blue native polyacrylamide gel electrophoresis 
(Blue native PAGE), which involves the separation of protein complexes according to their 
size is a valuable technique to study protein-protein interaction. Another approach to isolate 
membrane proteins which involves streptavidin beads, this captures surface proteins before 
addition of any detergent and washes which lowers the chances of losing low affinity proteins 
(Carilho Torrao et al. 2013). By using these techniques and other tools available we can 
possibly identify the binding partners of Trx1 on the membrane in the future. 
Trx1 is widely distributed across the cell including the cytosol, nucleus and the membrane. 
This chapter primarily focuses on the changes to Trx1 and Prx2 distribution between 
membrane and cytosol under oxidative stress conditions.  
Western blot experiments indicated that the distribution of Trx1 in the membrane was low with 
barely detectable band intensity. However, Trx1 levels in the cytosol is greater when the cells 
were treated with BSO. This may explain the retaining of Trx1 in the absence of GSH and that 
Trx1 may compensate for cytosolic reducing activity in the absence of GSH. Also, the 
possibility of Trx1 to redistribute from the membranes of Jurkat T cells as shown by Carilho 
Torrao et al. 2013 is shown in this chapter.   
Even though others have reported membrane localisation of Trx1, how the protein is anchored 
onto the membrane and why inhibiting the activity of TrxR would lead to redistribution of Trx1 
onto the membrane and oxidation of Trx1 leads to accumulation in the membrane, is still 
unclear. In addition, another form of TrxR inhibitor such as Lanthanum chloride (LaCl3) was 
shown to prevent accumulation of Trx1 in the nucleus hence excluding oxidised Trx1 from the 
nucleus in neutrophils (Trevelin et al. 2016). However, it is believed the cysteine residue allows 
127 
 
anchorage to the membrane and tend to dissociate when exposed to detergents including 
DTT and methyl-β-cyclodextrin (Kondo et al. 2007b). Under oxidising conditions the disulphide 
which crosslinks Trx1 onto the membrane proteins is likely attach onto the membrane lipid 
rafts and not be released. Thus it is unclear of how the cellular and membrane distribution of 
Trx1 is maintained.  It is assumed that, the thiols present in which make up Trx1 may be 
involved in the migration of the protein to the surface.  However, there are no membrane export 
or membrane localisation sequences present on Trx1 gene (Wollman et al., 1988). Previous 
work from our lab demonstrated that  Trx1 expression on the T cell surface is less in older 
adults compared to younger adults and may reflect the fact that the cells are more oxidised 
with age (Carilho Torrao et al. 2013).  
Regarding the role it plays on the surface, some studies indicate that the Trx1 present on the 
surface of T cells may reduce certain receptors which are crucial in T cell activation as T cell 
activation requires a reduced environment. This includes the membrane domain localisation 
of CD4 which is regulated by Trx1, providing a hypothesis that T cell activation could be directly 
related to Trx1 dependent CD4 translocation (Moolla et al. 2016b). Also, it induces redox 
changes in glycoprotein 120 (gp120) on the surface (Azimi et al. 2010). Additionally, Trx1 is 
known to regulate cytokine activity such as IL-2 by reduction of intramolecular disulphides 
(Curbo et al. 2009).  Besides, proteins on the surface may normally be oxidised and prevent 
T cell activation thus the –SH groups on the surface are maintained in a reduced state by 
redox active residues (Gelderman et al., 2006). Trx1 might modulate –SH of membrane target 
proteins to transduce its signal during cell-cell interaction. However, specific proteins or 
receptor which directly interact with Trx1 on the surface have not been discovered yet. It is 
also unknown to what state the Trx1 is on the surface; reduced or oxidised as ARF leads to 
accumulation of oxidised Trx1 in the cytosol. BSO and ARF have been shown to modify 
reduced free thiols on the membrane (Skalska et al. 2012). Further looking into thiol groups –
SH using optimised conditions of maleimide will provide the number of free thiols on the 
surface in the next chapter.   
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This chapter also looked at the distribution of Prx2 levels and how it is affected when Jurkat 
cells are exposed to BSO and ARF. The results obtained suggests that the levels of Prx2 does 
not change in the absence of GSH or reduced Trx1. There is very little evidence suggesting 
the presence of Prx2 on the membrane. However, Szabó-Taylor et al 2012 show significant 
higher levels of Prx2 on the membrane of B lymphocytes in RA and a greater frequency of 
cells with surface Prx2 (Szabó-Taylor et al. 2012a). Prx2 is widely known as redox partners of 
Trx1 (Wood, et al. 2003), thereby studying the role of Prx2 might develop an understanding 
how they regulate the ROS levels within cells or enable reduction of membrane proteins by 
acting in partnership. From the results obtained in this chapter, ARF leads to increased levels 
of Prx2 on the surface, consistent with Trx1. This might propose Prx as being Trx1 dependent 
antioxidant system. For example, H2O2 reacts directly with Prx which leads to Prx oxidation, 
this then is reduced by its interacting partner Trx1 (Netto & Antunes 2016). It is not necessary 
that oxidised Prx is due to increasing amounts of H2O2 but inhibition of Trx1 system by 
auranofin will have the same effect (Gromer et al. 1998). Hence all redox sensitive proteins 
monitored closely and inhibition of interacting protein may lead to oxidation as well rather than 
increased ROS generation. Another approach would be to analyse the redox state of Prx2 in 
the presence of auranofin by eliminating reducing agents including DTT. 
Healthy lymphocytes are reported to secrete Trx1 including T cells, macrophages and 
neutrophils which follows a non-classical pathway (Rubartelli et al. 1992; S. Salzano et al. 
2014). It has cytokine like function and acts as a chemoattractant in the extracellular 
environment, recruiting cells during infection and inflammation (R Bertini et al. 1999) Finally, 
this chapter looked at whether the increase in surface Trx1 is also associated with increased 
secretion. However, no significant difference of the Trx1 levels was observed in the cell 
supernatants under normal or treated conditions suggesting that the increased levels of 
surface Trx1 observed previously is not associated with Trx1 secretion into the extracellular 
environment. 
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Since no change was seen in the secretion of Trx1 by ARF-treated cells, secretion may be 
independent of the redox state of the cell. Tanudji et al, showed that the redox state of the cell 
or Trx1 itself does not impact on its secretion, and the secretion of Trx1 is a slow and efficient 
process (Tanudji et al. 2003). Alternatively, analysis of secreted Trx1 after 2h incubation may 
not be effective and non-classical secretion pathway may be time dependent.  
Therefore, this chapter has shown how each GSH and Trx1 redox system play a role in 
oxidative stress conditions within the cell in addition to Prx2 distribution. BSO depletes GSH 
and translocation of Trx1 on the surface.  However, in the absence of reduced Trx1, increased 
levels of Trx1 and Prx2 were observed on the surface of T cells. Jurkat T cell line was used to 
establish a model to detect redox regulating proteins on the surface which can further be 
carried on primary CD4+ T cell activation and collagen induced arthritis mice with or without 
Ncf1 gene expression. 
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Chapter 5. Identification of sulphenated membrane proteins during T cell 
activation in the presence and absence of H2O2. 
 
Preface  
 
T cell receptor signalling requires a reduced cell surface protein environment and increased 
reactive oxygen species (ROS) inhibit T cell activation. The main objective of this chapter was 
to identify sulphenated proteins on the membrane of T cells at rest, during activation and under 
oxidising conditions. Results show that increased peroxide concentration lead to a significant 
decrease in IL-2 secretion and intracellular GSH. Furthermore, activation alone did not affect 
the number of sulphenated membrane proteins. Activation in the presence of H2O2, which is 
associated with lower intracellular calcium flux, show a reduction in number of sulphenated 
proteins possibly due to further oxidation including disulphide bond formation  
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5.1. Introduction 
 
T cells are critical for developing a specific immune response to a foreign pathogen. Activation 
of T cells, including CD4+ and CD8+ T cells, occurs when antigenic peptide is presented by 
MHC I or II on the surface of antigen presenting cells (APC). This activates a signalling 
cascade which results in the secretion of IL-2 and increase in expression of IL-2 receptor 
(CD25) on the surface in CD4+ T cells. The binding of IL-2 to its receptors stimulates the CD4+ 
T cells to proliferate and differentiate into effector cells and different T cell subtypes. CD8+ T 
cells are mainly involved in killing virally infected cells with similar cytokine secreted as Th1 
and Th2 cells. The rapid induction of ROS by T cells upon TCR stimulation depends on 
NADPH oxidases (NOX) (Jackson et al. 2004; Belikov et al. 2014). Once the T cells are 
activated, the constituents of NOX-2 assemble at the plasma membrane and generate O2·- by 
transferring electrons from the cytosol to the extracellular space. Subsequently, 
O2·- dismutates into H2O2 (Bedard and Krause, 2007). NOX-2 is an important source of ROS 
in T cells as NOX-2-deficient T cells display strongly reduced O2·- and H2O2 production 
(Jackson et al. 2004; Belikov et al. 2014).  
ROS can cause oxidative damage to biomolecules and alter protein activity, regulate enzyme 
and transcription factor activity (Gelderman et al., 2006). Although ROS can modify 
macromolecules thus altering the signalling pathways and functions, the reversible oxidation 
of cysteine residues is necessary and is an important pathway by which protein function is 
regulated. There is evidence which suggests an increase in cell surface thiol (-SH) levels of 
stimulated T cells (K. A. Gelderman et al. 2006; Tse et al. 2017) while others have also 
demonstrated that activation leads to an increase in sulphenic acid (-SOH), the first reversible 
oxidation product of cysteine (Pellom et al. 2013). Historically, ROS have been considered as 
essential mediators in T cell function (Kesarwani et al. 2013b).  
Some reports indicated that certain antioxidants inside the cell such as cysteine would inhibit 
proliferation and IL-2 production when administered during the early stages of T cell activation 
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at dose dependent manner (Goldstone et al. 1995) and treatment of mice with the antioxidant 
Mn(III)tetrakis(4-benzoic acid) porphyrin chloride (MnTBAP) (metalloporphyrin-mimetic 
compound with superoxide dismutase activity) decreased proliferation and cytokine 
production in T cells in both autoimmune and infectious models (Piganelli et al. 2002; 
Laniewski & Grayson 2004). However, superoxide dismutases, catalase and ascorbic acid do 
not affect CD25 expression in human T cells (Belikov et al. 2014). This suggest that 
intracellular ROS released in response to TCR stimulation may act as mediators in T cell 
activation. However, sub lethal peroxide also caused, loss of transcription factor activity and 
reduced cytokine production in memory cells when stimulated by an antigen (Flescher et al. 
1998; Lahdenpohja et al. 1998 Rodica Lenkei et al. 2001). Also, scavenging of ROS by 
manganese metalloporphyrin leads to reduced CD4+ T cell responses (Previte et al. 2017).  
Although Prx 1 and 2 are highly abundant and required for its role of detoxifying H2O2 in the 
cytosol, cysteine residues of Prx are prone to be oxidised at low levels of H2O2 (Woo et al. 
2005; Wood et al. 2003). This may lead to accumulation of H2O2 within the cells inducing 
cellular damage or dampened T cell activation. Their presence on the membrane may be 
reducing disulphides (Carilho Torrao et al. 2013; Mullen et al. 2015a). However, some 
antioxidants may behave as pro-oxidants at higher concentrations such as vitamin C  (Uetaki 
et al. 2015; Mendes-da-Silva et al. 2014; Griffiths & Lunec 2001). In contrast,  oxidised Trx1 
forms a disulphide hence inactive and disrupted interaction between Trx1 and target protein 
(Du et al. 2013)  
Therefore, increased amounts on ROS can lead to potential oxidation of proteins.  Thus this 
chapter looks at the effect of H2O2 during T cell activation on the surface redox state including 
IL-2 receptor expression and surface Trx1 and Prx2. Also, to identify the possible proteins 
which undergo sulphenic acid modification on the membrane of T cells during activation and 
in the presence of peroxide, to identify susceptible sulphenated proteins or receptors.  
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The main objectives of this chapter on primary human T cells are as follows: 
- To optimise CD4+ T cell activation using anti-CD3 and anti-CD28 
- To analyse the surface redox state and analyse surface Prx2 and Trx1 including 
secreted Trx1 
- To increase ROS levels during activation by using H2O2 
- To identify sulphenated membrane proteins with and without activation in the presence 
and absence of peroxide 
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5.2. Methods 
 
5.2.1. Primary CD4+ T cell isolation and activation 
 
Fresh blood (20 ml) was collected from healthy donors with consent and CD4+ T cells were 
isolated as described and activated as described in the methods section 2.2.7.  
 
 
5.2.2. Competition Trx1 ELISA 
 
Trx-1 (0.2μg/ml) 50μl/well was applied to a Nunc microtiter 96 well plates (Nunc) in carbonate 
buffer pH9.6 and incubated for 1 hour at 37°C. The plate was washed 3 times with 250μl of 
phosphate buffered saline containing 0.05% Tween-20, w/v (PBST) and were gently tapped 
on absorbent tissue paper. Following washing, nonspecific sites were blocked by adding 
skimmed milk 4% w/v in PBS, 200μl/well overnight at 4°C. Standard curve (2.5μg/ml-0μg/ml) 
was prepared using recombinant human Trx1 protein (R&D); 25μl/well). The supernatants 
(25μl/well) were plated in triplicates. Mouse monoclonal anti-Trx1 (25μl of 1:2000 in PBS, 
ab16965; Abcam) was added to all standards and samples and was incubated at 37°C for 2 
h. Following incubation, wells were washed with PBST (250μl) 3 times and 200μl of peroxidase 
conjugated anti-mouse antibody (1:5000) was added to each well. The plate was incubated at 
37°C for 1h. Following washing 3 times with PBST (250μl), and 200μl of substrate solution 
containing o-phenylenediamine and hydrogen peroxide in 0.15 M citrate-phosphate buffer, 
was added. During incubation at room temperature, colour development was observed from 
2 to 10 min. The colour reaction was stopped with the addition of 2 M sulphuric acid (50μl/well). 
Absorbance was measured at 490 nm in a microplate reader (Bio Tek, UK). 
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5.2.3. Flow cytometric analysis of Trx1 and Prx2 
 
For flow cytometric analysis of Trx1, 5x105 cells were collected and washed two times in 500µl 
cold wash buffer (PBS supplemented with 1% w/v BSA). Following two washes in cold wash 
buffer, cells were resuspended in cold wash buffer and incubated with mouse monoclonal anti-
Trx1 (ab16965; Abcam, 1µl/106 cells) or IgG2b isotype control antibody (ab91366; Abcam, 
1µl/106 cells) on ice for 30 minutes. After a further two washes, cells were incubated with goat 
anti-mouse polyclonal conjugated dylight-488 (96879; Abcam, 0.5µl/106 cells) antibody on ice 
for 30minutes in cold wash buffer. Finally, cells were analysed on a Cytomics FC 500 flow 
cytometer (Beckman Coulter, Wycombe, UK). 
 
 
5.2.4. Cell viability  
 
Cell viability was determined with Nucleocounter NC 3000 (ChemoMetec) imaging cytometer 
according to the manufacturer’s instructions. Briefly 1x105 cells were collected after indicated 
treatments and inserted from the tip of the Via1-Cassette™ (ChemoMetec). The inside of the 
Via1-Cassette™ is coated with two different dyes, Acridine Orange staining the entire 
population of cells and DAPI staining the non-viable cells, respectively. 
 
 
 
5.2.5. Apoptosis Assay 
 
Briefly the 1x105 cells were resuspended in 500µl ‘binding buffer’ (150mM NaCl, 10mM 
HEPES and 2.5mM CaCl2) (Castro et al. 2017) and incubated with anti-human Annexin V/FITC 
(eBioscience, 1μl per 2x105 cells) or unstained control on ice for 10min and analysed by flow 
cytometer (Beckman coulter FC500, High Wycombe, UK).  
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5.2.6. Protein sulphenic acid detection on the membrane of human CD4+ T cells  
 
CD4+ T cells (1x106cells/ml) were isolated and activated as described in methods section 
above 2.2.7. The cells were activated with anti-CD3 and anti-CD28 in the presence or absence 
of H2O2 (20µM) and 0.5mM DCP-Bio1 (Merck, Millipore, UK) and incubated for 30mins. 
Activated cells for 24h were incubated with DCP-Bio1 30min before collection of cells. 
Following treatment, the cells were washed and cytosolic proteins (CP) and membrane 
proteins (MP) were isolated (section 2.2.4) then biotinylated proteins were captured using 
streptavidin magnetic beads (Thermo-Fisher, UK). Captured biotinylated proteins were 
analysed by LC-MS/MS and the list of sulphenated proteins was generated using Mascot 
Daemon database.  
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5.3. Results  
 
5.3.1. Purity of negatively isolated human CD4+ T cells using flow cytometry  
 
To determine the purity of negatively isolated CD4+ T cells before further experiments, cells 
were either stained with allophycocyanin/cy7 labelled anti-CD4+ antibody in the dark on ice for 
20min or its relevant isotype control IgG1 allophycocyanin/cy7 labelled antibody. The purity of 
CD4+ T cell gated population in Figure 5.1 was 99% (red).  
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Purity of the negatively isolated T cells: CD4+ T cells isolated from PBMCs were 
stained with anti-CD4 antibody or with Cy7 labelled isotype control and analysed by flow 
cytometry. CD4+ positive cells were gated (blue line) at 1% of isotype control (black) and the 
data was collected for 10000 events (red). 
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5.3.2. CD4+ T cells secrete IL-2 within 24h of activation 
 
To determine the conditions required for T cell activation, human primary CD4+ T cells were 
activated with anti-CD3 and anti-CD28 for 24, 48 and 72h (Figure 5.2). Activated T cells show 
a significant increase in IL-2 secretion after 24h, 48h, and 72h (0.5±0.1, 0.7±0.2, 0.7±0.1) 
compared to no activation (0.01±0.02) (Figure 5.2a) and increase in cells expressing surface 
CD25 (% cells; no activation: 3.71±1.33, 24h: 44.46±1.084, 48h:  50.01±1.681 and 72h: 
67.3±1.587 respectively (Fig 5.2b). Hence, further activation experiments were performed at 
the 24h time point.  
a)                                                                b) 
 
 
 
 
 
 
 
 
 
Figure 5.2: Increase in IL-2 secretion and CD25 expression after CD4+ T cell activation.  CD4+ 
T cells were isolated and activated with 1µg/ml anti-CD3 (OKT3) and 2µg/ml anti-CD28.2 for 
24, 48 and 72h. a) IL-2 secretion measured by sandwich ELISA. b) IL-2 receptor (CD25) 
expression on the surface, cells were incubated with anti-CD25 for 20mins and analysed by 
flow cytometry. Data expressed as the difference in cells expressing CD25 and isotype control 
signal at 1% over 5000 events n=3 mean and SEM, ANOVA ****p<0.0006, ****p<0.0001 
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5.3.3. Trx1 secretion levels after T cell activation 
 
Trx1 on the surface of cells may act as an immunomodulatory agent by regulating certain 
cytokine and chemokine activity via modulating receptor redox state (Nordberg and Arner 
2001). During inflammation and ageing, it is believed that secretion of cytoplasmic proteins is 
altered, including Trx1, into extracellular environment that is independent of the Golgi pathway 
(Rubartelli et al. 1992). In order to observe whether a change in Trx1 distribution is associated 
with T cell activation, CD4+ were stimulated with anti-CD3/CD28 antibodies for 24h, 48 and 
72h. A significant 3-fold increase in surface Trx1 was observed in activated T cells after 24h 
(Figure 5.3a), which suggests that activation leads to increased translocation of Trx1 to the 
membrane. Additionally, CD4+ T cells show an increased trend in Trx1 secretion in the 
supernatants after activation for 24h (1.5±0.4) and 48h (1.6±0.6) as compared to unactivated 
(1.3±0.2), but a decrease after 72h (1.2±0.5) of activation. To investigate whether the 
decrease after 72 hours is associated with apoptosis, Annexin V staining was carried out 
(Figure 5.3c); this suggests that the activated cells at 72h might be undergoing apoptosis.  
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Figure 5.3: Trx1 redistributes to the membrane after activation. CD4+ T cells were isolated and 
activated with 1µl/ml anti-CD3 (OKT3) and 2µg/ml CD28.2 for 24, 48 and 72h. The cells were 
isolated and washed with PBS 1% BSA and incubated with primary anti-Trx1 (ab16965) or 
isotype control (ab91366) for 30min. The cells were washed and secondary goat anti-mouse 
IgG H&L (ab96879) was added and incubated for 30min. RM ANOVA, Dunnett’s multiple 
comparison test. Mean and SEM *p<0.01, ***p<0.0006. b) Trx1 secretion measured in the 
culture supernatants by competition ELISA. c) Cells expressing AxV on the surface after 
activation (n=3 independent experiments). 
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5.3.4. CD4+ T cell activation leads to increase in surface thiols (-SH) 
 
In order to understand how the surface redox state is affected during activation, CD4+ T cells 
were activated and reduced surface thiols were determined by flow cytometry at early time 
points after activation (5 and 30minutes). Figure 5.4 shows an increased trend in –SH in 
activated T cells (X-mean; 633.6±96.86) after 5min compared to unactivated T cells 
(533±59.09). Additionally, a significant increase in –SH levels on the surface of activated CD4+ 
T cells (569.9±109.4) was observed after 30min of activation compared to unactivated T cells 
(301.6±60.35).  
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Figure 5.4: Surface thiol levels increases after T cell activation. CD4+ T cells were isolated 
from blood and activated with 1µg/ml anti-CD3 (OKT3) and 2µg/ml anti-CD28.2 for 24h. Cells 
were collected after 5 and 30mins of activation and incubated with FITC-conjugated maleimide 
for 30min and analysed by flow cytometry. a) –SH after 5min, b) surface -SH after 30min 
activation. Data represents Mean peak staining intensity for thiols with standard error of the 
mean from 3 independent experiments. Statistical analysis were calculated using two tailed, 
paired student t test **p<0.004.  
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5.3.5. Activation of T cells causes an increase in sulphenic acid formation on 
the surface of T cells  
 
To further understand the role of sulphenic acid in T cell activation and the surface redox state, 
this chapter looked at surface oxidised thiols (sulphenic acid) on the surface of T cells. 
Activated T cells show a significant increase in –SOH (X-Median 8.65±0.41) after 5min of 
activation compared to unactivated T cells (6.07±0.17) (Figure 5.5). Furthermore, activated T 
cells show an increased trend in –SOH on the surface (9.7±1.45) as compared to unactivated 
T cells (8.5±1.3) after 30min. 
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Figure 5.5: Surface -SOH increases after T cell activation. CD4+ T cells were isolated from 
blood and activated with 1µg/ml anti-CD3 (OKT3) and 2µg/ml anti-CD28. Cells were collected 
after 5 and 30mins of activation and incubated with 0.1mM DCP-Bio1 and 10mM 
iodoacetamide (IAA) for 30min added at time zero. The cells were further washed and 
incubated with streptavidin-PE (1:100) for 30min on ice and analysed by flow cytometry. a) –
SOH after 5min, b) surface –SOH after 30min activation, n=3. Data represents mean of X-
median and standard error of mean (SEM) and statistical analysis were calculated using two 
tailed, paired student t test **p<0.001.  
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5.3.6. Increased oxidative stress inhibits T cell activation  
 
In order to mimic the physiological phagocyte derived ROS, CD4+ T cells were activated in the 
presence or absence of exogenous H2O2. Figure 5.6 shows that expression of CD25 on the 
surface was significantly decreased in the presence of H2O2 suggesting excess oxidative 
stress inhibits T cell activation. Furthermore, treatment with NAC together with anti-CD3/CD28 
activation did not restore the activation response. Similarly, the cells show a significant 
decrease in IL-2 secretion when treated with H2O2 and NAC does not restore the effect (Figure 
5.6d) under the conditions used here. Moreover, T cells were treated with H2O2 at non-
cytotoxic concentration and thus the decrease in expression was not due to loss of viability, 
since there was no significant difference in viability in the presence and absence of H2O2 
(Figure 5.6c) 
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Figure 5.6. NAC does not restore CD25 expression on the surface of peroxide-treated T cells. 
CD4+ T cells were isolated and activated with 1µg/ml anti-CD3 (OKT3) and 2µg/ml CD28.2 for 
24h in the presence of H2O2 (20µM) and NAC (10mM). Cells were collected and stained for 
anti-CD25 for 20min on ice and analysed by FC. Supernatants were collected for IL-2 analysis 
a) X-Median CD25 expression on the surface of T cells, b) Log scale showing changes in 
CD25 expression with H2O2. c) Viability of activated cells after 24h. d) IL-2 secretion in the 
supernatants. Data expressed mean and SEM, n=3 ANOVA, Tukey’s multiple comparison 
test. ***p<0.0006 **p<0.003. 
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5.3.7. Activation in the presence of H2O2 has no effect on surface Trx1 and Prx2 
 
In order to observe the distribution of Trx1 and Prx2 onto the surface when activated in the 
presence of oxidative stress, CD4+ T cells were activated in the presence of H2O2 and surface 
Trx1 and Prx2 were analysed by flow cytometry after 24h. Figure 5.7 shows a significant 
increase in surface Trx1 after activation but no difference was observed when activated in the 
presence of H2O2. Also, a similar trend was observed for Prx2 on the surface.  
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Figure 5.7. Exogenous H2O2 has no effect on surface Trx1 and Prx2 expression induced by 
activation of T cells. 1x106/ml CD4+ T cells were isolated and activated with 1µl/ml anti-CD3 
(OKT3) and 2µg/ml anti-CD28.2 for 24h in the presence or absence of H2O2 (20µM). The cells 
were isolated and washed with PBS/BSA 1%w/v and incubated with primary anti-Trx1 
(ab16965) or isotype control (ab91366) for 30min. The cells were washed and secondary goat 
anti-Mouse IgG H&L (ab96879) was added and incubated for 30min and analysed by flow 
cytometry, MFI-X-median. a) Surface Trx1 expression b) washed cells incubated with primary 
anti-Prx2. The cells were washed and secondary goat anti-rabbit IgG was added and 
incubated for 30min and analysed by flow cytometry. Data represents Mean and SEM of three 
independent experiments, n=3. Ordinary one way ANOVA, Tukey’s Multiple comparison test, 
*p<0.019, **p<0.003.  
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5.3.8. H2O2 depletes intracellular GSH levels  
 
Glutathione is required for DNA synthesis in human T cells and plays an important role in T 
cell function and proliferation (Levring et al. 2015; Smyth 1991). In order to determine the 
effect of H2O2 on GSH levels during activation, CD4+ T cells were activated in the presence of 
H2O2 and NAC. Figure 5.8 shows a significant increase in GSH when the T cells were activated 
in the absence of H2O2 or NAC. However, H2O2 completely diminishes GSH levels, whereas 
T cells activated in the presence of H2O2 together with NAC slightly recovers GSH levels by 
twofold. This suggests that NAC protects against the effect of H2O2 on loss of intracellular 
GSH during T cell activation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8. Effect of H2O2 on intracellular GSH after 24h. CD4+ T cells were isolated and 
activated with 1µl/ml anti-CD3 (OKT3) and 2µg/ml anti-CD28.2 for 24h in the presence of H2O2 
(20µM). 1x105 cells were isolated and plated on a 96 well plate in duplicates, the GSH 
concentration was determined using GSH-GloTM glutathione assay (Promega) using a 
standard curve. Data represents three independent experiments, mean and SEM, n=3. 
Ordinary one way ANOVA, Tukey’s Multiple comparison test, *p<0.01, ****p<0.0001  
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5.3.9. Sulphenated proteins identified by MS/MS 
 
In order to identify proteins that are susceptible to sulphenic acid modification on the 
membranes of CD4+ T cells after activation and in the presence of H2O2, CD4+ T cells were 
activated in the presence or absence of H2O2 for 30mins and 24h and modified thiols were 
captured using DCP-bio1. Several proteins were identified to be sulphenated as shown in the 
tables below at different time and treatment conditions.  
 
ACCESSION SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION 
ALBU_HUMAN 4287 69321 394 Serum albumin  
IQCA1_HUMAN 507 95281 191 IQ and AAA domain-containing protein 1  
ACTB_HUMAN 2100 41710 72 Actin, cytoplasmic 1  
HNRPC_HUMAN 317 33650 25 Heterogeneous nuclear ribonucleoproteins C1/C2  
AFF3_HUMAN 76 133394 21 AF4/FMR2 family member 3  
CC134_HUMAN 98 26544 17 Coiled-coil domain-containing protein 134  
HNRPK_HUMAN 207 50944 11 Heterogeneous nuclear ribonucleoprotein K  
NMD3A_HUMAN 36 125385 11 Glutamate receptor ionotropic, NMDA 3A  
CH60_HUMAN 158 61016 10 60 kDa heat shock protein, mitochondrial  
HNRPD_HUMAN 209 38410 8 Heterogeneous nuclear ribonucleoprotein D0  
HNRH1_HUMAN 232 49198 7 Heterogeneous nuclear ribonucleoprotein H  
ROA2_HUMAN 143 37407 7 Heterogeneous nuclear ribonucleoproteins A2/B1  
PRDX1_HUMAN 117 22096 7 Peroxiredoxin-1  
GNAT3_HUMAN 108 40331 7 Guanine nucleotide-binding protein G(t) subunit alpha-3  
COF1_HUMAN 156 18491 6 Cofilin-1  
PTBP1_HUMAN 97 57186 6 Polypyrimidine tract-binding protein 1  
ROA1_HUMAN 171 38723 5 Heterogeneous nuclear ribonucleoprotein A1  
ZC3HD_HUMAN 45 196519 5 Zinc finger CCCH domain-containing protein 13  
COR1A_HUMAN 69 50994 4 Coronin-1A  
PDIA3_HUMAN 81 56747 3 Protein disulfide-isomerase A3  
     
Table 5.1: Membrane proteins which are sulphenated in unactivated CD4+ T cells after 30min. 
 
ACCESSION SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION 
HNRPM_HUMAN 445 77464 20 Heterogeneous nuclear ribonucleoprotein M  
ZC3HD_HUMAN 48 196519 12 Zinc finger CCCH domain-containing protein 13  
CH60_HUMAN 114 61016 11 60 kDa heat shock protein, mitochondrial  
MYH11_HUMAN 26 227199 11 Myosin-11  
ACTB_HUMAN 1085 41710 10 Actin, cytoplasmic 1  
CRCC2_HUMAN 32 185760 10 Putative ciliary rootlet coiled-coil protein 2  
TLL1_HUMAN 15 114635 10 Tolloid-like protein 1  
148 
 
ACINU_HUMAN 24 151771 9 Apoptotic chromatin condensation inducer in the nucleus  
TANC1_HUMAN 50 202093 8 Protein TANC1  
COR1A_HUMAN 41 50994 8 Coronin-1A  
IQCAL_HUMAN 496 94871 7 IQ and AAA domain-containing protein 1-like  
UACA_HUMAN 27 162404 7 Uveal autoantigen with coiled-coil domains and ankyrin repeats  
K0355_HUMAN 22 115946 7 Uncharacterized protein KIAA0355  
ABCA3_HUMAN 19 191239 7 ATP-binding cassette sub-family A member 3  
ALBU_HUMAN 5501 69321 6 Serum albumin  
HNRPC_HUMAN 307 33650 6 Heterogeneous nuclear ribonucleoproteins C1/C2  
GRP78_HUMAN 434 72288 6 78 kDa glucose-regulated protein  
SC31B_HUMAN 50 128615 6 Protein transport protein Sec31B  
PDIA3_HUMAN 126 56747 5 Protein disulfide-isomerase A3  
PTBP1_HUMAN 60 57186 5 Polypyrimidine tract-binding protein 1  
ATPB_HUMAN 38 56525 5 ATP synthase subunit beta, mitochondrial  
KIFC3_HUMAN 33 92718 5 Kinesin-like protein KIFC3  
LTBP1_HUMAN 23 186673 5 Latent-transforming growth factor beta-binding protein 1  
DLG1_HUMAN 22 100393 5 Disks large homolog 1  
AFF3_HUMAN 88 133394 4 AF4/FMR2 family member 3  
ROA2_HUMAN 420 37407 4 Heterogeneous nuclear ribonucleoproteins A2/B1  
ZFP37_HUMAN 25 71164 4 Zinc finger protein 37 homolog  
INT13_HUMAN 23 80174 4 Integrator complex subunit 13  
NALP2_HUMAN 22 120437 4 NACHT, LRR and PYD domains-containing protein 2  
GTPBA_HUMAN 20 42906 4 GTP-binding protein 10  
NMD3A_HUMAN 39 125385 3 Glutamate receptor ionotropic, NMDA 3A  
HNRH1_HUMAN 279 49198 3 Heterogeneous nuclear ribonucleoprotein H  
GNA12_HUMAN 164 44251 3 Guanine nucleotide-binding protein subunit alpha-12  
IDHP_HUMAN 81 50877 3 Isocitrate dehydrogenase [NADP], mitochondrial  
VAT1_HUMAN 25 41893 3 Synaptic vesicle membrane protein VAT-1 homolog  
SPA12_HUMAN 33 47145 3 Serpin A12  
CC152_HUMAN 27 29960 3 Coiled-coil domain-containing protein 152  
BAP29_HUMAN 26 28302 3 B-cell receptor-associated protein  
CS047_HUMAN 25 44718 3 Uncharacterized protein C19orf47  
APOL2_HUMAN 22 37069 3 Apolipoprotein L2  
TAGL2_HUMAN 18 22377 3 Transgelin-2  
MVD1_HUMAN 17 43377 3 Diphosphomevalonate decarboxylase  
WNT3_HUMAN 14 39619 3 Proto-oncogene Wnt-3  
 
Table 5.2: Membrane proteins which are sulphenated in activated CD4+ T cells after 30mins 
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ACCESSION SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION 
BPTF_HUMAN 38 338054 12 Nucleosome-remodeling factor subunit BPTF  
AKA11_HUMAN 29 210380 10 A-kinase anchor protein 11  
ACTB_HUMAN 2754 41710 9 Actin, cytoplasmic 1  
CH60_HUMAN 123 61016 9 60 kDa heat shock protein, mitochondrial  
HNRPM_HUMAN 88 77464 9 Heterogeneous nuclear ribonucleoprotein M  
UACA_HUMAN 30 162404 9 Uveal autoantigen with coiled-coil domains and ankyrin repeats  
RHG23_HUMAN 25 162092 9 Rho GTPase-activating protein 23  
PKHD1_HUMAN 38 446418 8 Fibrocystin  
ZSWM8_HUMAN 32 197173 8 Zinc finger SWIM domain-containing protein 8  
FND3A_HUMAN 20 131767 8 Fibronectin type-III domain-containing protein 3A  
ALBU_HUMAN 6676 69321 7 Serum albumin  
HNRPC_HUMAN 442 33650 7 Heterogeneous nuclear ribonucleoproteins C1/C2  
ZC3HD_HUMAN 53 196519 7 Zinc finger CCCH domain-containing protein 13  
YLPM1_HUMAN 20 219849 7 YLP motif-containing protein 1  
PEX1_HUMAN 73 142778 6 Peroxisome biogenesis factor 1  
AT1A4_HUMAN 34 114093 6 Sodium/potassium-transporting ATPase subunit alpha-4  
K2C75_HUMAN 29 59524 6 Keratin, type II cytoskeletal 75  
RAB7A_HUMAN 61 23475 5 Ras-related protein Rab-7a  
RHG39_HUMAN 41 121210 5 Rho GTPase-activating protein 39  
K2C5_HUMAN 31 62340 5 Keratin, type II cytoskeletal 5  
DLG1_HUMAN 20 100393 5 Disks large homolog 1  
PABP3_HUMAN 18 69987 5 Polyadenylate-binding protein 3  
IQCA1_HUMAN 375 95281 4 IQ and AAA domain-containing protein 1  
S14L4_HUMAN 45 46614 4 SEC14-like protein 4  
RAE1_HUMAN 45 73429 4 Rab proteins geranylgeranyltransferase component A 1  
TERA_HUMAN 39 89266 4 Transitional endoplasmic reticulum ATPase  
MVD1_HUMAN 29 43377 4 Diphosphomevalonate decarboxylase  
ADH4_HUMAN 27 40196 4 Alcohol dehydrogenase 4  
ADCY2_HUMAN 24 123523 4 Adenylate cyclase type 2  
ROA2_HUMAN 432 37407 3 Heterogeneous nuclear ribonucleoproteins A2/B1  
GRP78_HUMAN 128 72288 3 78 kDa glucose-regulated protein  
AFF3_HUMAN 101 133394 3 AF4/FMR2 family member 3  
COF1_HUMAN 76 18491 3 Cofilin-1  
HNRPK_HUMAN 66 50944 3 Heterogeneous nuclear ribonucleoprotein K  
COEA1_HUMAN 60 193394 3 Collagen alpha-1(XIV) chain  
RL12_HUMAN 47 17808 3 60S ribosomal protein L12  
NMD3A_HUMAN 46 125385 3 Glutamate receptor ionotropic, NMDA 3A  
HCD2_HUMAN 31 26906 3 3-hydroxyacyl-CoA dehydrogenase type-2  
FA30A_HUMAN 27 14616 3 Putative uncharacterized protein FAM30A  
Table 5.3: Membrane proteins which are sulphenated in unactivated CD4+ T cells in the presence of 
H2O2 after 30mins  
 
 
 
150 
 
ACCESSION SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION 
ACTB_HUMAN 1664 41710 12 Actin, cytoplasmic 1  
UACA_HUMAN 45 162404 8 Uveal autoantigen with coiled-coil domains and ankyrin repeats  
ALBU_HUMAN 2162 69321 7 Serum albumin  
WDR48_HUMAN 17 76162 7 WD repeat-containing protein 48  
CEL_HUMAN 13 79272 7 Bile salt-activated lipase  
HNRPC_HUMAN 99 33650 6 Heterogeneous nuclear ribonucleoproteins C1/C2  
NMD3A_HUMAN 34 125385 5 Glutamate receptor ionotropic, NMDA 3A 
OPLA_HUMAN 32 137371 5 5-oxoprolinase  
RPC2_HUMAN 18 127702 5 DNA-directed RNA polymerase III subunit RPC2  
HNRH1_HUMAN 115 49198 4 Heterogeneous nuclear ribonucleoprotein H  
AFF3_HUMAN 74 133394 4 AF4/FMR2 family member 3  
PLSL_HUMAN 65 70244 4 Plastin-2  
PDIA3_HUMAN 56 56747 4 Protein disulfide-isomerase A3  
FANCC_HUMAN 33 63388 4 Fanconi anemia group C protein  
TERA_HUMAN 32 89266 4 Transitional endoplasmic reticulum ATPase  
TMPS9_HUMAN 26 113948 4 Transmembrane protease serine 9  
RC3H2_HUMAN 21 131586 4 Roquin-2  
TANC1_HUMAN 55 202093 3 Protein TANC1  
IQCAL_HUMAN 496 94871 3 IQ and AAA domain-containing protein 1-like  
GNAS1_HUMAN 188 110956 3 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas  
CC134_HUMAN 151 26544 3 Coiled-coil domain-containing protein 134  
GRP78_HUMAN 85 72288 3 78 kDa glucose-regulated protein  
ABCC8_HUMAN 24 176879 3 ATP-binding cassette sub-family C member 8  
RN111_HUMAN 17 108794 3 E3 ubiquitin-protein ligase Arkadia  
EX3L1_HUMAN 17 81627 3 Exocyst complex component 3-like protein  
Table 5.4: Membrane proteins which are sulphenated in activated CD4+ T cells in the presence of H2O2 
after 30min. 
 
ACCESSION SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION 
ASXL3_HUMAN 29 241767 10 Putative Polycomb group protein ASXL3  
IQCAL_HUMAN 432 94871 7 IQ and AAA domain-containing protein 1-like  
UACA_HUMAN 56 162404 7 Uveal autoantigen with coiled-coil domains and ankyrin repeats  
ACTB_HUMAN 1658 41710 6 Actin, cytoplasmic 1  
HNRPC_HUMAN 534 33650 6 Heterogeneous nuclear ribonucleoproteins C1/C2  
C163B_HUMAN 41 159135 6 Scavenger receptor cysteine-rich type 1 protein M160  
ATS3_HUMAN 22 135515 6 A disintegrin and metalloproteinase with thrombospondin motifs 3  
ZN133_HUMAN 20 73341 6 Zinc finger protein 133  
ZN229_HUMAN 18 93647 6 Zinc finger protein 229  
ALBU_HUMAN 3835 69321 5 Serum albumin  
PEX1_HUMAN 46 142778 5 Peroxisome biogenesis factor 1  
AFF3_HUMAN 62 133394 5 AF4/FMR2 family member 3  
ZC3HD_HUMAN 38 196519 5 Zinc finger CCCH domain-containing protein 13  
MVD1_HUMAN 24 43377 5 Diphosphomevalonate decarboxylase  
HNRPK_HUMAN 63 50944 4 Heterogeneous nuclear ribonucleoprotein K  
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NMD3A_HUMAN 45 125385 4 Glutamate receptor ionotropic, NMDA 3A  
OPLA_HUMAN 43 137371 4 5-oxoprolinase  
CH60_HUMAN 42 61016 4 60 kDa heat shock protein, mitochondrial  
FANCC_HUMAN 39 63388 4 Fanconi anemia group C protein  
SC31B_HUMAN 38 128615 4 Protein transport protein Sec31B  
TAF5_HUMAN 36 86776 4 Transcription initiation factor TFIID subunit 5  
CHMP7_HUMAN 36 50879 4 Charged multivesicular body protein 7  
PKHD1_HUMAN 30 446418 4 Fibrocystin  
CC134_HUMAN 90 26544 3 Coiled-coil domain-containing protein 134  
PTBP1_HUMAN 49 57186 3 Polypyrimidine tract-binding protein 1  
ROA2_HUMAN 37 37407 3 Heterogeneous nuclear ribonucleoproteins A2/B1  
SHOC2_HUMAN 35 64848 3 Leucine-rich repeat protein SHOC-2  
INT13_HUMAN 23 80174 3 Integrator complex subunit 13  
K2012_HUMAN 20 135223 3 Uncharacterized protein KIAA2012  
AT134_HUMAN 14 133900 3 Probable cation-transporting ATPase 13A4  
Table 5.5: Membrane proteins which are sulphenated  after 24h in unactivated CD4+ T cells. 
 
ACCESSION SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION 
ZN229_HUMAN 18 93647 12 Zinc finger protein 229  
RP1L1_HUMAN 31 261049 11 Retinitis pigmentosa 1-like 1 protein  
ZC3HD_HUMAN 33 196519 10 Zinc finger CCCH domain-containing protein 13  
ALBU_HUMAN 843 69321 9 Serum albumin  
COR1A_HUMAN 39 50994 8 Coronin-1A  
SMC6_HUMAN 21 126246 8 Structural maintenance of chromosomes protein 6  
HNRPU_HUMAN 87 90528 7 Heterogeneous nuclear ribonucleoprotein U  
INT13_HUMAN 23 80174 7 Integrator complex subunit 13  
FLNC_HUMAN 21 290841 7 Filamin-C  
NPAT_HUMAN 21 154195 7 Protein NPAT  
KIF27_HUMAN 22 160184 6 Kinesin-like protein KIF27  
COXM1_HUMAN 16 12481 6 COX assembly mitochondrial protein homolog  
IQCAL_HUMAN 105 94871 5 IQ and AAA domain-containing protein 1-like  
ACTG_HUMAN 98 41766 5 Actin, cytoplasmic 2  
AFF3_HUMAN 34 133394 5 AF4/FMR2 family member 3  
POLK_HUMAN 19 98746 5 DNA polymerase kappa  
DDX55_HUMAN 36 68503 4 ATP-dependent RNA helicase DDX55  
CC134_HUMAN 35 26544 4 Coiled-coil domain-containing protein 134  
FA30A_HUMAN 25 14616 4 Putative uncharacterized protein FAM30A  
MEG10_HUMAN 25 122121 4 Multiple epidermal growth factor-like domains protein 10  
ADAM9_HUMAN 23 90497 4 Disintegrin and metalloproteinase domain-containing protein 9  
GRB10_HUMAN 21 67189 4 Growth factor receptor-bound protein 10  
MAST1_HUMAN 19 170572 4 Microtubule-associated serine/threonine-protein kinase 1  
SC31B_HUMAN 39 128615 3 Protein transport protein Sec31B  
GIMA7_HUMAN 27 34487 3 GTPase IMAP family member 7  
SHSA7_HUMAN 24 56179 3 Protein shisa-7  
TRI29_HUMAN 22 65793 3 Tripartite motif-containing protein 29  
RL23_HUMAN 21 14856 3 60S ribosomal protein L23  
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RUBIC_HUMAN 19 108553 3 Run domain Beclin-1-interacting and cysteine-rich domain-containing 
protein  
CCD80_HUMAN 18 108106 3 Coiled-coil domain-containing protein 80  
Table 5.6: Membrane proteins which are sulphenated after 24h in activated CD4+ T cells. 
 
 
ACCESSION SCORE MASS NUM. OF 
SEQUENCES 
DESCRIPTION 
LRP1B_HUMAN 15 515159 21 Low-density lipoprotein receptor-related protein 1B  
RBP2_HUMAN 35 357974 14 E3 SUMO-protein ligase RanBP2  
UACA_HUMAN 38 162404 12 Uveal autoantigen with coiled-coil domains and ankyrin repeats  
VWF_HUMAN 28 309058 11 von Willebrand factor  
ACTB_HUMAN 3148 41710 10 Actin, cytoplasmic 1  
CH60_HUMAN 37 61016 10 60 kDa heat shock protein, mitochondrial  
PDS5B_HUMAN 35 164563 10 Sister chromatid cohesion protein PDS5 homolog B  
TCF20_HUMAN 21 211641 10 Transcription factor 20  
ZC3HD_HUMAN 44 196519 9 Zinc finger CCCH domain-containing protein 13  
M3K4_HUMAN 29 181570 9 Mitogen-activated protein kinase kinase kinase 4  
ALBU_HUMAN 6454 69321 8 Serum albumin  
INADL_HUMAN 48 196247 8 InaD-like protein  
DEN4B_HUMAN 28 163743 8 DENN domain-containing protein 4B  
DHX57_HUMAN 20 155507 8 Putative ATP-dependent RNA helicase  
TANC1_HUMAN 50 202093 7 Protein TANC1  
HNRPC_HUMAN 52 33650 7 Heterogeneous nuclear ribonucleoproteins C1/C2  
TERA_HUMAN 38 89266 7 Transitional endoplasmic reticulum ATPase  
SLN11_HUMAN 34 102770 7 Schlafen family member 11  
OPLA_HUMAN 34 137371 7 5-oxoprolinase  
ISK5_HUMAN 32 120637 7 Serine protease inhibitor Kazal-type 5  
VWA3A_HUMAN 28 133935 7 von Willebrand factor A domain-containing protein 3A  
Z518B_HUMAN 23 119456 7 Zinc finger protein 518B  
NPAT_HUMAN 16 154195 7 Protein NPAT  
IQCA1_HUMAN 479 95281 6 IQ and AAA domain-containing protein 1  
AFF3_HUMAN 98 133394 6 AF4/FMR2 family member 3  
GRP78_HUMAN 272 72288 5 78 kDa glucose-regulated protein  
ENPL_HUMAN 54 92411 5 Endoplasmin  
ASTN1_HUMAN 26 144820 5 Astrotactin-1  
FA30A_HUMAN 24 14616 5 Putative uncharacterized protein FAM30A  
PEX1_HUMAN 43 142778 4 Peroxisome biogenesis factor 1  
RAE1_HUMAN 64 73429 4 Rab proteins geranylgeranyltransferase component A 1  
OPTN_HUMAN 38 65880 4 Optineurin  
NMD3A_HUMAN 37 125385 4 Glutamate receptor ionotropic, NMDA 3A  
ROA2_HUMAN 26 37407 4 Heterogeneous nuclear ribonucleoproteins A2/B1  
ATPB_HUMAN 24 56525 4 ATP synthase subunit beta, mitochondrial  
LSG1_HUMAN 19 75178 4 Large subunit GTPase 1 homolog  
ASPC1_HUMAN 18 60146 4 Tether containing UBX domain for GLUT4  
CP071_HUMAN 15 55647 4 Uncharacterized protein C16orf71  
ANT3_HUMAN 105 52569 3 Antithrombin-III  
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FKBP8_HUMAN 99 44534 3 Peptidyl-prolyl cis-trans isomerase FKBP8  
ATPA_HUMAN 36 59714 3 ATP synthase subunit alpha, mitochondrial  
RGPA2_HUMAN 27 210636 3 Ral GTPase-activating protein subunit alpha-2  
SLN14_HUMAN 25 103840 3 Protein SLFN14  
L1CAM_HUMAN 25 139915 3 Neural cell adhesion molecule L1  
AGRD2_HUMAN 20 104021 3 Adhesion G-protein coupled receptor D2  
 
Table 5.7: Membrane proteins which are sulphenated after 24h in unactivated CD4+ T cells in the 
presence of H2O2 (20µM) 
 
 
Table 5.8: Membrane proteins which are sulphenated after 24h in activated CD4+ T cells in the presence 
of H2O2 (20µM). 
The list of proteins were further characterised based on the molecular function within cells as 
shown in Figure 5.9. The “number of genes” identified refers to the number of proteins 
identified as being sulphenated. An observable increase in the number of proteins identified 
ACCESSION SCORE MASS NUM.  OF 
SEQUENCES 
DESCRIPTION 
FSIP2_HUMAN 31 780119 20 Fibrous sheath-interacting protein 2  
UACA_HUMAN 29 162404 12 Uveal autoantigen with coiled-coil domains and ankyrin repeats  
APC_HUMAN 24 311455 12 Adenomatous polyposis coli protein  
PKHD1_HUMAN 47 446418 10 Fibrocystin  
CH60_HUMAN 259 61016 9 60 kDa heat shock protein, mitochondrial  
ALBU_HUMAN 6341 69321 8 Serum albumin  
ACTB_HUMAN 3091 41710 7 Actin, cytoplasmic 1  
M3K4_HUMAN 27 181570 7 Mitogen-activated protein kinase kinase kinase 4  
ZC3HD_HUMAN 51 196519 6 Zinc finger CCCH domain-containing protein 13  
K2C75_HUMAN 26 59524 6 Keratin, type II cytoskeletal 75  
TERA_HUMAN 31 89266 5 Transitional endoplasmic reticulum ATPase  
PEX1_HUMAN 141 142778 4 Peroxisome biogenesis factor 1  
HNRPC_HUMAN 202 33650 4 Heterogeneous nuclear ribonucleoproteins C1/C2  
FANCC_HUMAN 39 63388 4 Fanconi anemia group C protein  
CBX4_HUMAN 28 61329 4 E3 SUMO-protein ligase CBX4  
DYH12_HUMAN 27 356713 4 Dynein heavy chain 12, axonemal  
CDK12_HUMAN 17 164054 4 Cyclin-dependent kinase 12  
IQCAL_HUMAN 495 94871 3 IQ and AAA domain-containing protein 1-like  
AFF3_HUMAN 86 133394 3 AF4/FMR2 family member 3  
RAE1_HUMAN 50 73429 3 Rab proteins geranylgeranyltransferase component A 1  
FA30A_HUMAN 34 14616 3 Putative uncharacterized protein FAM30A  
AT1A4_HUMAN 34 114093 3 Sodium/potassium-transporting ATPase subunit alpha-4  
RHG39_HUMAN 32 121210 3 Rho GTPase-activating protein 39  
ACOXL_HUMAN 31 61756 3 Acyl-coenzyme A oxidase-like protein  
SSX6_HUMAN 28 21675 3 Putative protein SSX6  
HERC2_HUMAN 20 526895 3 E3 ubiquitin-protein ligase HERC2  
CCNF_HUMAN 14 87584 3 Cyclin-F  
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by the DCP-bio1 probe when the T cells were activated after 30min shows that activation leads 
to increase in sulphenic acid modification (Figure 5.9a and b). However, activation for 24h 
shows a decrease in the number of sulphenated proteins identified suggesting that it is 
reversible and occurs during early TCR signalling. H2O2 causes an increase in sulphenated 
proteins (Figure 5.9c and d) while activation in the presence of H2O2 shows a decrease in 
sulphenic acid containing proteins (Figure 5.9g and h).  
Two proteins were specifically found in a sulphenated form only when cells were activated and 
at both time points; these were APOL2 and WNT2, and sulphenation was not detected after 
activation in the presence of hydrogen peroxide.  
Conversely, NMDA3 was sulphenated at 30mins irrespective of treatment, but at 24 hours was 
sulphenated in non-activated cells but was not detected as sulphenated in activated cells. 
A group of proteins was always detected as sulphenated, irrespective of treatment. These 
included serum albumin, actin, Heterogeneous nuclear ribonucleoproteins C1/C2, IQ and AAA 
domain-containing protein 1-like and Zinc finger CCCH domain-containing protein 13 shown 
below. 
 
ACTB_HUMAN 
ALBU_HUMAN 
HNRPC_HUMAN 
IQCA1_HUMAN 
ZC3HD_HUMAN 
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Figure 5.9: Summary of the identified proteins grouped based on their molecular function. 
CD4+ T cells were activated in the presence or absence of H2O2. The cells were probed with 
DCP-Bio1 to capture sulphenated proteins during activation, and membrane were isolated and 
biotinylated proteins separated using SDS-PAGE. The gel lanes were cut and digested using 
trypsin and digested peptides were analysed by LC-MS/MS. a) Unactivated cells at 30min, b) 
Activated cells at 30min, c) Unactivated cells + H2O2 at 30min, d) Activated cells + H2O2 at 
30min, e) Unactivated cells at 24h, f) Activated cells at 24h, g) Unactivated cells + H2O2 at 24h 
and h) Activated cells + H2O2 at 24h. Proteins identified by Mascot daemon database and 
grouped based on their molecular function by PANTHER gene ontology database 
(http://pantherdb.org/). 
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5.4. Discussion  
 
This chapter has described membrane sulphenic acid modified proteins in CD4+ T cells during 
activation for the first time and validated the effect of modulating ROS during activation as 
shown by others. The findings of this chapter also show the distribution of Trx1 and Prx2 on 
the surface during T cell activation. 
Under normal physiological conditions T cells require a reducing environment for efficient T 
cell proliferation and activation which leads to increased cytokine production and further 
proliferation.  
The interaction of the TCR and MHC II leads to the release of extracellular ROS including 
H2O2 by APC and T cells, suggesting that APC modulate T cell proliferation by regulating the 
availability of thiols including cysteine and thioredoxin (Hadzic et al. 2005). Data in this study 
shows a significant increase in surface Trx1 after activation which may play a role in reducing 
the thiols on the surface of T cells and APCs. As regards to the role it plays on the surface, 
some studies indicate that the Trx1 present on the surface of T cells may reduce certain 
receptors such as CD30 and CD4, which are crucial in T cell activation as T cell activation 
requires a reduced environment (Angelini et al. 2002; Moolla et al. 2016a; Schwertassek et al. 
2007a). Furthermore, proteins and receptors on the surface are susceptible to oxidation which 
may lead to impairment of T cell activation, thus the –SH groups on the surface are maintained 
in a reduced state (Gelderman et al. 2006). The results obtained show a significant increase 
in surface thiols after activation explaining the alteration in redox state within the cell. The 
increase in surface thiols may directly enhances T cell activation and proliferation in vitro and 
in vivo as shown by Gelderman et al 2006. Mitogenic stimulation of T cells leads to increase 
in surface thiol levels (Lawrence et al. 1996).  
Trx1 may modulate –SH of membrane target proteins to transduce its signal during cell-cell 
interaction. It is not clear yet of how Trx1 is translocated onto the membrane or its anchorage. 
The increase in surface Trx1 and Prx2 during activation may suggest that Trx1 may initiate 
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signal transduction by oxidising or reducing thiols of one or more membrane proteins or 
receptors and Prx2 acts as a reducing partner. In the Prx-Trx signalling pathway; H2O2 would 
oxidise the Prx and then transfer oxidation to Trx1 and then followed by transfer to a signalling 
protein (Netto & Antunes 2016). For example, a known interaction protein of Trx1 is CD4- Trx1 
is responsible for regulating the activity of CD4 by dimerization. This step is known to be critical 
for efficient TCR-MHC II CD4 function (Cerutti et al. 2014; Moolla et al. 2016a). Additionally, 
migration inhibitory factor (MIF) binds to Trx1 to form a complex through disulphide bond 
formation and the internalisation and signalling of MIF in ATL-2 cells is enabled by Trx1 (Son 
et al. 2009). Other techniques have allowed detection of target molecules on the surface of 
lymphocytes for Trx1 such as tumour necrosis factor receptor superfamily member CD30 
(TNFRSF8). The Trx1 mediated thiol disulphide exchange between Trx1 and CD30 facilitates 
CD30 effector functions in conditions of inflammation and infections, as CD30 is involved in 
the regulation of inflammation (Schwertassek et al. 2007b). The importance of membrane 
bound Trx1 may be the initiation of intracellular signal transduction mediated by surface Trx1. 
Cys35 active site can be replaced by serine which allows binding of membrane target 
molecules potentially entering the cells (Kondo et al. 2007a; Hara et al. 2007). This overall 
suggests the role of extracellular Trx1 in the interaction of membrane receptors including Trx1 
which may form dimers (Nakamura et al. 2009). Hence, it would be interesting to identify the 
interaction partners of Trx1 on the membrane in the future.  
 
Lymphocytes including T cells may secrete Trx1 which may act as an extracellular antioxidant 
or as a cytokine (Kondo et al. 2004; Rubartelli et al. 1992; Mougiakakos et al. 2010b; Sonia 
Salzano et al. 2014a; Riccardo Bertini et al. 1999). Once it is secreted, it can stimulate the 
effect of IL-2  promoting growth and survival (Gasdaska et al. 1995; Tanudji et al. 2003). In 
support of this, recombinant Trx1 has been shown to enhance the IL-2 cytokine effect 
(Léveillard & Aït-Ali 2017). Results in this chapter showed an increased trend in Trx1 secretion 
after T cell activation which may explain the association of Trx1 with proliferation and 
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activation. This also supports work done by Mougiakakos et al, whereby T cells showed 
increased secretion of Trx1 and blocking Trx1 decreased the –SH and resulted in H2O2 
induced cell death. They suggested that the increased production of Trx1 in Treg may protect 
the cells from enhanced oxidative stress as seen in inflammatory conditions and hence Trx1 
may exert effect in addition to antioxidative functions (Mougiakakos et al. 2010a). Moreover, 
Trx1 can act as a chemoattractant for monocytes and T cells (R Bertini et al. 1999).  
Besides Trx1, Prx2 has been shown to be released from macrophages and modifies cell 
surface receptors stimulating inflammatory responses (Sonia Salzano et al. 2014a; Mullen et 
al. 2015b), although macrophages may act differently to stimulation compared to T cells. 
H2O2 was used for further manipulating the amount of ROS during T cell activation. 
Physiologically, it remains unclear whether the interaction between H2O2 and T cells leads to 
activation or inhibition and the effect may be concentration and time dependent as low levels 
of H2O2 may be beneficial for the immune response. The estimated concentration of H2O2 in 
the microenvironment at the site of inflammation can reach up to 10-100µM (Cemerski et al. 
2002). Also, a unique feature of H2O2 among other ROS is that it can freely diffuse through the 
membrane hence can target intracellular signalling as well as extracellular surface receptors 
(Holmdahl et al. 2016) 
Here, CD4+ T cell activation in the presence of H2O2 decreased IL-2 secretion and CD25 
expression on the surface. This supports previous work showing that lower concentration of 
H2O2 abrogates T cell function which is not due to apoptosis (R Kiessling Aleksandra Mandic 
Havelka et al. 2005; Rodica Lenkei et al. 2001). This may affect further proliferation of T cells, 
as a decrease in IL-2 production is directly related to reduced proliferation (Hadzic et al. 2005). 
Also, H2O2 does not affect the distribution of Trx1 or Prx2 to the membrane. H2O2 is inhibiting 
T cell activation while Trx1 and Prx2 are present on the membrane. However, the presence of 
Trx1 and Prx2 on the membrane is prone to oxidation so it is not clear whether they are present 
in oxidised or reduced forms during activation or in the presence of H2O2.  
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Surface expression of CD25 along with IL-2 secretion was markedly decreased by H2O2. 
Others have shown that addition of exogenous IL-2 rescued T cell proliferation under thiol 
limiting conditions. This suggests that the role low molecular weight thiols is important in IL-2 
signalling and is sensitive to alteration in redox state (Hadzic et al. 2005). Hence, the 
significant role ROS may play including H2O2 mainly depends on the concentration, the 
duration of any optimum concentration and superoxide production and the target of action as 
in which particular receptor or signalling pathway it may affect (A. V Belikov et al. 2015) 
 
Further work here has examined the effect of NAC in H2O2 treated CD4+ T cells. The presence 
of NAC does not reverse the effect of H2O2 in terms of CD25 expression. This suggests that 
increased amount of ROS in form of H2O2 may possibly inhibit T cell activation by oxidising 
proteins and receptors and NAC is a poor extracellular agent for mitigating the effect of H2O2, 
possibly because NAC does not fully reduce the thiols affected by the presence of high H2O2 
concentration. Also, NAC is possibly regulating the intracellular redox signalling elevating 
intracellular cysteine levels suggesting that these compartments behave differently.  Further 
work would be to observe the effects of NAC and H2O2 on surface thiols whether it is efficient 
in restoring surface thiols and that NAC is not metabolised. This will clarify whether the 
oxidation of surface thiols is leading to inefficient T cell response. Intracellular GSH was 
measured after 24h of activation in the presence of H2O2 and had not been restored 
suggesting a sustained intracellular oxidation process that was essential for signalling. This 
contrasts with previous work from our lab which showed that after depletion in T cells, GSH 
was restored within 5 hours (Grant & Griffiths 2007).  
Others have shown that CD4+ T cells that were activated in the presence of NAC had a 
significant increase in IL-2 secretion after activation with anti-CD3 and CD28 (Eylar et al. 1995) 
but this was not confirmed here. NAC is used as a generic antioxidant and an indicator of H2O2 
involvement thus protecting proteins against oxidative damage and inactivation (Zafarullah et 
al. 2003). NAC may promote T cell proliferation and IL-2 secretion and possibly by 
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synthesising GSH which is required for DNA synthesis  (Levring et al. 2015; Zhang et al. 2011).  
However, some effects of NAC seem not to be mediated through GSH synthesis as suggested 
by some experiments involving NAC or GSH inhibitors (Jiang et al. 1999; Yan et al. 1995; 
Laragione et al. 2003). The lack of NAC effect on thiols, GSH and T cell activation here needs 
further investigation. 
 
The mechanism of how increase in ROS inhibits T cell activation is unclear but evidence 
suggests that higher amounts of ROS may lead to increased oxidation of certain receptors 
and proteins crucial for downstream intracellular signalling pathways (Phillips et al. 2010). For 
example, anti-CD3 stimulation in the presence of H2O2 impaired the phosphorylation of Zap-
70 (Chakravarti & Abraham 2002). This further leads to the hypothesis that increased oxidative 
stress may lead to T cell hypo-responsiveness by further oxidation of specific intracellular 
proteins.  
Calcium-signalling pathways may also be thiol sensitive. This hypothesis is supported by 
studies carried out showing that heat shock induced oxidative stress down regulated CD3 
mediated Ca2+ signalling and that NAC reversed the observed effect (Nambiar et al. 2002). 
Also, Bogeski et al, evaluated the effects of H2O2 and how it may affect T cell activation and 
proliferation. One way H2O2 in which may affect T cell differentiation is by oxidising calcium 
release activated channels (CRAC). The plasma membrane protein ORAI1 was found to be 
inhibited in the presence of H2O2 due to oxidation (Bogeski et al. 2010). Further measure of 
Ca2+ in the presence of H2O2 would provide more insight on the effects of H2O2 on T cell 
activation with respect to Ca2+ signalling.  
This study shows an increase in thiol oxidation and sulphenic acid modification after 5min of 
activation. Data in this chapter has demonstrated antigen stimulation, mimicked by anti-CD3 
and anti-CD28 activation, may lead to an increase in sulphenic acid formation and may cause 
additional proteins to be oxidised. However, what is not clear form the methodology here is 
whether the concentration and composition of proteins on the membrane also increases during 
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activation, as might be expected. Protein sulphenic acids as well known, are important and 
considered as a molecular switch which regulates protein function (Denu & Tanner 1998; 
Gupta & Carroll 2014). The mass spectrometry technique applied here has previously 
identified several proteins within the cytosol and cell membrane which are involved in 
inflammation via this molecular redox switch such as actin, integrins cell adhesion molecules 
and kinases (Jones & Go 2010; Go et al. 2010). 
 
An increase T cell intracellular ROS, including O2•- and H2O2, has been described immediately 
after TCR stimulation (Devadas et al. 2002; Belikov et al. 2014; Sharon H. Jackson et al. 
2004), which  can react with intracellular cysteine residue to form sulphenic acid (Kettenhofen 
& Wood 2010). This contrasts with the extracellular reduction in surface thiols that has been 
reported in proliferating T cells. Hence, the effect of excess H2O2 during T cell activation on 
the formation of membrane sulphenic acid formation was investigated and potential proteins 
identified. Activated CD4+ T cells show an increase in numbers of sulphenic acid modification 
on the membrane proteins after 5min of activation compared to unactivated T cells. It was 
critical to find out what proteins may be susceptible to oxidation on the membrane during T 
cell activation. This was achieved by prior incubation of dimedone which allows capturing of 
CysSOH species as they are formed following TCR stimulation. The timing of ROS induced 
oxidative modification is critical and hence the dimedone was incubated immediately prior to 
activation. Dimedone incubation traps oxidised cysteine by forming a covalent bond to 
CysSOH. However, it is important to note that any subsequent functional studies would be 
limited because this may alter the activity and or function of the protein leading to non-
physiological increase in ROS (Furdui & Poole 2014; Michalek et al. 2007) . However, this 
issue can only be questioned when the DCP-Bio1 concentration is higher than 1mM for a 
longer period of time whereas this study used 0.5mM for 30min. 
In the presence of dimedone during T cell activation, proteins which undergo sulphenic acid 
formation will form a stable bond with DCP-Bio1. Membrane proteins were isolated and 
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sulphenated proteins were pulled out of total membrane proteins pool using streptavidin 
magnetic beads. The modified proteins were separated using SDS-PAGE and each lane 
within the gel with different treatments were cut and digested with trypsin. Subsequent 
experiments by LC-MS/MS analysis and protein identification using Mascot Daemon database 
revealed a list of protein hits undergoing sulphenic acid modification during T cell activation 
under oxidative stress conditions. 
The number of membrane sulphenic acid modified proteins increases when the T cells are 
activated after 30min. This further supports the hypothesis that activation leads to increase in 
sulphenic acid formation, possibly due to local ROS production. Also, unactivated cells in the 
presence of H2O2 (20µM) yield a similar number of sulphenated membrane proteins as 
activated at 30min. However, when the cells were activated in the presence of H2O2 at 30min, 
a decrease in sulphenic acid proteins was observed. This may suggest irreversible protein 
oxidation or intra or inter disulphide bond formation which is unreactive to DCP-Bio1. 
Additionally, the number of proteins identified to be sulphenated may be similar but the results 
show different proteins are oxidised under different treatment conditions. Major target of 
sulphenated proteins are catalytic proteins which suggest their role in intracellular signalling 
(Heppner et al. 2017). Also, activation may also change the total number of proteins oxidised 
as observed in the molecular function grouping of proteins.  
Interesting sulphenated proteins were identified on the membrane of CD4+ T cells at baseline 
i.e. untreated. Peroxiredoxin 1 was only identified to be sulphenated in unactivated CD4+ T 
cells after 30mins. It is widely known to undergo protein modification as its main role is 
reduction of peroxides such as H2O2 (Hall et al. 2009). This is through the formation of 
sulphenic acid followed by disulphide bond formation with the resolving cysteine. Prx1 can 
form dimers and decamers at physiological pH (Morais et al. 2015).  
PDI on the surface of cells are responsible for thiol-disulphide interchanges resulting in the 
formation of protein disulphide bonds (Jiang et al. 1999). Although PDI is predominantly 
associated in the cytosol and Golgi, it is also shown to be secreted and associated with the 
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plasma membrane. This chapter identified PDIA3 undergoing sulphenic acid modification on 
the membrane after 30minutes only under resting and activated conditions. This suggests that 
PDI is susceptible to early sulphenic acid at normal physiological conditions. Peroxynitrite has 
been shown to oxidise the redox active Cys residue to sulphenic acid which further reacts to 
form disulphide with adjacent Cys residues (Peixoto et al. 2018).  
The importance of actin reorganisation following TCR stimulation is well defined during T cell 
activation and migration of T cells (Burkhardt et al. 2008). Actin was identified as a 
sulphenated protein under all conditions. It is closely associated with and anchored to the 
membrane in order to mediate cell migration and formation of the immune synapse, hence it 
is not unexpected to find actin within the membrane proteins that were isolated. Also, 
components which make up the actin cytoskeleton is shown to be sensitive to oxidation 
(Fratelli et al. 2002a; Klemke et al. 2008). Coronin is described as actin binding factor which 
is involved in protein-protein interactions, phagocytosis, cell migration and cytokinesis. 
Coronin in mouse T cells has been shown to be associated with the plasma membrane and 
play a role in TCR stimulation and T cell activation. It recruits and promotes downstream 
signalling pathways following TCR-CD3 stimulation (Nal et al. 2004). It is not clear whether 
coronin is undergoing oxidation during activation, but this chapter has identified coronin on the 
membrane undergoing –SOH after 30 and 24h of activation. However, coronin was also 
identified in unactivated cells at 30min further suggesting that it may undergo sulphenic acid 
modification at normal physiological conditions. Also, the treatment with H2O2 did not show 
coronin. Thus it is not clear whether activation leads to oxidation of coronin. On the other hand, 
coronin was shown to undergo posttranslational modification mediated by cyclin dependent 
kinase 5 (CDk5) inducing TCR mediated actin polarisation (Pareek et al. 2010) 
Additionally, cofilin is a key component of actin cytoskeleton regulating the formation of new 
filaments (Samstag et al. 2013). The oxidation state of cofilin is important  in the migration and 
activation of T cells (Hoffmann & Griffiths 2018). The function of cofilin is regulated by the 
posttranslational modification of S3. Dephosphorylation of this residue promotes actin 
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remodelling upon TCR stimulation via Ras and PI3K signalling. Interestingly, cofilin was shown 
to be sulphenated in unactivated T cells; untreated and when treated with H2O2. This is an 
interesting finding as cofilin has four Cys residues that can possibly be oxidised (Samstag et 
al. 2013) but two out of four were confirmed to be sensitive to oxidation, 147 and 139 forming 
sulphenic acid (Yang et al. 2014). Other studies have shown that two Cys are involved in the 
formation of disulphide bridge and C139 is sulfonylated under oxidative stress. (Klemke et al. 
2008; Samstag et al. 2013). Furthermore, the biological function of cofilin can be affected by 
reversible cysteine oxidations. Inactivation of cofilin by ROS may lead to T cell 
hyporesponsiveness and cell death. These findings may possibly suggest the role of cofilin 
oxidation corresponding with the loss of S3 in T cell hypo-responsiveness.  
Previous experiments show the importance of cysteine sulphenic acid for ERK1/2 
phosphorylation, cell growth and calcium flux. This was shown by a study by Michalek et al, 
whereby T cells incubated with dimedone showed a decreased calcium influx. This was due 
to the binding of dimedone to sulphenic acid intermediate hence inhibiting further calcium 
signalling. Also, there is evidence which suggests that cysteine oxidation is required for 
calcium signalling (Redondo et al. 2004). Several cysteine residues which can undergo 
oxidation in PMCA, Orai1 and STIM1 (Hawkins et al. 2010; Bogeski et al. 2010; Galan et al. 
2010; Lushington et al. 2005).  
Here, NMDA receptor thiols were oxidised in all conditions after 30minutes and this protein 
plays a role in calcium signalling (Lombardi et al. 2001; Miglio et al. 2005; Affaticati et al. 2011). 
Further oxidation of this receptor may lead to decreased calcium flux in T cells as shown in 
chapter 3. While NMDA may not be a key receptor involved in calcium influx as it has low 
permeability to calcium, NMDA inhibitors have been shown to inhibit lectin induced T cell 
proliferation suggesting that it may be very important for T cell proliferation (Miglio et al. 2005). 
Interestingly, this NMDA3 was not sulphenated in activated cells at 24 hours and whether this 
is preferentially reduced during activation merits further investigation. Furthermore, the use of 
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gold compounds led to a decreased calcium flux that was associated with defective T cell 
response (Langston et al. 2015).  
After 24h, no difference was observed in the number of proteins identified to be sulphenated 
between unactivated and activated and in the presence or absence of oxidative stress, 
however, the pattern of modified proteins was different. This highlights that sulphenic acid 
formation is transient and may be important in signalling. 
The proteins sulphenated proteins were characterised according to their molecular function to 
further suggest which group of proteins on the membrane might be active during the activation 
process and hence sulphenated. Catalytic proteins were most affected. 
Activated cells in the presence H2O2 at 24h show increased number of catalytic proteins 
sulphenated compared to activated cells at 24h. This may suggest a contribution of these 
proteins in the proliferation of T cells that maybe further modified in the presence of H2O2. For 
example Mitogen-activated protein kinase kinase (MAP3K4) was identified in activated cells 
treated with peroxide after 24 hours, in the regulation of T cell proliferation and activation 
(ZHANG & LIU 2002). M3K4 is shown to mediate IFNɣ in differentiating T cells (Chi et al. 
2004). T cell proliferation leads to the translocation of cyclin dependent kinase 2 (Cdk2) 
associated with MAPK and IL-2 secretion (Blanchard et al. 2000). Also MAPK signalling 
inhibits Fas mediated apoptosis to allow further proliferation of activated T cells (Holmström 
et al. 2000). Using the same approach, Keyes et al, have shown the sulphenylation of ERK1/2 
which prevents the phosphorylation of ERK. This in turn inhibits proliferative responses in a 
number of cells (Keyes et al. 2017). 
The antioxidant protein Prx2 was identified as sulphenated. Prx1 and 2 were found to undergo 
irreversible oxidation at concentration of 20μM H2O2 in the cytosol of Jurkat T cells (Baty et al. 
2005). Others have shown the loss of Prx thiols and oxidised products formed in the presence 
of H2O2 and Trx1 required for reducing the oxidised Prx, this controls the redox state within 
cells (Wood, Schröder, et al. 2003; Woo et al. 2003; Yang et al. 2002). 
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Some sulphenated proteins were identified that are mainly expected to present in the golgi, 
ER and mitochondria. This discovery may be due to the enrichment of membrane proteins 
rather than specifically exofacial membrane proteins. A smaller number of cytosolic proteins 
were also detected and may be contaminants form the method used to isolate membrane 
proteins. The kit uses mild detergents to solubilise membrane and membrane associated 
proteins. Intracellular sources of ROS, which is the mitochondria or exogenous H2O2 which 
penetrates through membrane may oxidise intracellular signalling proteins, partly an essential 
step (Holmdahl et al. 2016). 
Although multiple mechanisms may be involved in controlling the signalling pathways, 
reversible cysteine modification allows the cells to modulate protein activity (Michalek et al. 
2007; Charles et al. 2007). Intracellular proteins such as, PTPs including PTEN, cdc25C can 
be activated by oxidation (Holmdahl et al. 2016). In most cases, oxidation of the cysteine leads 
to decreased protein activity. In addition, SHP-2 protein oxidation in Jurkat T cells have been 
reported to occur within 5min of stimulation (Kwon et al. 2005). And the redox regulation of 
SHP2 modulates the downstream TCR signalling. Michalek et al. showed an increase in total 
cysteine sulphenic acid after activation of CD8+ T cells suggesting that cysteine sulphenic acid 
modification plays a key important role in activation and proliferation of CD8+ T cells (Michalek 
et al. 2007). However, this study specifically looked at membrane sulphenic acid formation. 
TCR stimulation is rapid and this thesis focused on early time points (5 and 30min). TCR 
stimulation leads to relocalisation of membrane bound receptors, hence moving the receptors 
to the surface in theory to initiate signalling. This supports the hypothessis that increased 
number of membrane proteins are susceptible to oxidation during TCR interaction in the 
presence of extracellular ROS.  
Therefore, during T cell activation ROS can affect the rate of proliferation. This chapter has 
shown the proteins which may be susceptible to oxidation on the membrane when T cells are 
activated in the presence or absence of H2O2. This will provide the possibility of exploring 
whether these proteins are differentially affected in disease conditions, such as RA. 
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Chapter 6. The effect of NOX2 activators on T cell function and CIA 
 
Preface 
 
A reduced cell surface protein redox state is required for receptor mediated T cell stimulation. 
Increases in reactive oxygen species (ROS) are predicted to inhibit T cell receptor signalling 
and activation. The main objective of this study was to investigate the effects of specific NOX 
activating compounds on T cell activation and a model of RA. T cell activation in the presence 
of NOX activating compounds showed a significant decrease in IL-2 secretion and intracellular 
ROS after 24h. Also, ROX2 showed a decreased CIA severity in WT mice. Hence, NOX 
compounds have a profound effect on T cell activation.   
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6.1. Introduction 
 
ROS play a major role in autoimmune disease progression including rheumatoid arthritis (RA). 
However, it was established that rodents with a lack of functional NADPH oxidase (a 
decreased ability to produce ROS), have increased susceptibility and severity of RA (Olsson 
et al. 2016; Holmdahl et al. 2016). 
Collagen-induced arthritis is the most commonly used rodent model for RA. In this model, the 
major type of collagen found in cartilage, type II collagen is used to induce arthritis in 
combination with adjuvants (Courtenay et al. 1980; Trentham et al. 1977). The prominent 
features of RA are chronic inflammation and oxidative stress leading to bone erosion in the 
joints (Szabó-Taylor et al. 2012a). CIA is critically dependent on both T and B cells. It is a T 
cell mediated disease. Cells present in the joints are activated but respond poorly to TCR 
stimulation, this might be due to defective TCR signalling. Previous studies have implicated 
ROS and the redox state in T cell-driven arthritogenicity (Hultqvist et al. 2009b). 
The cellular redox state may be influenced by the activity of NADPH oxidase complex. The 
phagocytic cell form of NADPH oxidase enzyme consists of several subunits which assemble 
during activation and are mainly responsible to generate ROS. NADPH oxidase has different 
forms and functions. The catalytic part is located in the membranes (NOX2 dimerising with 
p22 phox forming flavocytochrome b558 complex). Some regulatory components of NOX2 
including Ncf1 (p47phox), Ncf2 (p67phox) and Ncf4 (p40phox) are cytosolic when the enzyme 
is said to be in resting state. Upon activation the Ncf1 is phosphorylated and undergoes a 
conformational change allowing translocation to the membrane and interaction with p22phox. 
The Ncf1 is necessary for the oxidative function and binding of the other subunits and hence 
is considered as an essential organising protein during immune activation. The Ncf1 gene was 
one of the first genes identified to regulate arthritis severity (Olofsson et al. 2007). The NOX2 
complex is mainly expressed in phagocytes and is essential in generating ROS during 
inflammation. Several other cell types including T cells were shown to express phagocyte type 
NOX2 enzyme which acts as a major source of oxidants (Sharon H Jackson et al. 2004). Ncf1 
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via NOX2 was shown to be mainly responsible for continuous production of ROS by T cells. 
Ncf1 mutation in mice leads to increased serum levels of anti-CII antibodies which suggests 
the presence of activated autoreactive T cells when ROS production is inhibited.  
Any direct role of thiol antioxidants in RA is not clear, however, several studies have suggested 
the presence of increased Trx1 in the synovial fluid of RA patients compared to healthy 
individuals and that plasma and Trx1 positively correlated with disease progression (Jikimoto 
et al. 2002; Staal et al. 1997). Also Trx1 negatively regulates apoptosis by binding to ASK1. 
This supports the idea that Trx1 may act as a proinflammatory molecule promoting cell 
proliferation and activation. Nevertheless the specific role of Prx2, a Trx1 interaction partner, 
has not been studied extensively in RA. A greater proportion of RA lymphocytes expressed 
surface Prx2 compared to healthy control (Szabó-Taylor et al. 2012a). Also, the previous 
chapter showed a significant increase in Trx1 and Prx2 on the surface of CD4+ T cells after 
activation with anti-CD3 antibodies. 
ROS, which can be detected upon TCR stimulation (Devadas et al. 2002), can either act as a 
promoting factor for T cell activation or in certain circumstances can suppress signalling 
effectors including ERK-pathway (Kwon et al. 2003), hence acting as negative regulators of 
activation. NOX activating compounds have been found promising and efficacious in the 
treatment of RA in rats, however the mechanism is still not understood (Hultqvist et al. 2006). 
Therefore, NOX2 activators were used in this chapter to observe the effect it might have on 
CD4+ T cell activation followed by CIA. Modulation of the T cell function using has shown 
promising disease outcomes as opposed to immunosuppression (Cope et al. 2007).  
Hence the aim of this chapter was to determine the importance of ROS in RA, by looking at 
CIA in mice with mutation in Ncf1 gene. The aims was to see whether a decreased ability to 
produce ROS affects the redox state of T cells and how efficacious NOX2 activators are in the 
routine treatment of mice immunised with CII. 
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The objectives of the chapter were as follows; 
 To analyse the effects of NOX 2 activating compounds on the surface redox state 
during T cell activation 
 To assess T cell functions in the presence of NOX 2 compounds (IL-2 and CD25; 
activation markers) 
 To induce collagen induced arthritis (CIA) in WT and NOX2 deficient mice (Ncf1-/-)  
 To analyse T cell responsiveness in CIA induced splenocytes in the presence and 
absence of NOX2 activity 
 To validate the effect of a NOX2 activating compound on RA severity  
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6.2. Methods and Materials  
 
6.2.1. Animals and disease induction.  
 
Compounds ROX1 and ROX 2 used in this chapter are quinolinone derivatives described in 
US 2014/0018384 A1 patent. Ethical permit: N229-14 (Swedish research council given to 
Redoxis AB, Lund, SE). 
For eliciting the collagen induced arthritis (CIA), 15 B6N.Q females (8 weeks old) and 
17B6N.Q.Ncf1-/- (6 weeks old) females were used from Redoxis (Lund, Sweden) developed 
by in house breeding. The Ncf1 mutation in mice results into the impairment of the 
relocalisation of Ncf1 (p47phox) protein when activated, hence inhibiting the function of NOX2 
complex. Collagen type II (CII) (Chondrex, Inc, Redmond, USA) was dissolved in 0.1M 
acetic acid to a final concentration of 5 mg/ml and all of the mice were immunised except 3 
from each group annotated as naïve. Collagen emulsion was injected (100µl subcutaneous) 
at the base of the tail and the mice were weighed and marked. Arthritis development was 
monitored using the macroscopic scoring system whereby all four limbs were monitored for 
swelling and redness. Each red or swollen knuckle, toe or midfoot digit scored as 1point and 
ankles which were swollen scored at 5points resulting in a maximum of 60points per mice. 
The mice were scored three times following day 19.  At day 21 a boost emulsion was 
prepared in the lab and injected into the mice according the same procedure as used at 
immunisation. Peripheral blood was collected before termination for analysis and after the 
mice were terminated and spleens were collected at the end point.  
6.2.2. Flow cytometric analysis of cell surface thiols, sulphenic acid and Trx1, 
Prx2 from whole blood 
 
Peripheral blood was collected and RBC were lysed in a 96 well plate with 1:10 Pharmlyse 
(BD Biosciences) and incubated for 6mins. Following incubation the plate was centrifuged and 
the supernatant was discarded. The cells were incubated with antibodies specific to CD4-
PE/FITC (BD Bioscience; 553048/553651 and CD8 (PB, Biolegend; 140414) (1:40) and 
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treated with 10μM maleimide and Alexa Fluor® 488 C5 maleimide (Life Technologies, 
Carlsbad, CA) for 20 min in the dark. Cells were resuspended with PBS and analysed for free 
surface thiol groups by Attune flow cytometry (Thermo Scientific, Sweden). 
 
For sulphenic acid labelling, whole blood was collected and lysed in a 96 well plate with 1:10 
Pharmlyse (BD Biosciences) and incubated for 6mins. Following incubation the plate was 
centrifuged and the supernatant was discarded. 0.1mM biotin-linked dimedone derivative 
(DCP-Bio1) Merck (Poole et al. 2007; Michalek et al. 2007) and 10mM iodoacetamide (IAA) 
(Sigma) were employed in order to block free thiols on ice for 30min. Following incubation, the 
cells were washed with PBS and streptavidin-PE was added (1:40, BD Bioscience) and 
antibodies specific to CD4-FITC (BD Bioscience; 553048/553651 and CD8-PB (Biolegend; 
140414) (1:40) and incubated in the dark for 20min and analysed on flow cytometry.  
 
For flow cytometric analysis of surface Trx1 and Prx2, peripheral blood was collected and 
lysed in a 96 well plate with 1:10 Pharmlyse (BD Biosciences) and incubated for 6mins. 
Following incubation, the plate was centrifuged and the supernatant was discarded. Cells were 
washed in cold wash buffer (PBS supplemented with 1% w/v BSA). Following the wash in cold 
wash buffer, cells were incubated with mouse monoclonal anti-Trx1 (ab16965; Abcam, 
1:1000) or rabbit polyclonal anti-Prx2 (ab109367; Abcam, 1:1000) for 30 minutes at room 
temperature. After a further two washes, cells were incubated with goat anti-mouse polyclonal 
conjugated dylight-488 (ab96879; Abcam) antibody and antibodies specific to CD4 conjugated 
to PE/FITC (BD Bioscience; 553048/553651 and CD8-PB (Pacific blue) (Biolegend; 140414), 
anti-mouse Ly6G-PerCP (127653; Biolegend) (1:40) and incubated in the dark for 20min and 
analysed on flow cytometry (Attune NxT flow cytometer, Sweden) 
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Figure 6.0: Gating strategy for T cells and neutrophils. Blood was collected and lysed with 
pharrmlyse. Lymphocytes were harvested, stained and analysed by flow cytometry. Gating on 
single, viable lymphocytes, the T cell population was identified by gating on CD4+ cells and 
neutrophils by gating on Ly6G+ cells. Using unstained as a negative control, the population of 
cells expressing Trx1/Prx2 on the surface was determined.  
 
6.2.3. 2′,7′-Dichlorodihydrofluorescein diacetate (DCF-DA) oxidation by flow 
cytometry. 
 
Intracellular ROS levels were measured as DCF oxidation. The non-fluorescent probe DCF-
DA (Sigma Aldrich, UK) rapidly diffuses into the cytosol. In the presence of peroxide, DCF-DA 
oxidises to fluorescent DCF. 2x105 CD4 T cells were loaded with 50µM DCF-DA 30min before 
the termination of the treatment. Immediately after 30min DCF-DA incubation, the cells were 
analysed by flow cytometry on the FL1 channel.  
 
6.2.4. Extracellular ROS production measured by isoluminol 
 
Spleens were collected from naïve mice and homogenised in 50ml of HBSS. RBC were lysed 
using pharmlyse and cells were further resuspended in HBSS. 25μl (12.5μM) of ROX 2 
(Quinolinone derivative, patent no: US 2014/0018384 A1) was added in a 96 well plate 
followed by 25μl of isoluminol assay buffer (HBSS, Isoluminol (10mg/ml), HRP II (100U/ml). 
Luminescence was measured to eliminate the background and 50μl of cell suspension was 
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injected using the sample injector. ROS measurement was initiated for every min for 
20minutes (Fluostar Optima, BMG Labtech). 
 
6.2.5. Ex vivo re-stimulation assay 
 
Spleens were collected and homogenised in 50ml of Dulbecco’s Hanks balanced Salt solution 
(HBSS) (Gibco, Life Technologies) using 40µm cell strainers and the piston of 5ml syringe to 
a single cell suspension. The RBC were lysed using 1:10 Pharmlyse (BD Bioscience) for 5min 
and the cells were washed with HBSS. The cells were further resuspended in HBSS and cell 
concentration was determined by using ScepterTM cell counter (Merck, Millipore).  
The cells were re-suspended in complete RPMI (10% FBS and 1% penicillin/streptomycin) at 
a concentration of 2x106cells/ml and 100µl was plated in a 96well plated coated with or without 
1μg/ml of anti-CD3ε (Biolegend; 145-2C11). Anti-CD28 (2µg/ml) (Biolegend; E18) was added 
to the appropriate wells along with rat CII (100µg/ml) (Chondrex) and ROX 2 (12.5µM) 
(Redoxis AB, Lund, Sweden) and incubated for 24h at 37°C, 5% CO2 incubator. 
Following stimulation, the cells were washed and supernatants were stored for IL-2 and TNF-
α cytokine analysis. The cells were resuspended in PBS 1% w/v BSA for flow cytometry of 
surface Prx2 and Trx1 analysis.  
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6.3. Results  
 
6.3.1. ROX 2 increased extracellular ROS production in WT mice splenocytes. 
 
To investigate whether ROX 2 compound increases extracellular ROS production, 
splenocytes from naïve WT and Ncf1-/- mice were isolated and stimulated with ROX 2. The 
luminescence was recorded every minute for 20minutes. Figure 6.1 shows an increasing 
pattern in superoxide production in splenocytes from WT mice. In contrast, no ROS was 
released from splenocytes of Ncf1-/- mice after treatment with ROX 2, confirming that the 
compound targets functional NOX 2 to release ROS. 
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Figure 6.1: Extracellular ROS production in splenocytes from WT and Ncf1-/- mice after ROX 
2 stimulation. Spleens were homogenised and single cell suspensions were prepared. RBC 
were lysed using BD Pharmlyse. Splenocytes were stimulated with ROX 2 in the presence of 
isoluminol to detect extracellular ROS production. Line plots show mean of 5 animals per 
group.  
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6.3.2. Activation of T cells show significant increase in surface thiols levels after 
30min compared to unactivated and ROX compounds have no effect. 
 
To understand how the surface redox state behaves after activation of CD4+ T cells in the 
presence or absence of the NOX-2 activating compounds. T cells were activated with anti-
CD3/CD28 antibodies and the cell surface reduced thiol (-SH) levels were determined by flow 
cytometry. Five minutes after activation T cells show no change in surface –SH levels between 
activated and unactivated T cells (Figure 6.2a). Additionally, ROX compounds had no effect 
on surface thiol levels in activate and unactivated cells. however,  after 30min of activation 
(Figure 6.2b), a significant increase in -SH was detected on the T cell surface compared to 
unactivated cells and ROX compounds did not change the activation-induced surface –SH 
levels.   
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Figure 6.2: Surface thiol levels increases after T cell activation. CD4+ T cells were isolated 
from blood and activated with 1µg/ml anti-CD3 (OKT3) and 2µg/ml anti-CD28 (CD28.2) for 
24h in the presence or absence of ROX compounds; ROX 2 and ROX 1. Cells were collected 
after 5 and 30mins of activation and incubated with FITC-conjugated maleimide for 30min and 
analysed by flow cytometry. a) –SH after 5min, b) surface -SH after 30min activation. c)  A 
schematic showing the increase in –SH after activation. Data represents three independent 
experiments, n=3, mean and SEM, ANOVA, Tukey’s multiple comparison test *p<0.02 
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6.3.3. Activation of T cells causes an increase in sulphenic acid formation on 
the surface with no effect of ROX compounds. 
 
Although ROS are a major cause of post-translational modification to macromolecules, 
reversible oxidation of cysteine thiols e.g. sulphenic acid (-SOH) is important for signalling 
proteins (Michalek et al. 2007). To understand the role of –SOH during T cell activation, this 
chapter looked at the surface oxidised thiols (sulphenic acid) on primary T cells after activation 
and in the presence of NOX-2 regulatory compounds (ROX 2 and ROX 1). Activated CD4+ T 
cells in Figure 6.3 show an increased surface –SOH levels after 5min whereas no significant 
effect 30min was observed. Also, no difference in the trend was observed when the 
compounds were added. 
 
 
 
a)                                                                      b) 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: Surface -SOH increases after T cell activation. CD4+ T cells were isolated from blood and 
activated with 1µg/ml anti-CD3 (OKT3) and 2µg/ml anti-CD28.2 for 24h in the presence or absence of 
compound ROX 2 and ROX 1. Cells were collected after 5 and 30mins of activation and incubated with 
0.1mM DCP-Bio1 and 10mM iodoacetamide (IAA) for 30min. The cells were further washed and 
incubated with streptavidin-PE (1:100) for 30min on ice and analysed by flow cytometry. a) –SOH after 
5min, b) surface –SOH after 30min activation. Data represents three independent experiments, 
n=3, mean and SEM, ANOVA, Tukey’s multiple comparison test *p<0.01 
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6.3.4. Intracellular ROS is increased after 24h of activation 
 
T cells generate ROS via at least two sources; from the mitochondrion (Laura A. Sena et al. 
2013) and NOX type enzyme (Sharon H Jackson et al. 2004). In order to determine whether 
CD4+ T cells produce peroxide during activation and whether the NOX compounds have any 
effect on the production of ROS in T cells, the cells were activated and intracellular ROS were 
measured using DCF-DA. This dye only fluoresces within the cell and upon contact with 
peroxides. Therefore, DCF oxidation was measured from 5 minutes after anti-CD3/CD28 
activation followed by 30minutes and 24h. From figure 6.4a, an increased trend in DCF MFI 
(Median fluorescence intensity) was observed when T cells were treated with H2O2 after 5min. 
However, after 24h of activation, T cells showed a significant increase in DCF MFI fold change 
compared to unactivated cells suggesting increase in intracellular ROS and a similar result 
was observed in T cells activated in the presence of H2O2 at 20µM. ROX 2 decreased DCF 
MFI after 30minutes and 24h of activation. ROX 1 shows no change to DCF oxidation within 
early time points of activation (5 and 30minutes) but a significant decrease after 24h of 
activation. Moreover, H2O2 increases intracellular peroxide within 5min of incubation 
irrespective of activation, however, unactivated cells treated with H2O2 show decreased 
intracellular ROS compared to activated cells.  
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Figure 6.4. Intracellular ROS is increased 24 after T cell activation. CD4+ T cells were isolated 
and activated with 1µl/ml anti-CD3 (OKT3) and 2µg/ml anti-CD28.2 for 24h in the presence of 
12.5µM of ROX 2, ROX 1 and 20µM H2O2. . Before the end of the incubation period, cell 
samples were loaded with 50 µM DCFH-DA for 30min. Samples were analysed immediately 
for DCF fluorescence by flow cytometry and the MFI of 5000 cells was recorded. a) 5 minutes 
after activation, b) 30minutes after activation, c) histogram showing the Median X (pink fill-
unactivated cells) & d) 24h after activation. Results are presented as the mean and SEM from 
three individual experiments. Ordinary one-way ANOVA, Tukey’s multiple comparison test, 
*p<0.02, **p<0.004, n=3. 
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6.3.5. Effects of NOX-2 activating compounds on surface Trx1 and Prx2 after T 
cell activation. 
 
Trx1 may have a crucial role in T cell function and proliferation (Hadzic et al. 2005). The 
distribution of the surface Trx1 level in activated cells was investigated in the presence or 
absence of ROX compounds; ROX 2 and ROX 1. Trx1 was increased on the exofacial surface 
during T cell activation. A significant inhibition of increased surface Trx1 levels was observed 
when cells were activated in the presence of ROX 1 but no difference was observed in the 
presence of ROX 2. To further validate that the inhibition of the increase in surface Trx1 by 
activation is not a result of cell death, the viability was determined after 24h.  Figure 6.5 shows 
that the compounds (ROX 2 and ROX 1) do not affect the viability at 12.5µM after 24h, 
suggesting that the decrease in surface Trx1 is not a result of cell death. 
Prx2 is present on the surface of lymphocytes including T and B cells (Szabó-Taylor et al. 
2012b). In order to detect changes in surface Prx2 during T cell activation, surface Prx2 was 
analysed in the presence or absence of NOX compounds. Prx2 was increased on the exofacial 
surface during T cell activation. From figure 6.5a, it can be seen that surface Prx2 increase is 
significantly inhibited when CD4+ T cells were activated in the presence of compound ROX 1. 
However no significant difference was observed when activated in the presence of ROX 2. 
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Figure 6.5: The presence of compound ROX 1 show decreased Trx1 and Prx2 expression on 
the surface after 24h compared to activated T cells. 1x106/ml CD4+ T cells were isolated and 
activated with 1µl/ml anti-CD3 (OKT3) and 2µg/ml anti-CD28.2 for 24h in the presence or 
absence of compound 12.5µM ROX 2 and ROX 1. The cells were isolated and washed with 
PBS/BSA 1%w/v and incubated with primary anti-Trx1 (ab16965), primary rabbit anti-Prx2 
(ab109367) for 30min. The cells were washed and secondary goat anti-Mouse IgG H&L 
(ab96879) or goat anti-rabbit IgG Alexa-488 was added and incubated for 30min and analysed 
by flow cytometry. a) Surface Prx2 expression after 24h, b) Surface Trx1 expression after 24h, 
c) Cell viability measured by nucleocounter as described in methods after 24h. Data expressed 
as the difference in MFI between antigen specific and isotype control signal over 5000 events. 
n=3 mean and SEM, ANOVA, Tukey’s multiple comparison test. ****p<0.0001, ***p<0.004, 
*p<0.02 
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6.3.6. Effect of compounds on CD4+ T cell GSH levels during activation 
 
GSH plays an essential role in T cell function and proliferation (Levring et al. 2015). In order 
to determine the effect of ROX compounds on intracellular GSH levels during activation, the 
cells were activated in the presence of ROX 2 and ROX 1. Activation of CD4+ T cells leads to 
a significant increase in intracellular GSH levels after 24h as shown in Figure 6.6. However, 
the presence of compound ROX 1 during activation significantly prevented the increase in 
GSH levels after 24h while ROX 2 showed no significant difference. Also, unactivated cells 
treated with ROX 1 shows a decreased trend by 3 fold compared to untreated. 
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Figure 6.6: Effect of NOX compounds on intracellular GSH after 24h. CD4+ T cells were 
isolated and activated with 1µl/ml anti-CD3 (OKT3) and 2µg/ml anti-CD28.2 for 24h in the 
presence or absence of compounds12.5µM (ROX 2 and ROX 1). 1x105 cells were isolated 
and plated on a 96 well plate in duplicates, the GSH concentration was determined using 
GSH-GloTM glutathione assay (Promega) using a standard curve. Data represents three 
independent experiments n=3, mean and SEM. Ordinary one-way ANOVA, Tukey’s multiple 
comparison test *p<0.03, **p<0.005 
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6.3.7. NOX2 compounds inhibit T cell activation. 
 
The secretion of IL-2 is critical and an early landmark in the activation process of CD4+ T cells, 
which suggests further proliferation and differentiation of T cells (Sojka et al., 2004). To be 
able to determine the effect of NOX 2 compounds on T cell activation, CD4+ T cells were 
activated in the presence or absence of ROX 2 and ROX 1 at 12.5µM for 24h. As expected, 
IL-2 secretion was increased 8-fold during the first 24 hours of activation. Figure 6.7a shows 
that there was a significant inhibition of IL-2 secretion when cells were activated in the 
presence of either of the compounds; ROX 2 (0.79±0.19ng/ml) and ROX 1 (0.59±0.11ng/ml) 
compared to absence of compounds (1.76±0.02ng/ml) after 24h, which suggests that these 
compounds inhibit the activation of T cells. The binding of the secreted IL-2 to IL-2 receptor 
(CD25) leads to further proliferation, we looked at the effect of these compounds on surface 
CD25 expression. From Figure 6.7b, CD25 expression was increased during the first 24 hours 
of activation.  The compound ROX 2 show no significant effect on CD25 after 24h activation, 
however compound ROX 1 significantly inhibited the upregulation of surface CD25 after 24h 
suggesting that T cell activation is suppressed in the absence of ROS. 
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a)                                                                              b)  
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Effect of NOX-2 compounds on T cell activation. CD4+ T cells were isolated and 
activated with 1µl/ml anti-CD3 (OKT3) and 2µg/ml anti-CD28.2 for 24. a) Supernatants from 
each condition were collected and IL-2 secretion was measured using a sandwich ELISA. b) 
Cells were washed in PBS with BSA (1%w/v) and incubated with ant-CD25 cy5 for 20mins on 
ice and analysed by flow cytometry. Mean values are shown with standard error of the mean. 
These values are the results from three independent experiments, n=3 mean and SEM, 
Ordinary one-way ANOVA, Tukey’s multiple comparison test ****p<0.0001. ***p<0.0004, 
*p<0.04 
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6.3.8. Induction of Arthritis in B6NQ and B6NQ.Ncf1 mice 
 
In order to investigate the effect of decreased Ncf1 and NADPH oxidase function on arthritis, 
collagen induced arthritis was induced in WT and Ncf1 mutated mouse using collagen type II 
derived in rat. From figure 6.8, Ncf1 mutated mice show a rapid disease progression after day 
25 compared to WT B6 mice. This is due to the lack of functional NADPH oxidase complex, 
confirming that the presence of Ncf1 mutation leads to increased collagen induced arthritis 
(CIA).  
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Figure 6.8: Mice with mutation in Ncf1 develop enhance arthritis compared to WT. Mice were 
immunised with 100µg of rat CII in complete Freud adjuvant (CFA) injected at the base of the 
tail. A boost at day 21 of 50µg rat CII in incomplete Freud’s adjuvant was performed. 
Macroscoping scoring of arthritis after day 18 of immunisation. Results show 3 individual mice 
in each group. Two way ANOVA, multiple comparison test ***p<0.0009 comparing immunised 
NCF-/- and naïve Ncf1-/- mice. ##p<0.05 comparing immunised Ncf1-/- vs immunised WT 
mice.  
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6.3.9. CIA does not change the T cell surface redox state.  
 
In order to investigate the surface redox state in CIA, whole blood was collected during disease 
period (day 28) and at termination (day 35) and surface thiols (-SH) and sulphenic acid (-SOH) 
were determined on the surface of CD4+ T cells. Figure 6.9 below shows that Ncf1-/- mice 
have higher levels of CD4+ T cells surface thiols in the naïve state compared to naïve WT mice 
at day 28. Also, the Ncf1 mutated mice show an significant increase in surface thiol levels after 
immunisation (Figure 6.9a) whereas no observable change in WT thiols after immunisation at 
day 28. At termination (day 35) wild type animals have higher levels of CD4+ T cell surface 
thiols in the naïve state but that after immunisation there was no difference in –SH on the 
surface thiols between Ncf1 mutated and wild type mice (Figure 6.9c). Conversely, the–SOH 
was higher in two of the three naïve WT animals than in the mutants, and this difference was 
removed after immunisation. Arbitrary thiol oxidation and reduction indices were calculated as 
ratios between sulphenic acid and thiols at both time during the disease period. The overall 
picture at day 28 shows less proportion of reduced thiols in WT mice upon CII immunisation. 
Also, the analysis at day 35 highlights that the presence of NOX2 in WT animals is associated 
with a 50% higher oxidation of thiols and that activation of WT T cells tends towards greater 
surface reduction. Thiol levels on Ncf1-/- T cells were unaffected by immunisation throughout 
the disease period.  
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Figure 6.9: Surface thiol and sulphenic acid levels at day 28 and 35 of immunisation in WT 
and Ncf1-/- mice. Whole blood was collected and lysed using BD pharmlyse and washed twice 
with PBS. Cells incubated with FITC-conjugated maleimide for 30min and analysed by flow 
cytometry. Cells were incubated with 0.1mM DCP-Bio1 and 10mM iodoacetamide (IAA) for 
30min. The cells were further washed and incubated with streptavidin-PE (1:100) for 30min 
on ice and analysed by flow cytometry. a) –SH levels and –SOH formation in CD4+ T cells at 
day 28, b) redox index at day 28. c) –SH levels and –SOH formation in CD4+ T cells at day 
35, d) redox index at day 35. Data represents three mice per group. n=3, mean and SEM, one 
way ANOVA, Tukeys multiple comparison test, *p<0.049 
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6.3.10. Distribution of Trx1 and Prx2 in CD4 T cells from CIA mice  
 
To further investigate the distribution of Trx1 and Prx2 during CIA in CD4 T cells, surface Prx2 
was analysed in CD4+ T cells from whole blood after day 28 and 35 of immunisation. Figure 
6.10 shows no difference in % cells positive for Trx1, however, there was a significant increase 
in % cells positive for Trx1 in the CII immunised Ncf1-/- mice. Moreover, figure 6.10b shows 
no difference in % of cells positive for surface Trx1 between naïve and CII immunised Ncf1-/- 
mice after day35. However, a trend for increased number of Trx1 positive cells was observed 
in T cells from WT mice after immunisation. Furthermore, more cells tended to be positive for 
Prx2 in WT animals than in  Ncf1-/- mice and the % of cells that were positive for surface Prx2 
was increased after immunisation in Ncf1-/- and WT compared to naïve at day 35 as shown 
in the figure below. 
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Figure 6.10. CD4+ T cells from CIA mice show no difference in Trx1 but an increase in Prx2 
after day 28 and 35. Whole blood was collected and lysed using BD pharmlyse and washed 
twice with PBS/BSA 1%w/v and incubated with primary anti-Trx1 (ab16965), primary rabbit 
anti-Prx2 (ab109367) for 30min. The cells were washed and secondary goat anti-Mouse IgG 
H&L (ab96879) or goat anti-rabbit IgG Alexa-488 was added and incubated for 30min and 
analysed by flow cytometry a) Surface Trx1 and Prx2 expression at day 28, b) Surface Trx1 
and Prx2 expression at day35. Data expressed as % of cells expressing specific antigen on 
the surface. n=3 mean and SEM, ****p<0.0001, **p<0.004, *p<0.02, *p<0.01 
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6.3.11. Distribution of Trx1 and Prx2 in neutrophils from CIA mice  
 
To further evaluate the distribution in other cells involved in inflammation, surface Trx1 and 
Prx2 expression was also analysed in neutrophils. More neutrophils from Ncf1-/- immunised 
mice were positive for surface Prx2 compared to naïve mice after day 35 but not at day 28 as 
shown in Figure 6.11, whereas immunisation did not change in the proportion of the WT cells 
expressing Prx2 on the surface as compared to naïve mice. Additionally, immunisation led to 
an increase in Trx1 positive neutrophils from both groups (Ncf1-/- and WT) after day 28 and 
35 as shown in the figure below.  
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Figure 6.11. Increased number of neutrophils expressing Trx1 and Prx2 after day 28 and 35 
of immunisation. Whole blood was collected and lysed using BD pharmlyse and washed twice 
with PBS/BSA 1%w/v and incubated with primary anti-Trx1 (ab16965), primary rabbit anti-
Prx2 (ab109367) for 30min. The cells were washed and and incubated with anti-mouse Ly6G-
PerCP and secondary goat anti-Mouse IgG H&L (ab96879) or goat anti-rabbit IgG Alexa-488 
for 30min and analysed by flow cytometry. a) Surface Trx1 and Prx2 expression at day 28 b) 
Surface Trx1 and Prx2 expression at day35. Data expressed as % of cells expressing specific 
antigen on the surface. Data analysed from 3 mice per group (Naïve WT, immunised WT, 
Naïve Ncf1-/- and immunised Ncf1-/-) n=3. Two way ANOVA, Sidaks multiple comparison test. 
*p< 0.05, **p<0.002, ***p<0.0008 
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6.3.12. T cell responses in WT and Ncf1-/- B6 mice 
 
To further investigate the T cell responses in naïve and immunised with CIA mice, splenocytes 
were isolated from WT and Ncf1-/- mice after termination. T cell responses were assessed by 
measuring cytokine levels, IL-2 and TNF-α secreted in the supernatants after 24h stimulation 
with CII and anti-CD3/CD28 antibodies. T cells from all groups of mice were activated when 
stimulated with anti-CD3 and CD28 as shown in Figure 6.12. In contrast, only immunised WT 
cells responded to CII stimulation in vitro whereas Ncf1-/- splenocytes responded to CII 
whether they had been immunised with the antigen or not.  
However, when treated with ROX 2, T cells from immunised WT mice secreted significantly 
less IL-2 whereas naïve WT show no difference in secretion. Furthermore, strong antigen 
response which led to increased cytokine secretion were observed in splenocytes from Ncf1-
/-, naïve Ncf1-/- and WT but no IL-2 secretion in naïve WT mice. 
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Figure 6.12: Exvivo stimulation of mice splenocytes with anti-CD3/CD28 and rat CII. Spleens 
were collected and single cell suspensions were prepared. RBC were lysed using BD 
pharmlyse and lymphocytes were stimulated with 1µg/ml of anti-CD3 and 2µg/ml of anti-CD28. 
Also splenocytes were re-stimulated with rat CII at 100µg/ml for 24h with or without ROX 2 
(12.5µM). Supernatants were collected and analysed for IL-2 and TNF-α. Data analysed from 
3 mice per group (Naïve WT, immunised WT, Naïve Ncf1-/- and immunised Ncf1-/-) n=3. 
*comparing to the unstimulated. #comparing the treatment ROX 2 to stimulated control. Two 
way ANOVA, Tukey’s multiple comparison test. ****p<0.0001, ####p<0.0001, ##p<0.008 
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6.3.13. Surface Trx1 and Prx2 in CD4 T cells increases after activation with anti-
CD3 antibodies 
 
In order to determine the distribution of Trx1 and Prx2 in T cells re-stimulated from CIA induced 
mice (WT and Ncf1-/-),  splenocytes were collected and re-stimulated with anti-CD3/CD28 
antibodies for 24h and surface Trx1 and Prx2 was analysed. The proportion of T cells 
expressing Trx1 and Prx2 was significantly increased by stimulation in vitro as shown in Figure 
6.13 but the proportion of Trx1 expressing cells was lower in Ncf1-/-. The effect of ROX 2 on 
surface Trx1 and Prx2 was analysed after T cell activation, the compound did not show 
observable effect on the distribution of Trx1 and Prx2, however, the proportion of Prx2 
expressing cells tended to be lower in naïve cells that had not been previously immunised  
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Figure 6.13: Surface Trx1 and Prx2 in CD4 T cells from immunised mice stimulated with anti-
CD3/CD28. Spleens were homogenised and single cell suspensions were prepared. RBC 
were lysed using BD pharmlyse and lymphocytes were stimulated with 1μg/ml of anti-CD3 and 
2μg/ml of anti-CD28 with or without ROX 2. Cells were collected and stained with mouse anti-
Trx1 and or rabbit anti-Prx2 for 30min in PBS (1% w/v BSA). The cells were washed and 
further incubated with goat anti-mouse FITC and or mouse anti-rabbit in addition to anti-CD4-
PE for 20mins and analysed by FC. Data analysed from 3 mice per group (naïve WT, 
immunised WT, Naïve Ncf1-/- and immunised Ncf1-/-) n=3. ****p<0.0001, ***p<0.0004, 
*p<0.02. 
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6.3.14. No change in neutrophils expressing Trx1 and Prx2 in unactivated T 
cells compared to activated T cells 
 
The proportion of neutrophils expressing Trx1 or Prx2 when splenocytes were re-stimulated 
with anti-CD3 antibodies after immunisation was investigated. The expression of redoxins was 
more variable between animals after immunisation, whereas expression on non-immunised 
neutrophils was more consistent between animals.  No difference was observed in the 
proportion of cells expressing Trx1/Prx2 on the surface of neutrophils. However, a trend for 
lower expression of Prx2 on neutrophils was observed in naïve animals that were stimulated 
with anti-CD3/CD28 antibodies and this was not affected by ROX. WT animal neutrophils were 
more sensitive to the bystander effects of splenocyte activation and showed a trend for lower 
proportions of cells expressing Trx1 after restimulation. This effect was lost in the presence of 
ROX 2.   
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Figure 6.14: Surface Trx1 and Prx2 in neutrophils from immunised mice stimulated with anti-
CD3/CD28. Spleens were homogenised and single cell suspensions were prepared. RBC 
were lysed using BD pharmlyse and lymphocytes were stimulated with 1ug/ml of anti-CD3 and 
2ug/ml of anti-CD28 with or without ROX 2. Cells were collected and stained with mouse anti-
Trx1 and or rabbit anti-Prx2 for 30min in PBS (1% w/v BSA). The cells were washed and 
further incubated with goat anti-mouse FITC and or mouse anti-rabbit in addition to anti-CD4-
PE and anti-mouse Ly6G-PerCP for 20mins and analysed by FC. Data analysed from 3 mice 
per group (naïve WT, immunised WT, Naïve Ncf1-/- and immunised Ncf1-/-) n=3. 
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6.3.15. ROX 2 treated WT mice show a decreased arthritis severity while no 
change in disease activity was seen in Ncf1-/- mice compared to WT 
 
The effect of NOX compounds in CIA was investigated to see if enhanced ROS production 
might protect against CIA in animals with functional NADPH oxidase and hence may have 
potential use as therapeutic targets. WT and Ncf1-/- mice were immunised with CII and treated 
with ROX 2 (Redoxis AB) 3 times a week after immunisation. Ncf1-/- mice showed severe 
arthritis with earlier onset compared to WT mice. Additionally, the compound ROX 2 has no 
effect on Ncf1-/- CIA immunised mice as shown in Figure 6.15. However, the mild arthritis 
score observed in WT mice showed a trend for decrease in the WT mice group treated with 
ROX 2 at a later stage of the disease.  
 
Figure 6.15: Treatment with ROX 2 show decreased severity in WT mice after day 35. WT 
and Ncf1-/- mice were immunised with rat CII in CFA. The mice were boosted with CII in 
incomplete Freund adjuvant at day 18 ad macroscoping scoring was performed from day 19 
until termination. The chart represents 5mice per group.  
  
Ncf1-/- Vehicle 
Ncf1-/- ROX 2 
WT Vehicle 
WT ROX 2 
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 6.4. Discussion 
 
This chapter has looked at the effects of ROS inducing compounds on T cell function in vitro, 
in vivo and on the frequency of Trx1 and Prx2 expressing cells. The findings of this chapter 
have validated the effect of compounds targeting NOX2 in CIA, a model that is associated 
with increased T cell activation. Also, it shows increased disease severity in mice with 
decreased NADPH oxidase function as shown by others (Hultqvist et al. 2004). 
T cell proliferation is increasingly influenced by alteration in the redox state with a majority of 
studies focussing on the intracellular ROS and few showed a reducing extracellular 
environment is beneficial for T cell proliferation (Survival et al. 2010).  
Firstly this study used compounds which have been shown to increase superoxide production 
from NOX in vitro to establish a model in human primary T cells to study the effects of these 
compounds on T cell activation and the distribution of Trx1 and Prx2 analysing the surface 
redox state by looking at reduced and oxidised thiols on the surface of T cells.  
NOX-2 plays an important role in regulating T cell activation by generating superoxide anion 
within adjacent cells during antigen presentation. ROS also play an important role 
intracellularly initiating a signalling cascade, possibly by oxidising proteins in the TCR pathway 
including PTPs  (Hultqvist et al. 2009a; Salmeen et al. 2003; Sareila et al. 2011). 
Results obtained from this thesis show an increase in –SH and –SOH after activation but no 
significant effect of ROX compounds. This suggests that the ROX compounds have no effect 
on overall membrane protein sulphenic acid formation. However, an increased trend of –SH 
was observed in the presence of ROX 1 and 2. Cell surface –SH is widely known as a critical 
component for T cell activation and function (Pellom et al. 2013).  
 
The effect of ROX compounds was however unknown in terms of whether they stimulate ROS 
production in T cells and hence intracellular ROS was measured using DCF oxidation. H2O2 
was added as a positive control. Numerous studies suggest that T cell receptor activation 
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leads to production of ROS (Sharon H Jackson et al. 2004). An increasing pattern was 
observed of DCF Median X in cells activated in the presence of H2O2 after 30minutes. 
Furthermore, a significant increase in intracellular ROS when T cells were activated for 24h 
further supports hypothesis that T cell receptor stimulation leads to increase in intracellular 
ROS. This may suggest H2O2 is metabolised in unactivated cells but activation of T cells 
require intermediate amounts of ROS. This is also consistent with the work done by Phillips et 
al, whereby T cells produce cytosolic ROS after mitogenic stimulation for up to 72h in culture 
(Phillips et al. 2010). The observation also relies on the sources of ROS. The major sources 
of ROS are the mitochondria and hence an increase in DCF oxidation maybe due to an 
increase in mitochondrial ROS and metabolic activity resulting from proliferation as compared 
to resting cells. Further work using dyes such as MitoSOx which detects mitochondrial ROS 
can provide an idea of mitochondrial superoxide generation. ROS released from the 
mitochondria are required for T cell activation and are induced by a calcium influx as shown 
by Sena et al. 2013; T cells activated in the presence of mitochondrial targeted antioxidant- 
Mito-Vitamin E, completely reduced IL-2 secretion (Laura A. Sena et al. 2013).  Mitochondiral 
ROS also play an important role in T cell proliferation along with cell death (Simeoni & Bogeski 
2015b; Murphy & Siegel 2013). 
However, the NOX compounds show an interesting trend such that the intracellular ROS is 
decreased in the presence of compounds suggesting an inhibition of activation in isolated T 
cells. This contradicted the results from figure 6.3.1 which clearly show an increase in RLU 
when splenocytes were treated with ROX 2 and this increase was absent in Ncf1-/- mice. This 
is supported by the same compound (ROX 2) used in a study showing increasing extracellular 
ROS production in peritoneal cells (Kienhöfer, et al. 2017). This is interesting because it is 
thought that the compound may act on surface enzymes to generate ROS to target surface 
proteins e.g. calcium channels responsible for intracellular signalling, which may lead to 
increased metabolic activity including the production of ROS by mitochondria. This may be 
the reason it may affect T cell activation as inhibition of intracellular ROS during immune 
activation results in reduced CD4+ T cell responses (Previte et al. 2017). Alternatively, 
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detecting ROS production in T cells during activation in the presence of these compounds will 
provide an idea of how they may affect T cell activation. ROX might inhibit signalling pathways 
involved during T cell activation and hence low levels of ROS produced, since temporary 
production of ROS is essential for receptor mediated cell signalling (Kesarwani et al. 2013b). 
From the data obtained a reduction in intracellular ROS may impair T cell function (Phillips et 
al. 2010), shown in Figure 7.2.  
Although ROS plays a critical role in T cell responses, the ability to detect ROS remains a 
challenge. The DCF oxidation technique used in this chapter is the most widely used to detect 
intracellular ROS. This reagent reacts with the peroxides and generate fluorescence but they 
exhibit a range of limitations including the lack of specificity to a particular oxidant and highly 
prone to autoxidation with time resulting in increased fluorescence (Poole & Nelson 2008). T 
cells have been shown to produce intracellular ROS upon TCR stimulation possibly 
mitochondrial ROS (Belikov et al. 2014; Sharon H. Jackson et al. 2004). ROS present in the 
extracellular space may influence the surface redox state, but intracellular ROS from the 
mitochondria may play an important role in intracellular cell signalling. This suggests that the 
compound may vary in its action depending on the cell type, location and source of ROS.  
 
Interestingly, when the T cells were activated in the presence or absence of ROX 2 and ROX 
1, intracellular GSH levels were significantly lowered in the presence of ROX 1 in activated 
and unactivated cells. However unactivated cells treated with ROX 1 also showed a decrease 
that was not significant. This lack of significance may be due to the variability in the data 
obtained and the low range of detection. GSH synthesis is required for DNA synthesis which 
allows further T cell proliferation (Levring et al. 2015), T cell effector functions and metabolic 
activity (Mak et al. 2017). This is achieved by the import of oxidised cysteine through the 
plasma membrane xc- transporter.  Naïve T cells express very low levels of x-c but shortly after 
activation, the expression is upregulated and the cells are provided with the required cystine 
for differentiation and proliferation (Castellani et al. 2008; Garg et al. 2011). Therefore, the 
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decrease in intracellular GSH might be due to the lack of cystine transporter on the membrane 
of T cells. Also, there is a possibility of excess GSH exported out of the cells into the 
extracellular environment or perhaps the compound inhibiting GSH synthesis as the measure 
was after 24h.  
Likewise, CD4+ T cells activated in the presence of NOX-2 compounds show a significant 
effect on surface Trx1 and Prx2. A significant decrease in T cell surface Trx1 was seen in the 
presence of ROX 1 after 24h suggests that compound ROX 1 (which inhibits intracellular 
peroxides measured as DCF oxidation) may inhibit the translocation of Trx1 to the surface.  
Also, another study by World et al. shows that endothelial cells treated with H2O2 for 30min 
leads to increased levels on Trx1 on the surface (World et al. 2011). In general redox-sensitive 
cysteine residues of proteins are largely dependent on Trx1, which restores their reduced state 
(Hanschmann et al. 2013a). Elevated serum and plasma levels of Trx1 are observed in 
patients suffering from RA (Jikimoto et al. 2002; Maurice et al. 1999; Lemarechal et al. 2006). 
Moreover, the synovial fluid of RA patients showed higher levels of Trx1 compared to healthy 
individuals (Yoshida et al. 1999). This finding might support the idea that high concentrations 
secreted into the SF is in fact due to the hypo-responsiveness of T cells in RA (Maurice et al. 
1997). Studies show increase in serum Trx1 and CD30 in conditions of autoimmunity including 
SLE, RA. Both of these proteins play a role in the regulation of the immune response through 
the thiol disulphide exchange to changes in lymphocyte function (Schwertassek et al. 2007a; 
Horie & Watanabe 1998).  
Increased secretion of IL-2 suggests that effective T cell activation upon stimulation.  The 
interaction of IL-2 and CD25 allows T cells to differentiate and proliferate (Malek & Castro 
2010). IL-2 secretion was measured by ELISA and CD25 by flow cytometry. In both cases, 
the data shows that IL-2 secretion is inhibited in the presence of NOX-2 compounds (ROX 2 
and ROX 1) suggesting the compounds inhibit T cell activation. It is reported that certain 
antioxidants are likely to affect the IL-2 secretion such as mitovitamin E; this abrogates IL-2 
production (Laura A. Sena et al. 2013). In contrast, others have shown that gp91phox−/− (NOX-
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2 heme binding subunit) mice T cells have no difference in CD25 expression or IL-2 production 
upon anti-CD3/CD28 stimulation when compared to WT mice  (Shatynski et al. 2012). These 
approaches have been made to further understand the functional importance of ROS in the 
activation of T cells. It is not clear of whether ROX 2 and ROX 1 are specific to activating 
NOX2.  Additionally, it is not clear yet whether the decrease of IL-2 is due to the signalling 
pathway such as the possible oxidation of NFAT pathway involved in IL-2 gene expression 
(Chow et al. 1999), thus analysis of mRNA expression of IL-2 would provide more insight. It 
has been debated whether T cells express NOX 2 enzyme on the surface. However a study 
has shown that T cells express a NOX2 like enzyme on the surface responsible for generating 
superoxide extracellularly (Sharon H Jackson et al. 2004). Also, since NOX-2 is 
transmembrane protein and is made up of different subunits, identifying targets to which these 
compounds act will be interesting for further studies.  
There is evidence suggesting that NOX derived ROS may play a role in immunosuppression 
in conditions such as tumours and autoimmune conditions (Kono et al. 1996; Otsuji et al. 1996; 
Björkman et al. 2008). Hence chapter 6 has endeavoured to look at the effect of ROS deficient 
cells on T cell responsiveness. Ncf1 is strongly associated with arthritis and deletion of this 
gene leads to arthritis progression (Olsson et al. 2016).  
Here in chapter 6, mice with decreased NADPH oxidase function show increased arthritis 
severity compared to WT mice. 
It is described previously that T cell proliferation and activity is influenced by ROS which can 
be endogenously or exogenously generated (Lawrence et al. 2000; Kesarwani et al. 2013a).  
It continues to be challenging and interesting how a mutation in Ncf1 gene leads to severe 
arthritis. This phenomenon was also observed in other autoimmune conditions including 
chronic encephalomyelitis (EAE) and SLE (Hultqvist et al. 2004; Holmdahl et al. 2016; 
Kienhöfer, et al. 2017). Other studies show a complete lack of ROS production due to Ncf1 
deficiency leads to chronic granulomatous disease in mice (Jackson et al. 1995), and patients 
with this disease are also more susceptible to infections. Hence, the increased susceptibility 
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to infection may be due to decreased pathogen elimination. This further explains the role of 
ROS in not only invasion of pathogens but also immune regulation. It has been shown that co-
incubation of T cells with granulocytes producing ROS inhibits T cell cytokine production, 
apoptosis and proliferation due to altered ROS levels (Hultqvist et al. 2009b). This evidence 
suggests that the treatment with NOX compounds may lead to T cell suppression by changes 
in the oxidation status. Secondly, a reducing environment is required for efficient T cell 
proliferation and activation. Increase in ROS release by NADPH oxidase can alter the redox 
environment hence affecting T cell mediated pathways. Thirdly, oxidation of proteins on the 
membrane of T cells are crucial for T cell activation including LAT which is highly sensitive to 
oxidation, resulting in lowered TCR signalling (Gringhuis et al. 2002). Moreover, evidence 
suggests that ROS is required for activation induced cell death of T cells (Hildeman et al. 1999; 
Goldstone et al. 1996; Sharon H Jackson et al. 2004; Hildeman et al. 2002; Bauer et al. 1998). 
This is required to shut down the immune response and hence protect the cells against 
autoimmunity (Brenner et al. 2008). A failure to eliminate T cells either by activation induced 
cell death does not only result in hyperactive T cells but enhances pro-inflammatory functions. 
The paradox is hence not clear such that; on one side ROS may lead to damage of 
macromolecules promoting inflammation and autoimmunity by posttranslational modifications 
and extracellular redox changes, but on the other hand ROS are essential in regulating the T 
cell response possibly by induction of apoptosis. This irony can be explained considering the 
extent of ROS production in subcellular compartments and the antioxidant defence in different 
cell types ( Phillips et al. 2010). Hence, the balance of ROS production during an immune 
response may indeed be important for the removal of autoreactive T cells, and in situations of 
a redox shift which may lead to apoptosis failure and thus survival of autoreactive T cells. A 
reduction in intracellular ROS levels may impair T cell function. This study has shown mice 
with NADPH oxidase ROS production deficiency show severe arthritis, which supports the 
idea that loss of ROS production and loss of intracellular ROS as shown in human and animal 
models (K. A. Gelderman et al. 2006), may lead to T cell mediated autoimmunity.  
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The surface redox state plays an essential role in the progression of the disease, hence this 
thesis has looked at the surface reduced and oxidised thiols and the distribution of Trx1 and 
Prx2 to understand the activity of T cells and surface proteins in RA. No difference in the 
sulphenic acid intermediate in the surface of T cells from Ncf1-/- mice was seen and this may 
be due to the fact that it is transient and hence no changes are detected at steady state. T 
cells from WT mice show a decreased reduction index suggesting that the membrane thiols 
are more oxidised upon CII challenge at day 28. This is supported by a study which suggests 
lower levels of surface thiols (-SH) in leukocytes from RA patients (Pedersen-Lane et al. 2007). 
Also, a decreased trend in oxidised thiols in T cells from Ncf1-/- mice may indicate the absence 
of ROS production hence decreased oxidation in comparison to WT mice. The increased –SH 
levels in naïve Ncf1-/- compared to WT may be explained by the lack of ROS. This is also 
supported by previous work done by Hultqvist et al, suggesting that T cell membrane proteins 
are less oxidised in Ncf1-/- mice and have higher levels of reduced thiols on the cell surface. 
-SH on the surface of T cells is regulated by the release of ROS, produced by and that the 
level of –SH influences activation, RA development and proliferation (K. A. Gelderman et al. 
2006). Additionally, the –SH may be determined by other cells within the surrounding that are 
responsible for producing ROS including APC and neutrophils (Matsue et al. 2003). Hence it 
forms an essential step in regards to T cell function as these changes are observed during 
thymic selection and direct interaction of APC to T cells during antigen presentation which 
requires a reducing extracellular environment (Angelini et al. 2002; Oliveira-dos-Santos et al. 
1998; Yan & Banerjee 2010). The present study involved 3 mice per group due to the 
susceptibility of CIA in B6 mice, which limits the confidence in the data shown, increasing the 
number of mice per group would sufficiently power the result obtained. High individual 
variability on the results contribute to the lack of statistical significance in the results. 
The proportion of T cells expressing Trx1 on the surface show no difference between WT and 
Ncf1-/- mice, but an increased trend in the number of WT CD4+ T cells expressing Trx1 on the 
surface compared to naïve CD4+ T cells. The proportion of T cells expressing Prx2 on the 
surface was however increased in immunised mice (WT and Ncf1-/-) compared to naïve. This 
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chapter looked at the percentage of cells expressing Trx1/Prx2 on the surface whereas 
previous chapter looked at median X (surface expression). This was due to the variability in 
the MdX obtained from lower number of mice. Increasing the number of mice per group will 
provide the quantitative and powered analysis of Trx1/Prx2 expression in CD4+ T cells in the 
future.  
Earlier observations in the literature described that a higher number of cells expressed Prx2 
on the surface of RA cells compared to normal lymphocytes but there was no difference in the 
secreted Prx2 levels in the plasma (Szabó-Taylor et al. 2012a). However, higher proportion of 
IL17+ve T cells showed Prx2 on the surface compared to total lymphocytes suggesting it may 
promote redox mediated signalling on the surface of pro-inflammatory T cell subsets.  
Therefore, it may be possible to suggest that Prx2 maintains a reducing environment on the 
surface which contributes to T cell activation seen in RA. The functional role of increased Prx2 
can be studied in the future including the regulation of inflammation and apoptosis in T cell 
subpopulations (Mullen et al. 2015a).  
Increased attention has grown over the past few years on the roles of other phagocytic cells 
including monocytes and neutrophils cells in the progression of the autoimmune RA. 
Neutrophils are predominantly present in the synovial fluid making up to 90% of the cells 
during the peak phase of the disease (Edwards & Hallett 1997). Studies with depletion of 
neutrophils in vivo have shown the impairment of lymphocyte and monocyte recruitment to the 
inflammatory sites. This possibly leads to decreased production of autoantibody in joints hence 
diminishing the progression of the disease (Schimmer et al. 1997; Wipke et al. 2004). 
Neutrophils from RA synovial fluid produce increased amount of ROS as compared to 
peripheral neutrophils (Capsoni et al. 2005). This chapter has looked into the distribution of 
Trx1 and Prx2 in neutrophils from CIA induced mice. Mice with NADPH oxidase deficiency 
show increased number of neutrophils expressing Prx2 on the surface suggesting the possible 
role of Prx2 in activated neutrophils in the periphery. Additionally, similar trend of increased 
neutrophils expressing exofacial Trx1 was observed in NOX deficient mice. Also, an increase 
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in surface Trx1 was also seen in immunised WT mice as compared to naïve. Trx1 on the 
surface of neutrophils may modulate clearance through phagocytic mechanisms. In mice 
models of RA, neutrophils have been suggested to a play a critical role in the progression of 
the disease by generating autoantigens (Wright et al. 2014), however they may be also 
powerful inducers of apoptosis in bystander cells. The T cell redox status is affected by ROS 
produced from macrophages/monocytes but also granulocytes, presumably neutrophils, 
which are believed to be strongest ROS producers (Hultqvist et al. 2007). Neutrophils and 
monocytes have increased NADPH oxidase activity and the redox state of these neutrophils 
is regulated by antioxidants (Abbas & Monireh 2000). Increased neutrophils survival in the 
joints associated with increased ROS production may promote oxidative damage in the joints 
(Phillips et al. 2010). Hence, further understanding is needed regarding the role of neutrophils 
in RA. 
The T cell plays an important role in the development of CIA and hence the cytokine profile of 
T cells was assessed after re-stimulation with anti-CD3/CD28 antibodies. Restimulation of 
activated T cells is widely used to characterise T cell responsiveness and cytokine profile 
(Sharon H. Jackson et al. 2004). This chapter describes the responsiveness of T cells from 
CIA induced WT and Ncf1 mice upon antigen stimulation including anti-CD3/anti-CD28 and 
CII. Additionally, the cells were either treated with ROX 2. Upon stimulation with anti-
CD3/CD28 antibodies T cells from both groups (WT and Ncf1-/-) show a significant increase 
in IL-2 secretion suggesting the activation of T cells in response to an antigen is not 
compromised by lack of NOX2. No difference in IL-2 secretion was seen in Ncf1-/- mice when 
stimulated in the presence ROX 2 further supporting the fact that the compound is specific to 
functional NADPH oxidase as a significant decrease was observed in T cells from WT mice. 
Furthermore, a similar result was observed when splenocytes were restimulated with CII 
stimulation. However the responsiveness of T cells to CII antigens was approximately 10 fold 
lower, the stronger cytokine response to anti-CD3 may suggest functional potential of cells 
from both the groups (WT and Ncf1-/-) mice and CII immunisation has no effect. CII stimulation 
in T cells suggests more sort of a physiological response to CII antibodies. Interestingly, cells 
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from naïve Ncf1-/- mice show a response to CII whereas naïve WT T cells show no secretion 
of IL-2 when stimulated with CII. This confirms that general responsiveness and increased T 
cell activation is only detectable in antigen stimulated cells which may not be affected by ROS 
(Gelderman et al. 2007). However, the mice weren’t immunised with CII and this may be 
explained by the hyper-responsiveness of naïve T cells to CII in the absence of NOX2, again 
suggesting a regulatory role for ROS. Others have evaluated the CII specific immune response 
at different stages of CIA and shown that the T cell response to CII is dominated by Th1 cells 
that produce IL-2, which initiates pathogenesis of CIA (Rosloniec et al. 2002; Batsalova et al. 
2012). Another study showed a strong proliferative responses against CII (mouse, chicken 
and bovine) suggesting the T cell reactivity and autoimmunity evidence (Inglis et al. 2007). A 
significant decrease in IL-2 from WT T cells upon CII stimulation further suggests the inhibitory 
effect of ROX 2 on T cell response against CII antigen. How ROX compounds inhibit T cell 
activation in vitro and ex vivo is unclear and hence a further experiment followed that involved 
treating mice immunised with CIA with ROX 2 to observe whether it affects arthritis severity in 
vivo. Similar studies have shown the prevention of T cell activation in the presence of these 
compounds ex vivo and decreased T cell transfer autoimmunity by NOX2 knockout (Hultqvist 
et al. 2015a). It was shown that ROS produced by NOX2 expressing cells have the ability to 
alter T cell reactivity and function during antigen presentation by shifting the redox state in 
both, intracellular and extracellular of neighbouring cells as the ROS produced was detected 
in intracellularly and in mitochondrial matrix (Enyedi et al. 2013). Hence a further experiment 
was designed to treat CIA immunised mice with ROX 2 to observe whether it affects arthritis 
severity in vivo. 
 
 
 
CIA, the most common form of induced arthritis comprises of two phases, an immune 
response and inflammatory process (Nandakumar et al. 2003a). The development of CIA 
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depends on the strain with greater susceptibility in DBA1 and B10 strains (Inglis et al. 2007). 
B10 mice developed severe and chronic arthritis on immunisation with rat CII (Bajtner et al. 
2005). This results in this chapter shows a mild arthritis in WT B6 mice. The severity of CIA 
depends on the breed of the mice and the CII used. Others have shown milder CIA in B6 mice 
compared to DBA1 suggesting B6 strain is somehow resistant to CIA (Asquith et al. 2009). 
This may be due to the collagen type used as chicken type 2 CII is widely capable of inducing 
the disease in B6 strain (Campbell et al. 2000; Campbell et al. 1998). In comparison to DBA1 
mice developed arthritis in all cases of chicken, bovine and mouse CII. This in fact may explain 
the resistance of B6 to CIA may vary on the type of collagen used (Pan et al. 2004). Also, 
other factors may be the quality of CII emulsion preparation and how they have been 
immunised as the location at the base of the tail and a clear suspension should be carefully 
administered. Also, the incidence of CIA in B6 strain is variable across different sub strains of 
B6 (Asquith et al. 2009).  
This variability may raise an interesting question on the therapeutic outline of CIA in different 
strains of mice. Available redox-modulatory therapies of RA include methotrexate, auranofin 
and penicillamine (Suarez-Almazor et al. 2000). The therapeutic action of methotrexate in B6 
mice was indeed effective compared to DBA mice, as DBA mice are shown to be resistant to 
methotrexate treatment (Delano et al. 2005). The anti-inflammatory effect of methotrexate is 
to increase ROS levels which in turn reduces inflammation (Phillips et al. 2003). Auranofin, 
used in previous chapter is a gold compound which limits the progression of arthritis perhaps 
by inhibiting the activation of monocytes and other blood cells and lowered secretion of 
cytokines including TNF-α. additionally, several lines of evidence suggests that auranofin may 
act by altering the redox balance by oxidising Trx1 and activation of Nrf2 (Omata et al. 2006). 
however, the use of these compounds may have serious toxic side effects and proteinuria 
(Omata et al. 2006; Eisler 2003).  
T cells in human synovial joints display markers of activation but show decreased proliferative 
response such as IL-2 and IFNɣ secretion, this is due to low TCR signalling which may be due 
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to loss of GSH (Maurice et al. 1997). However, there is little understanding on the role of Ncf1 
in the determination of T cell activation. The studies so far have directed towards the 
intracellular ROS produced by the T cells itself as a result of metabolism (Kwon et al. 2010). 
Interestingly it was observed that DCs were responsible for a reduced environment during 
interaction with T cells and macrophages(Yan et al. 2009) which lack NOX2 function allow 
priming of CII reactive T cells, eventually leading to arthritis (Pizzolla et al. 2011).  
This led to the hypothesis that ROS produced by activating the NOX2 expressing cells may 
alter T cell activation during antigen presentation (Hultqvist et al. 2009b; Holmdahl et al. 2013). 
ROX 2 compound was used in CIA mice as a potential therapeutic agent to investigate if 
enhanced ROS production by activating the NOX 2 complex reduces severity of arthritis. The 
results obtained were promising as the WT mice show a decreased severity in CIA at a later 
onset of the disease. It was also shown that the compound is targeting NOX2 complex as 
Ncf1-/- mice show no change in severity when treated with the compound. Similar work has 
been carried out using the same NOX2 agonist (ROX 2) in pristine induced lupus (PIL), where 
the compound led to decreased autoantibody production in WT mice compared to untreated 
vehicle. It also showed a strong trend towards diminishing PIL in WT mice and Ncf1-/- mice 
had no ROS production compared to WT (Kienhöfer, et al. 2017). This supports the idea of 
increased ROS by activators could serve as potential therapeutic agents by specifically 
targeting cells expressing NOX2. However, it is necessary to determine the consequences of 
targeting NOX2 in diseases as it may lead to different outcomes depending on specificity, 
dose and production of ROS (Hultqvist et al. 2015b). The intervention might shift the balance 
towards an anti-inflammatory state either by promoting apoptosis or cytokine degradation.  
This chapter has described the timing of redox change in immune cells on activation in the 
presence and absence of NOX2 compounds and has explored the potential role of NOX2 
activators during T cell activation in the context of RA. The data obtained shows that 
intracellular ROS, surface Trx1 and Prx2 are inhibited by ROX compounds and that this 
associates with lower intracellular GSH, reduced cytokine secretion and CD25 expression. 
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Future investigation into membrane partner proteins of Trx1 and Prx2 and their oxidation state 
would be of interest and to understand whether de novo DNA synthesis may be inhibited, 
possibly inhibiting proliferation.  Together this also suggests a new strategy to modulate T cell 
functions by targeting NADPH oxidase complex to reduce arthritis severity. However, the 
relation between ROS production by granulocytes/APC and autoimmune arthritis, which is 
mainly mediated by T lymphocytes needs further clarification. 
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7. General Discussion 
 
The role of ROS in T cell function is complex and its effects depend on the amount, the location 
and the source. Large quantities may lead to oxidative stress but controlled release of 
significant ROS is essential for cell signalling. Signalling ROS target free cysteines on proteins 
leading to reversible protein oxidation. Regardless of the source, ROS have clearly been 
shown to affect T cell downstream pathways and hence T cell functions. Mitochondria may be 
an important source of ROS  (Murphy & Siegel 2013; Torrao et al. 2014), that can induce cell 
differentiation through metabolic programming. Considering the intracellular effects, H2O2 has 
been shown to directly influence the activity of protein tyrosine kinases by oxidising the Cys 
residues on the site other than catalytic site. (M. Lee et al. 2011; Paulsen et al. 2012; Yoo et 
al. 2011). A number of studies have focused on protein modifications after T cell activation, 
but have not selectively focused on the reversible cysteine modification, hence cysteine 
modification has become of increasing interest (Kesarwani et al. 2013b; Simeoni & Bogeski 
2015a) 
Oxidative modification of cysteine to cysteine sulphenic acid may play an essential role in 
protein function and signalling pathways. However further oxidation in the presence of excess 
ROS may lead to irreversible cysteine oxidation which may lead to protein dysfunction. There 
is accumulated evidence suggesting the presence of oxidatively modified proteins in disease 
including RA (Phillips et al. 2010). Given the essential role of cysteine oxidation as a modulator 
of cell signalling, cysteine sulphenic acid may act as both a product and an intermediate of 
signalling processes (Furdui & Poole 2014). Cysteine sulphenic acid detection has always 
been challenging to study, until recently when advanced techniques became available, due to 
its unstable nature.  
This study used a biotin tagged dimedone based approach to detect surface –SOH followed 
by identifying specific proteins which undergo protein sulphenic acid modifications on the 
membrane and cytosol. The dimedone based probe conditions were optimised in chapter 3 
identifying protein sulphenic acid formation in the cytosol and membrane in Jurkat T cells. This 
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was achieved by prior incubation of dimedone which allows capturing of CysSOH species as 
they are formed following TCR stimulation. The limitation of this approach may be the free 
probe interfering with the biotinylated proteins during affinity bead capture. Reports suggest 
that reactivity of dimedone towards non-CysSOH derivatives is low (Furdui & Poole 2014), but 
removal of the free probe would eliminate any non-specific binding. Furthermore, additional 
steps will be required to remove contaminants depending on downstream application. For 
example, sticky proteins can be removed using a pre-clearing step and stringent washing 
using DTT for mass spectrometry analysis. 
Following the model established using Jurkat T cells to detect the sulphenated proteins and 
redox systems under oxidative stress, this thesis looked at the proteins susceptible to undergo 
sulphenic acid modification during CD4+ T cell activation in the presence or absence of H2O2. 
T cells encounter ROS including O2•- and H2O2 immediately after TCR stimulation in small 
amounts (Devadas et al. 2002; Belikov et al. 2014; Jackson et al. 2004), which can react with 
cysteine residue to form sulphenic acid due to increased ROS release from the 
phagocytes/APC (Kettenhofen & Wood 2010). Firstly, the total sulphenic acid content was 
analysed by flow cytometry using biotin tagged DCP-Bio1 and streptavidin-HRP which allowed 
fluorescent detection of –SOH proteins on the membrane shown in chapter 5.  
Activated CD4+ T cells show an increase in sulphenic acid modification on the membrane after 
5min of activation compared to unactivated T cells. Early time points of 5 and 30min were 
mainly focussed upon in this study due to the transient nature of sulphenic acid intermediate 
and TCR signalling. It was critical to find out what proteins may be susceptible to oxidation on 
the membrane during T cell activation.  
Protein oxidation was further studied in chapter 3 using Jurkat T cells, which show protein 
aggregates, possible disulphide formation and carbonylation. In the presence of H2O2, the T 
cell cytosolic and membrane protein show distinct bands suggesting aggregate formation, 
possibly due to disulphide formation as these bands were not visible under reducing 
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conditions. Moreover, significant bands shown in the carbonyl western blot indicate that 
general protein oxidation was increased in the presence of H2O2.  
Using different concentrations of the H2O2, it was possible to detect the first reversible 
oxidation of cysteines as under concentrations of 2mM H2O2, the band intensity in streptavidin 
HRP western blot decreased suggesting high concentrations may lead to further protein 
oxidation including sulphinic or sulphonic which are not detected by DCP-Bio1, and or 
formation of aggregates. Therefore an optimum concentration of 200μM was used to capture 
the sulphenated proteins in the membrane and cytosol. Mass spectrometry analysis identified 
a list of proteins with suphenic acid modifications among which NMDA and Prx would be an 
interesting target to further explore in T cell responses.  
The NMDA receptor plays a key role in T cell activation by maintaining cellular Ca2+ influx. 
Mass spectrometry results indicated that NMDA receptor is susceptible to sulphenic acid 
modification at rested stage. In vitro analysis confirmed that increased oxidative stress induced 
by H2O2 decrease cellular Ca2+ influx. While NMDA is not a key receptor for Ca2+ signalling 
several other studies have shown that oxidative stress may inhibit Ca2+ by oxidising other 
calcium channels such as Orai1 on the membrane of T cells (Bogeski et al. 2010).  
This thesis also identified the distribution of the critical reducing enzyme/protein Prx2 and Trx1 
providing insight on localisation in the membrane of T cells under different redox conditions. 
From the proteins identified from MS, a small number of them are involved in oxidation-
reduction process as shown in the chart characterising proteins based on their molecular 
function, including Prxs, alpha enolase and protein disulphide isomerases. Under normal 
physiological conditions, these oxidised proteins are readily reduced via the presence of Trx1, 
GSH, Grx and Prxs (Salmeen et al. 2003). There are two prominent cellular physiological 
electron donors for protein reduction, GSH and Trx1 (Holmgren 2000). Oxidised Trx1 is 
reduced by TrxR in the presence of NADPH where as GSH reduces proteins either directly or 
indirectly through the enzyme Grx. 
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ARF depletes cellular GSH levels in the cells suggesting that Trx1 and GSH might depend on 
each other to respond to oxidative stress, given the relationship of Trx1 and GSH in the cytosol 
(Jones & Go 2010). Trx1 and GSH regulates the redox state of proteins within the cell either 
by scavenging peroxides via Grx and Prx/Trx1 pathways or reducing oxidised cysteine thiols 
(Holmgren 2000; Dickinson & Forman 2002). A broad smear in the absence of β-
mercaptoethanol suggests that proteins attached to Trx1 are linked by a disulphide bridge 
under non-reducing conditions. Trx1 has a number of binding partners in the cytosol as stated 
in the literature (Carilho Torrao et al. 2013), but further work to identify Trx1 binding partners 
on the membrane by western blotting of the targeted protein would provide potential new 
significant interacting partners involved. Trx1 and Prx2 are widely associated with the 
membrane of lymphocytes (Carilho Torrao et al. 2013; Szabó-Taylor et al. 2012a; Mullen et 
al. 2015a). This thesis looked at the distribution of Trx1 and Prx2 and how it may be affected 
in the presence of BSO, ARF, H2O2 and T cell activation. This may explain the redistribution 
of Trx1 and Prx2 to shed light as Trx1 and Prx2 is exported via a leaderless secretory pathway 
(Mougiakakos et al. 2010b; Salzano et al. 2014a). ARF leads to an increase in surface Prx2 
and Trx1. It is however not clear of how inhibiting the TrxR enzyme leads to distribution of 
Trx1 and Prx2 to the membrane and awaits further investigation.  
The extracellular environment during an immune response is more oxidised compared to the 
intracellular compartment (Hanschmann et al. 2013b; Belikov et al. 2014). This may provide 
an explanation for the increase in the translocation of Trx1 and Prx2 to the surface during T 
cell activation. Potential functions have been described previously in this thesis, but primarily 
it could be involved in the elimination of ROS which is present in higher amounts in the milieu 
or due to leakage through phagosomes. It is not anticipated that the redistribution of Trx1 to 
the extracellular surface may influence the surface redox state but its regulatory role of 
catalysing chemical reduction of receptors may be promoted due to high presence of ROS on 
the surface. Also, the interaction between Trx1 and surface receptors such as CD30 may 
suggest a link to regulate further lymphocyte function in an oxidative environment 
(Schwertassek et al. 2007). Similarly, this study did not measure Prx2 in the culture 
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supernatants. A study by Salzano et al. clearly showed the release of Prx2 and Trx1 from 
macrophages upon LPS stimulation via a non-classical secretory pathway (Salzano et al. 
2014b).  
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Figure 7.1:  Activation of T cells. Upper panel- resting CD4+ T cell, whereby no antigen 
interaction. Lower panel- Activated CD4+ T cell showing T cell activation leads to increase in 
–SH and –SOH on the surface and the redistribution of Trx1/Prx2 to the membrane possibly 
responsible to interact with binding proteins on the surface indicated with orange dotted arrow.,  
 
 
The interaction of the TCR and MHC II leads to the release of extracellular ROS including 
H2O2 by APC and T cells suggesting that APC modulate T cell proliferation by regulating the 
availability of thiols including cysteine and thioredoxin (Hadzic et al. 2005). Exogenous 
treatment with H2O2 shows a significant decrease in T cell activation. Surface expression of 
CD25 along with IL-2 secretion was markedly decreased by H2O2. Also, the decrease in GSH 
in the presence of H2O2 suggests T cells with depleted GSH negatively affects the adaptive 
immune response and T cell proliferation by inhibiting IL-2 dependent DNA synthesis and 
Activated CD4 T cell 
H2O2 
H2O2 
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restoration of GSH elevated Th1 cytokine response (Rose et al. 2012; Gmünder et al. 1990; 
Liang et al. 1989). The mechanism of how an increase in ROS affects T cell activation is 
unclear but evidence suggests that higher amounts of ROS in the extracellular environment 
may lead to increased oxidation of certain receptors and proteins and may overoxidise 
intracellular proteins that support signal transduction crucial for downstream TCR signalling 
pathways intracellularly (Phillips et al. 2010), for example protein tyrosine kinases and 
phosphatases including ZAP70 and calcium channels (Bogeski et al. 2010) (briefly shown in 
Figure 7.2 and 7.3). PTP are generally impaired by ROS where as PTK are hyper activated, 
both of which may modulate T cell proliferative responses, so the net effect of moderate ROS 
generation is for MAP kinase signalling to be active (Chiarugi & Buricchi 2007; Salmeen & 
Barford 2005). It is important to note the sources of ROS, that includes the NADPH oxidase 
from surrounding macrophages and neutrophils may have a significant impact in the 
intracellular ROS in T cells (Hultqvist & Holmdahl 2005). Also, to note, the mitochondria as a 
source of ROS at later stages of T cell activation (Belikov et al. 2014). Extracellular ROS may 
affect the surface proteins and surface redox state but intracellular ROS (e.g. mitochondria) 
may regulate the downstream signalling. Mitochondrial ROS controls T cell activation by 
regulating IL-2 expression (Kaminski et al. 2010). 
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Figure 7.2: ROS signalling in T cells. Extracellular source of ROS from NADPH oxidase may 
lead to oxidation of proteins on the surface preventing release of ROS from the mitochondira 
which in turn inhibits signalling and activation. 
 
 
A number of proteins identified are mainly present in the mitochondria and cytosol. This may 
be due to the technique used to isolate membrane proteins and hence the fraction involves 
enrichment rather than complete separation.  
The treatment of T cell membranes with H2O2 did not yield any additionally modifiable proteins. 
This may be due to the transient nature of sulphenic acid modification or the limitations in the 
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experimental approach. It is possible that the experimental techniques and handling leads to 
observed baseline oxidation of susceptible thiol moieties on proteins. Therefore, care should 
be taken on handling, temperature and buffer conditions to minimise any additional oxidation. 
 
This thesis then applied the knowledge gained through in vitro studies to investigate the role 
of ROS in T cell activation in a rheumatoid arthritis disease mouse model. Defective NOX is 
widely associated with various animal models of autoimmunity via a polymorphism in Ncf1 
gene resulting in diminished production of superoxide and increased susceptibility of arthritis 
(Olofsson et al. 2003). ROS produced by NADPH oxidase complex affects the severity of 
arthritis and development as shown in this thesis and others. NOX 2 compounds were used 
to establish a model to analyse the effects on T cell activation and surface redox state in vitro 
using human primary CD4+ T cells. Previous work showed significant decrease of RA severity 
by activating ROS release by NADPH oxidase and mice deficient of functional NADPH oxidase 
show increased severity of autoimmune disorders including RA and SLE. The compounds had 
a profound effect on T cell activation by inhibiting IL-2 secretion in vitro. Furthermore, to 
evaluate whether the compounds increase ROS production in T cells, intracellular ROS was 
measured after activation in the presence of the compounds using DCF. Interestingly, the 
compounds did not show an increase in intracellular ROS but a decrease after 24h of 
activation suggesting possible inhibition of intracellular ROS production by the mitochondria. 
On the other hand, splenocytes stimulated with ROX 2 showed an increase in extracellular 
superoxide production using isoluminol as the detector as shown in chapter 6. Subsequently, 
this compound has shown to release ROS by NOX2 from peritoneal cells, which includes T, 
B cells and macrophages, and cells from NOX deficient mice show no response to the 
compound (Kienhöfer et al. 2017).  
In vitro studies show that Jurkat cells treated with ARF; a compound that inhibits the enzyme 
TrxR, show an increase in surface Trx1. This might suggest that Trx1 translocates to the 
membrane in the absence of reducing enzyme.  The T cells from WT and Ncf1-/- mice show 
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no significant difference in expressing exofacial Trx1, but an increased trend in the number of 
immunised WT CD4+ T cells expressing Trx1 on the surface compared to naïve CD4+ T cells. 
The proportion of T cells expressing Prx2 on the surface was however increased in immunised 
mice (WT and Ncf1-/-) compared to naïve. This may also be supported by earlier observation 
in the literature that a higher number of cells expressed Prx2 on the surface of RA Th17 cells 
compared to normal lymphocytes (Szabó-Taylor et al. 2012a). Thus, Prx2 and Trx1 may 
regulate autoimmunity through their oxido-reductase activity of membrane disulphides or thiols 
as hypothesised previously. In general, the main limitation of this study is the low number of 
mice showing severity of arthritis. This is an important factor that can be overcome by the 
repetition of the study using a more susceptible strain to induce CIA in WT and Ncf1-/- mice. 
This additional work will possibly have the potential to understand the relevance of surface 
redox index in CIA. Despite this, this study had an innovative approach whereby the in vitro 
study was used to develop methodological optimisation. Therefore, in vivo study was crucial 
to possibly identify the effect of the compound in disease and the potential of ROS deficiency.  
Promising results from the compound in vitro human CD4+ T cells allowed follow up ex vivo 
stimulation of immunised WT and Ncf1-/- mice splenocytes with anti-CD3/CD28 and CII. A 
significant decrease was seen in IL-2 secretion in T cells from WT only when stimulated in the 
presence of ROX 2. This was an interesting finding as no effect was observed in T cells from 
Ncf1-/- mice in the presence of ROX 2 and hence the compound specific to functional NOX2 
enzyme. Also, further experiment followed treating mice immunised with CIA with ROX 2 to 
observe how it affects arthritis severity in vivo. Routine treating the mice with this compound 
showed favourable outcome as the WT mice show a decreased severity in CIA at a later onset 
of the disease. It was also shown that the compound is targeting NOX2 complex as Ncf1-/- 
mice show no change in severity when treated with the compound. Similar work has been 
carried out using NOX2 agonist in pristine induced lupus (PIL), whereby the compound (ROX 
2) led to decreased autoantibody production in WT mice compared to untreated vehicle. It also 
showed a strong trend towards diminishing PIL in WT mice and Ncf1-/- mice had no ROS 
production compared to WT (Kienhöfer et al. 2017). Moreover, one other readout to determine 
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the severity of arthritis either ex vivo stimulated cell supernatants or in plasma from these mice 
would be collagen II ELISA, which detect anti-type II collagen antibodies. It is understood that 
anti-type II collagen antibodies are significantly increased in RA NOX2 deficient mice (K. Lee 
et al. 2011). 
From this study, the use of NOX2 agonist and the effect may vary such that; the cell type 
targeted to produce ROS, the location of ROS production being extracellular, cytosol or the 
intracellular organelles, timing of the production of ROS and the target cell or receptor. These 
issues needs to be clarified before further use of these agonists as therapeutic targets. 
According to the screening of these compounds, different compounds appeared to target 
various pathways and could possibly provide an insight of the molecular mechanism as to how 
NOX2 derived ROS may protect from autoimmunity (Hultqvist et al. 2015a). 
 
The increased severity of arthritis in mice with Ncf1 mutation (chapter 6) was also  previously 
shown that low ROS as a result of dysfunctional NADPH oxidase, led to higher immune 
response to CII in mice and rats (Holmdahl et al. 2016). NOX released ROS protects against 
progression of the disease by down regulating T cell activation (Gelderman et al. 2007). 
NADPH oxidase not only expressed in granulocytes but also expressed in APC including 
macrophages and not in T cells  (Kobayashi et al. 1995; Mizuki et al. 1998).  
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Figure 7.3: Different components of downstream TCR signalling regulated by the presence 
of ROS. The engagement induces a cascade leading to ROS production (red stars) 
extracellularly and from the mitochondria. Possible targets of oxidation indicated with a red 
star. Adapted from (Simeoni & Bogeski 2015a)  
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Also, decreased T cell receptor signalling may enhance T cell auto reactivity to antigens 
including CII. Sakaguchi et al. reported that a mutation in Zap70 lead to increased arthritis in 
mice (Sakaguchi et al. 2003). T cells from synovial joints of RA patients show increased 
oxidative stress which presumably affects LAT signalling suggesting possible regulatory 
mechanism of ROS in human RA (S. I. Gringhuis et al. 2000).  
ROS play roles firstly in the interaction between the APC and T cells that occurs at several 
stages during T cell development in the thymus, periphery and migration, a decrease in the 
APC oxidative burst response may affect the interaction leading to enhanced T cell function. 
T cells from low ROS production mice showed efficient transfer of the disease compared to T 
cells from functional NOX2 (Olofsson et al. 2003). Hence, it possible that ROS produced by 
APC may have an impact on the interacting cell such as T cells. Restoring NOX2 functions in 
macrophages but not DCs by reinstating Ncf1 mutation in CD68 promoter. This showed 
protection from severe arthritis suggesting that surface and intracellular pathways are affected 
by ROS produced by APC (Gelderman et al. 2007; Hultqvist et al. 2015a). Recently, NOX2 
derived ROS have also been shown to differentiate Th17 subsets into Th2 phenotype (A. V 
Belikov et al. 2015). Therefore, it is critical to maintain the equilibrium between the ROS 
produced and antioxidant levels with surface redox state possibly playing a role, and this 
crucial balance is believed to be disrupted in RA.  
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Conclusions  
 
This thesis has shown that protein oxidation in Jurkat T cells occurs in the presence of 
oxidative stress e.g. BSO, ARF and H2O2 and that proteins undergo sulphenic acid 
modification in the membrane and cytosol. Further manipulation of the redox state towards 
and oxidising potential within cells by interfering GSH or Trx1 signalling pathways increases 
the redistribution of Trx1 and Prx2 onto the surface. For the first time, proteins on the 
membrane have been identified to undergo sulphenic acid modification during T cell activation. 
The presence of Trx1 and Prx2 on the surface of T cells from CIA mice and any relationship 
with regulating other protein activity requires further understanding in vivo.  
 
 
Future work  
 
Several studies can be suggested to support and complement the approach used to identify 
sulphenated proteins and possible disulphides formed here. The method used here in vitro 
has though identified susceptible proteins on the membrane of CD4+ T cells during activation. 
However, to further quantify the data obtained on the oxidative sulphenic acid formation in 
proteins and abundance in complex samples, quantitative proteomic strategies which include 
label-based and label free approaches. The use of tags such as iTRAQ (isobaric tags for 
relative quantification), which labels primary amino acid in combination with NEM. This is 
useful to identify redox sensitive moieties such as sulphenic acids. Also, ICAT (isotope coded 
affinity tags), which is commercially available tags based on IAA reactive thiols. This can be 
effectively used to detect and quantify cysteine oxidation. Similarly, it is important to 
understand the role of sulphenic acid modification by identification and how these proteins 
including Trx1 and Prx2 on the surface may possibly modulate T cell activation. This can be 
achieved by adding exogenous recombinant Trx1 or Prx2 to determine the effects of these 
reducing proteins on the surface of T cells during activation. Trx1 has been shown to reduce 
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inflammatory response possibly by inducing the expression of genes involved in antioxidant 
activity. Also, presence of exogenous Trx1 will increase the chance of it binding to the surface 
proteins hence using advanced techniques of isolating membrane proteins and CO-IP, further 
studies can possibly identify the interacting partner on the membrane. There is evidence that 
thiol oxidation, and disulphide bond formation controls further signalling in cells and so Trx1 
present will bind to target proteins. This will be an interesting study as these surface receptor 
can further be targeted to modulate an immune response. The first reversible oxidation is 
cysteine sulphenic acid which is an intermediate step before over oxidation or binding to target 
proteins. The physiological significance of Trx1 binding to other proteins is yet to be 
determined. The bands observed under non-reducing conditions can be further looked into 
using techniques such as mass spectrometry to identify the proteins. Analysing the expression 
of Trx1 at gene and protein level will aid in the better understanding of the intracellular 
molecular mechanisms involved. Also, it will be essential to repeat the membrane protein 
isolation using different techniques such as biotinylated based methods that use reagent which 
is cell permeable labelling the exposed primary amines on the surface of intact cells.  
Since Ca2+ signalling is one of the first early response upon antigen stimulation, the readout 
of calcium influx is challenging but using developed techniques such as self-injecting plate 
reader with real time data acquirement, it is possible to analyse calcium influx in activated T 
cells in the presence of H2O2 in the future to explore the effects of oxidation. This may include 
cells with reduced NMDA function and how they may respond to T cell activation in the 
presence or absence of peroxide. 
In order to understand the impairment of the IL-2 T cell response in the presence of NOX2 
agonists, gene expression of IL-2 would ideally be a preferable indicator. Whether the 
decrease in IL-2 secretion is down to the transcription level or the translation of IL-2 protein or 
as a result inhibited secretion. Other possible readout would be longer activation times to 
evaluate the effect of the compound on T cell proliferation by looking at CFSE dye dilution on 
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FC. These experiments would provide a better understanding on the proliferation of T cells in 
the presence of these compounds taking toxicity into consideration. 
CIA serum redox markers can further complement the results obtained in terms of the redox 
status in the peripheral environment. Plasma GSH/GSSG will further provide an indication of 
oxidised and reduced GSH levels. Also, mouse specific ELISAs to detect plasma Trx1 in the 
future in WT and Ncf1-/- mice immunised with CII, detect Trx1 in plasma of these mice to be 
able to evaluate the presence of Trx1 in high concentration is associated with RA (Jikimoto et 
al. 2002).  Autoantibodies against collagen type II plays an important role in the pathogenesis 
of RA, using CII ELISA to detect CII antibodies in the plasma of WT and Ncf1-/- mice treated 
with the compound would provide information of the concentration of antibodies and their role 
in RA incidence.  
Appropriate techniques for ROS measure in the cells from the treated mice will provide an 
indication of what the compounds do during T cell activation, and as to whether they release 
or inhibiting superoxide anion radical formation thus decreasing arthritis severity   
Additionally, the use of ROS inducing drugs in this study has shown promising effects on the 
severity of CIA. Further immunological pathways of the new compound in the treated CIA mice 
will complement the results obtained and provide the insight of how they may affect T cells. 
ROS generated form macrophages is likely to affect T cell activation during antigen 
presentation presumably by oxidising the TCR signalling pathway. Identification of the target 
mechanism would possibly allow targeting specific protein hence minimising side effects. 
Additional investigation of the pharmaceutical efficacy and safety may lead to the development 
of a strong effective ROS inducer targeting NOX2. These experiments may include looking at 
different T cell subsets and redox markers, specifically focussing on the proliferative response 
of CD4+ T cells to Th17 subsets as previous work has shown increased surface Prx2 levels in 
human RA Th17 cells.  
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